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ABSTRACT 
Background: Prevention of mother-to-child transmission of HIV (PMTCT) is an 
important component of HIV programs in generalized epidemics. Malawi has made 
significant progress in expanding access to PMTCT services, yet little information is 
available to assess the impact on transmission rates. Surveillance to assess transmission 
rates is particularly important given the recent adoption of the ' Option B+' strategy, 
offering all HIV -positive pregnant and breastfeeding women life-long antiretroviral 
therapy. This evaluation introduced a novel surveillance approach to assess rates of 
mother-to-child transmission and to gauge feasibility for implementation in Malawi. 
Methods: Estimates of the vertical transmission rate were derived by testing a 
population-based sample of infants presenting for their first immunization clinic visit in 
four districts . Fifty-three clinics were sampled randomly and all caregivers of infants < 3 
months old attending the immunization clinic were invited to participate. Infant dried 
blood spot (DBS) samples were tested for HIV exposure with an antibody test to 
determine maternal seropositivity. Positive samples were tested for HIV antigen using 
DNA PCR to determine infant seropositivity and the vertical transmission rate. 
Caregivers were surveyed about maternal receipt of PMTCT services. 
v 
Findings: Of the 5,068 DBS samples included in the analysis 764 were ELISA positive, 
indicating 15.1% (14.1-16.1 %) of mothers were HIV-infected and had passed HIV 
antibodies to their infant. Sixty-five ofthe 764 ELISA-positive samples tested positive 
with DNA PCR, indicating a vertical transmission rate of 8.5% (6.6-10.7%). Survey data 
indicated 64.8% ofHIV positive mothers and 46.9% ofHIV exposed infants received 
some form of antiretroviral prophylaxis. · 
Conclusions: The observed vertical transmission rate was substantially lower than earlier 
modeled analyses, suggesting that Malawi's PMTCT program has generated substantial 
benefits through averting perinatal HIV infection. However, challenges to 
implementation of PMTCT remain, particularly around low reported coverage of 
antiretroviral prophylaxis for both mothers and infants. The evaluation approach was 
successfully carried out by existing clinic staff and can likely be scaled up successfully to 
assess temporal changes in PMTCT effectiveness in Malawi as Option B+ is introduced. 
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CHAPTER 1: INTRODUCTION AND AIMS 
1.1. Problem Statement 
In 2011, 330,000 children were infected with HIV, with over 90% of these 
children living in sub-Saharan Africa (UNAIDS, 2012). Transmission ofHIV from 
mother to child remains the primary mode of infection in children (Fasawe et al., 2013 ; 
Koye & Zeleke, 2013) and prevention of mother-to-child transmission ofHIV (PMTCT) 
programs are the primary strategy to decrease vertical transmission of HIV. PMTCT is 
not a single intervention but a series of interventions with each step relying on the 
completion ofthe preceding step. In Malawi, an estimated 16,000 children were newly 
infected with HIV in 2011, the majority from mother-to-child transmission (MTCT) 
(Moses et al., 2008; UNAIDS, 2012). Despite the rapid scale-up ofPMTCT interVentions 
since programming launched in Malawi in 2003 , it is unclear to what extent these 
programs have actually reduced transmission. While previous evaluations have focused 
on measuring the success of implementing each individual component ofPMTCT, there 
is no information available on the collective effectiveness of PMTCT in Malawi as it is 
practiced in the real world (Rollins, Little, Mzolo, Horwood, & Newell, 2007). In fact, 
studies in similar settings have found coverage measures overestimate participation in 
PMTCT (E. M. Stringer et al., 2010; J. S. Stringer, Sinkala, Goldenberg, Vermund, & 
Acosta, 2003), as pregnant women who are dispensed antiretroviral drugs (ARVs) to take 
during labor may not actually ingest the drugs (E. M. Stringer et al. , 201 0), or clinic 
record keeping may be poor (Mate, Bennett, Mphatswe, Barker, & Rollins, 2009). By 
extension, the overall transmission rate remains unknown since data on HIV -positive 
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women who do not participate in PMTCT are not captured. Routine and standardized 
collection ofPMTCT impact data using surveillance methodologies is critical to 
understand the true reach ofPMTCT, particularly among those who do not participate in 
PMTCT, and to adjust implementation ofPMTCT services as needed (UNAIDS/WHO, 
2002). 
1.2. Specific Aims 
This evaluation project had three specific aims: 
1. Determine vertical transmission rate of infants attending their first immunization 
visit 
2. Determine the rate of participation in prevention of mother-to-child transmission 
(PMTCT) among mothers whose infants receive their first immunization 
3. Develop a toolkit to provide guidance on implementing a routine surveillance 
system at immunization sites 
1.3. Methods Overview 
The evaluation was to piloted a surveillance system during infant immunization 
visits to measure the effectiveness of PMTCT efforts in reducing vertical HIV 
transmission in Malawi. The approach modified the methodology developed by Dr. Nigel 
Rollins in South Africa (Rollins et al., 2007; Rollins, Mzolo, Moodley, Esterhuizen, & 
van Rooyen, 2009). Infants attending their first immunization visit scheduled at 6-weeks-
of-age were sampled in selected districts in Malawi. At each evaluation site caregivers 
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bringing an infant for her or his first immunization visit were invited to participate in the 
evaluation. The Malawi infant immunization program is strong with participation rates 
exceeding 90% (National Statistical Office Malawi & UNICEF, 2006; WHO & UNICEF, 
2009), therefore, sampling at the first immunization visit approximates the total 
population of caregiver-infant pairs. 
A dried blood spot obtained from infants via a heel stick was measured for 
antibody to HIV (to obtain estimates of maternal HIV prevalence); HIV positive samples 
were tested with DNA-PCR (to obtain estimates of neonatal HIV infection), and a 
vertical transmission rate was calculated. A short survey on mother's experiences with 
HIV testing and PMTCT was conducted to contextualize the biological data. The data 
provided information on coverage of PMTCT interventions among pregnant women in 
the chosen districts. 
1.4. Advancing Public Health Practice 
The evaluation demonstrates the potential for routine testing at immunization 
clinics to monitor mother-to-child (MTCT) transmission rates in Malawi, and illustrates 
the feasibility of this method for regular data collection for surveillance purposes. 
Additionally, the results provide empirical information on the MTCT HIV transmission 
rate at three months of age and younger, and thus, the cumulative effectiveness of 
PMTCT activities in the selected districts up to that age. This information, in conjunction 
with the results of the survey on maternal participation in PMTCT, provides data for 
District Health Officers to make adjustments to PMTCT programs in their selected 
3 
districts as needed. In addition, these data are vital for assessing the true number of HIV-
infected infants in the selected districts to ensure sufficient resources are allocated for 
their identification, care, and treatment. 
Two products developed for the dissertation intended to inform and support 
public health practice are a manuscript to be submitted to a peer reviewed publication 
(included in the dissertation as chapter 6), and a PMTCT Evaluation Toolkit (the 
"Toolkit" throughout; included in the dissertation as chapter 7). The Toolkit is a 
transportable "how to" guide to replicate the evaluation in Malawi and other similar 
settings. The Toolkit provides public health practitioners a user-friendly guide set up 
PMTCT surveillance in the same sites, expand to additional· sites within Malawi, or 
expand the evaluation to other high-prevalence, low-resource settings. The 
implementation process was carefully documented for the Toolkit, which contains the 
training manual and slides, the survey instrument, sample logs, and other implementation 
details. 
1.5. Overview of Chapters 
The following seven chapters provide context and support for achieving the 
dissertation ' s three specific aims. In Chapter 2, Background and Significance, the 
literature review supplies an evidence base for the evaluation and the interpretation of the 
results. The chapter examines the current status of the HIV epidemic globally, focusing 
on vertical transmission and PMTCT recommendations. Next the chapter investigates the 
HIV epidemic in Malawi specifically and the country's prevention and treatment efforts 
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as they relate to vertical transmission. The chapter then examines approaches to 
evaluating PMTCT that have been implemented in similar settings. Finally, the chapter 
describes the conceptual framework used in designing the study and interpreting the 
results. 
Chapter 3, Research Design and Methods, provides details. on the evaluation 
methods including study partners, training, sampling, recruitment, human subjects 
protection, quality assurance activities, and analysis. 
Chapter 4, Results, presents the evaluation results. In the chapter I characterize 
the overall sample and the subset of caregiver-infant pairs with a positive ELISA result, 
present study results for Aims 1 and 2, and present data on the performance of 
implementing this approach in Malawi. 
In Chapter 5, Discussion, I interpret the evaluation results. In this chapter I 
contextualize and interpret the findings for Aims 1 and 2, examine the implementation of 
the approach focusing on factors that contributed to implementation success and areas for 
adjustment, discuss study limitations, and examine the performance of the conceptual 
framework. I conclude with final recommendations for repeating the methodology in 
Malawi. 
Chapter 6 is the complete draft manuscript of key findings of the evaluation. The 
manuscript will be submitted to a peer-reviewed journal for publication. 
Chapter 7 contains the Toolkit developed for Aim 3. The Toolkit contains 
information on the training manual and slides, the survey instrument, sample logs, and 
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other implementation details compiled as a step-by-step user-friendly guide for setting up 
PMTCT surveillance in Malawi or other high-prevalence, low resource settings. 
6 
CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
2.1. Global Status of the AIDS Epidemic 
In 2011 , UNAIDS estimated 34.0 million people were living with HIV around the 
globe (UNAIDS, 2012). Sub-Saharan Africa remains the region of the world most 
affected by the AIDS epidemic accounting for 69% of all individuals living with HIV or 
nearly one in 20 adults (UNAIDS, 2012). Despite the continued severity of the epidemic, 
progress is being made. The number of new HIV infections globally continues to fall, 
down 20% from 2001 to 2.5 million in 2011. One ofthe regions with the sharpest 
declines in new infections is sub-Saharan Africa with a 25% decrease since 2001 (2.4 
million to 1.8 million) (UNAIDS, 2012). 
Considerable improvement has been made in the provision of HIV treatment 
globally. By the end of 2011, an all-time high of eight million people around the world 
were receiving ARV, a 20-fold increase from 2003 (UNAIDS, 2012). In 2008 only 42% 
of individuals in low and middle income countries eligible for ARVs based on World 
Health Organization (WHO) treatment guidelines received it (WHO, 2010a). This 
proportion increased to 54% in 2011 (UNAIDS, 2012), yet continued progress is needed. 
Significant treatment gaps exist in coverage among women (68% of those eligible receive 
treatment), men (47% of those eligible receive treatment), and children (28% of those 
eligible receive treatment) (UNAIDS, 2012). 
WHO released updated treatment guidelines in June 2013. The new guidelines 
lower thresholds for initiating treatment thereby increasing the number of individuals 
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eligible for treatment. Despite increasing access to treatment, the dual tasks of treatment 
and prevention will likely remain daunting as WHO reports that for every two individuals 
who start an antiretroviral therapy (ART) regimen, five more are infected with HIV 
(WHO, 2010a). 
About 330,000 of the new infections in 2011 were among children under the age 
of 15, a 43% decline from 2003 (UNAIDS, 2012). Despite a 24% decrease in new 
infections among children in sub-Saharan Africa between 2009 and 20 11 , the region still 
accounted for more than 90% of all new pediatric infections in 2011 (UN AIDS, 20 12). 
Most childhood infections are the result of vertical transmission from mothers to infants 
in utero, during delivery, or during breastfeeding (Fasawe et al., 2013). 
New international initiatives have set ambitious goals for prevention and 
treatment. The United Nations Political Declaration on HIV and AIDS: Intensifying Our 
Efforts to Eliminate HIV and AIDS created specific steps to achieve HIV I AIDS-related 
goals by 20 15. UN AIDS set 1 0 specific targets aligned with the UN goals to facilitate 
operationalization of effort. UN AIDS goal number three is to eliminate new infections 
among children and substantially reduce the number of mothers dying from AIDS-related 
causes (referred to as "the Global Plan") (UNAIDS, 2012). To achieve this goal, the 
Global Plan has a 1 0-point strategy, the last of which is to improve impact assessment 
(WHO, UNAIDS, & UNICEF, 2011). The Global Plan also identified 22 priority 
countries that account for 90% of HIV positive pregnant women, 21 of which are in sub-
Saharan Africa. The identified countries are targeted to receive additional support (WHO 
et al., 2011). Meeting the UN goal of eliminating new infections in children by 2015 will 
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require tremendous commitment from both the international community and from the 
governments in settings where rates of vertical transmission remain high. 
2.2. Prevention of Mother-to-Child Transmission of HIV 
Interventions to prevent mother-to-child transmission (MTCT) have made 
substantial progress at reducing vertical transmission globally. The number of newly 
infected children peaked in 2002 and 2003 at 560,000 annually and has decreased to 
about 330,000 in 2011 (UNAIDS, 2012; WHO et al., 2011). Yet in low- and middle-
income settings it is estimated that almost 1,000 children are newly infected with HIV per 
day (J. S. Stringer et al., 2013). 
PMTCT is the primary strategy to decrease vertical transmission ofHIV. Without 
intervention, the estimated transmission rate of HIV from mother to child is between 30% 
to 35% (UNAIDS/WHO, 2009). The risk oftransmission is 5% to 10% during 
pregnancy, 5% to 20% during labor and delivery, and 5% to 20% during breastfeeding 
(WHO & UNICEF, 2007). 
Figure 2.1. PMTCT Cascade Diagram 1 
1 Adapted from www.avert.org. · 
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PMTCT interventions exist which can reduce transmission risk to less than 2% 
and are standard practice in developed countries (WHO & UNICEF, 2007; World Health 
Organization, 2004), yet implementation difficulties have prevented programs from 
achieving this level of effectiveness in developing countries. Successful PMTCT 
programming requires a sequence of interventions and health system contacts described 
as the "PMTCT cascade" (see Figure 2.1.). Even minor losses at each stage of the 
cascade can result in substantially reduced effectiveness (E. Stringer, 2008). To 
successfully complete PMTCT, pregnant women move successively through the 
following steps: first, pregnant women must attend an antenatal care (ANC) clinic, be 
offered (and agree to) HIV counseling and testing, and receive their results. Pregnant 
women who are identified as HIV positive then need to be offered, accept, and adhere to 
the recommended ARV and breastfeeding regimen (WHO, 2009). (WHO et al., 2011). It 
is estimated that a third of HIV positive pregnant women are unaware of their status. 
In some countries, attendance of ANC is low, representing a missed opportunity 
for testing and identifying HIV positive pregnant women. In sucp settings, testing at labor 
and delivery represents a second opportunity to identify and treat HIV positive women 
(WHO et al. ,2011). 
In middle- and low-income countries, access to PMTCT interventions is 
continuing to expand. In 2005, only 8% of pregnant women tested for HIV, in 2010 that 
number increased to 35% Additionally, in 2004 coverage of ARVs for HIV -positive 
pregnant women to prevent MTCT was only 9%, but rose to 59% in 2010, however these 
numbers include single-dose nevirapine at the onset of labor which is no longer a 
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recommended treatment (WHO et al., 2011 ). Excluding single-dose nevirapine, coverage 
of ARVs for preventing MTCT is 48% (WHO et al., 2011). 
Despite data on participation in the specific components ofPMTCT, the field 
lacks consensus on a functional model to assess the impact of PMTCT programs on 
transmission (E. Stringer, 2008). Some of the current evaluation efforts focus on uptake 
of HIV testing at antenatal clinics (AN C), however these efforts are not providing a 
complete picture of the success of PMTCT as women who do not attend ANC are missed. 
2.2.1. PMTCT Antiretroviral Treatment Regimen 
In June 2013 the WHO released updated treatment guidelines that for the first 
time consolidating treatment recommendations for adult and adolescent, infant and child, 
and pregnant and nursing women into a single guidance document (WHO, 2013). The 
new guidelines build on the previous guidelines from 2010 (WHO, 201 Ob ), but with 
some important changes to the recommended treatment of pregnant and breastfeeding 
women. The 201 0 version provided separate treatment options for pregnant women who 
require ARV treatment for their own health and for pregnant women who do not need 
ARVs for their own health. For the women who do not meet the CD4 count or clinical 
diagnosis thresholds for treatment for their own health, two treatment "tracks" were 
offered: 1.) Option A- AZT from 14 weeks gestation, a single dose of nevirapine during 
labor, plus AZT and 3TC twice daily until one week postpartum, and 2.) Option B-
triple ARV therapy from 14 weeks gestation until one week post weaning (WHO, 
201 Ob ). In 2012 the WHO released a programmatic update describing so-called "Option 
11 
B+," in which all pregnant and nursing women are provided triple ARV therapy (Option 
B track) "plus" the addition of ARV s for life, regardless of CD4 count or clinical stage 
(WHO, 2012a). 
Figure 2.2. WHO 2013 Treatment Recommendations for Lifelong ART for All HIV 
Positive Pregnant and Breastfeeding Women (Option B+) 
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The new guidelines for 2013 reflect advances in evidence of effective treatments. 
Lower thresholds for starting treatment are recommended, along with earlier start and 
longer duration for prophylactic use. For pregnant and nursing women specifically, the 
guidelines shifted away from the terms Option A, Option B, and Option B+ and now 
recommend two options: 1.) ART; a combination of three or more ARVs to achieve viral 
suppression) for life for all pregnant and breastfeeding women, regardless of CD4 count 
or clinical stage (previous guidelines referred to as Option B+) (Figure 2.2.), or 2.) ART 
for pregnant and breastfeeding women during MTCT risk period with continued lifelong 
ART for women who qualify for treatment for their own health based on CD4 count or 
clinical stage (previous guidelines referred to as Option B) (Figure 2.3.) (WHO, 2013). 
2.2.2. Breastfeeding Recommendations 
Evidence increasingly shows that extended ARV therapies for mothers and infants 
effectively reduces transmission ofHIV through breastfeeding (Chasela et al., 2010; 
Kumwenda et al., 2008). The 2013 WHO guidelines recommend national authorities 
determine if breastfeeding or alternative feeding is the most appropriate strategy as 
formula feeding may not be safe or appropriate in settings where clean water is not 
available, among other issues. If breastfeeding is determined to be the best option, the 
WHO guidelines recommend women exclusively breastfeed for the first 6 months, then 
introduce complimentary foods while continuing to breastfeed until 12 months (WHO, 
2013). 
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Figure 2.3. WHO 2013 Treatment Recommendations for Prophylactic ART for HIV 
Positive Pregnant and Breastfeeding Women (Option B) 
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2.3. HIV/AIDS in Malawi 
Malawi, a country of about 14 million people (WHO, UN AIDS, & UNICEF, 
2008) in South Eastern Africa, has one of the highest HIV prevalence rates in the world. 
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An estimated 910,000 people are living with HIV, of which 18% are children under the 
age of 15 (UNAIDS, 2012). About 46,000 new infections occurred in 2011 (UNAIDS, 
20 12). Despite continued high levels of HIV, prevalence has declined steadily from 
13.8% in 2001 to 10.0% in 2011 among those aged 15 to 49 (UNAIDS, 2012). 
The epidemic is not evenly distributed in the country or in the population. Malawi 
is divided into three regions, North, Centre, and South. The majority of the population 
lives in the Central and Southern regions (42% and 45% respectively) (Government of 
Malawi, 201 Oa). The highest prevalence of HIV is found in the Southern region ( 17.6%) 
compared to 8.2% and 9.0% in the Northern and Central regions respectively (National 
Statistical Office & ICF Macro, 2010). HIV prevalence is higher in urban areas (17.4%) 
than in rural areas (8.9%), and is higher in women in the 15 to 49 age group (12.9%) than 
men (8.1 %) in the same age group (National Statistical Office & ICF Macro, 201 0). 
Key drivers ofthe epidemic in Malawi are (Government of Malawi, 2010a): 
• Multiple and concurrent sexual partnerships 
• HIV discordance within long-term couples 
• Low prevalence of male circumcision 
• Low and inconsistent condom use 
• Suboptimal implementation of HIV prevention interventions 
• Late initiation of HIV treatment 
• HIV-TB co-infection 
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2.3.1. PMTCT in Malawi 
The government of Malawi estimates between 57,000 and 76,000 HIV positive 
women delivered in 2010, transmitting HIV to between 16,000 to 24,000 infants (WHO 
et al., 2011). Without PMTCT interventions, about 35% ofthese HIV-exposed infants 
would have been infected by their mothers (UNAIDS/WHO, 2009). In similar settings as 
Malawi, the outcomes for HIV -infected infants who do not receive treatment are poor, 
with 35% dying within 12 months ofbirth and over 50% dying before their second 
birthday (Newell et al., 2004). 
There is considerable need for PMTCT programming in Malawi. Malawi was 
designated by the Global Plan as one of22 priority countries to receive intensified 
support for achieving the goal to eliminate new infections among children by 2015 (see 
section 2.1.) (WHO et al., 2011). The global gap is the difference between the number of 
HIV positive pregnant women who have access to the most effective ARV regimens for 
PMTCT, and the number that must be reached to achieve 90% coverage of ARVs for 
HIV positive pregnant women. Nearly 50% ofthe global gap in 2010 was composed by 
four countries, Nigeria, the Democratic Republic of Congo, Uganda, and Malawi (WHO 
et al., 2011). Given this context, the government of Malawi has placed significant 
attention on addressing the need for PMTCT services. 
PMTCT programming in Malawi is identical to the PMTCT cascade described 
above (Figure 2.1.), and Malawi faces the same challenges of sub-optimal 
implementation. However, Malawi has made significant progress in scaling up PMTCT 
services since programs began in 2003. 
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In Malawi, the number of new infections in children has decreased from 21 ,000 in 
2001 to 16,000 in 2011. The number of sites offering PMTCT services increased from 
357 in 2007 to 585 in 2012 and PMTCT is now considered fully integrated into maternal 
and child care (Government of Malawi, 2012a; Schouten et al., 2011). As a result, HIV 
testing of pregnant women increased from 10% in 2005 to 66% in 2010 (WHO et al., 
2011). In 2004 only 4% ofHIV infected pregnant women received ARV prophylaxis for 
PMTCT (UNAIDS, 2008), which increased to 39% by 2009 (Government of Malawi, 
2010a) and 53% by 2011 (UNAIDS, 2012). But these successes still leave room for 
continued improvement, and challenges remain. For example, among women who give 
birth outside of institutions (46%) (UNICEF, 2009), provision oftake-home prophylaxis 
remains uneven, and adherence to regimens is unknown. 
2.3.1.1. Option B+ 
Option B+ is a new PMTCT strategy that places all pregnant and breastfeeding 
women on ART for life regardless of clinical stage or CD4 count. Malawi was the first 
country in the world to adopt Option B+ as its primary PMTCT strategy. In July 2011 , 
immediately prior to training and data collection for the evaluation, Malawi began 
implementing Option B+. 
The decision to implement Option B+ was influenced by barriers to initiating 
treatment by requiring CD4 count testing, as documented in a paper on Malawi's decision 
to launch the strategy (Schouten et al., 2011). Listed barriers included: 
• Limited number of machines for testing CD4 count 
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• Machines for testing CD4 count are located in tertiary and district hospitals 
requiring patient or sample transport from rural health facilities, sometimes 
rendering samples unusable 
• Frequent stock out of necessary reagents 
• Loss-to-follow-up of patients who may need to travel to a different clinic where 
CD4 count testing can be conducted 
Option B+ simplifies access to ARV s by pregnant women. Given high fertility 
rates in Malawi, complexities of stopping and restarting ARVs between pregnancies for 
women who do not need ARVs for their own health include viral rebound, drug 
resistance, and increased risk of opportunistic infections (Schouten et al. , 2011). In 
addition, ARVs for life has the potential to protect subsequent pregnancies from 
conception, protect uninfected male partners, reduce vertical transmission, and is cost 
effective (Fasawe et al., 2013 ; Schouten et al. , 2011). 
Since its launch, Option B+ has made considerable progress in initiating treatment 
among HIV positive pregnant and breastfeeding women in Malawi. The number of 
pregnant and breastfeeding women on ART per quarter increased by 748% from the 
quarter prior to the launch of Option B+ in 2011 to the third quarter in 2012 (1 ,257 
women to 10,663) (MMWR, 2013). Retention, a critical component of Option B+, has 
been recorded at 77%, which is similar to the retention rate of other adults on ART in 
Malawi (MMWR, 2013). 
The policy has received considerable international support and several other 
countries have announced its adoption, including Rwanda, Uganda, and Haiti (MMWR, 
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2013). The June 2013 WHO treatment guidelines include Option B+ as one ofthe two 
recommended treatment plans for pregnant and breastfeeding women, although they do 
not use the name "Option B+" (see Figure 2.2.). 
Despite the rapid expansion ofthe PMTCT program in Malawi over the past 10 
years and the adoption of the innovative Option B+ strategy, there has been limited 
evaluation on the program's effectiveness. Comprehensive evaluation must examine 
impact to understand the program's performance and value. 
2.4. Current Approaches to PMTCT Evaluation 
2.4.1. Current Efforts and Gaps in Evaluating PMTCT 
Despite the rapid scale-up of PMTCT services in sub-Saharan Africa, it is unclear 
to what extent these programs have actually reduced HIV transmission. Previous 
evaluations have focused on measuring success in implementing individual components 
ofPMTCT (Delva et al., 2010; Kominami, Kawata, Ali, Meena, & Ushijima, 2007; 
Manzi et al., 2005; Moses et al., 2008; Sarker, Papy, Traore, & Neuhann, 2009; J. S. 
Stringer et al., 2003), yet fail to provide information on overall program effectiveness 
(Rollins et al., 2007; J. S. Stringer et al., 2013). Measuring PMTCT coverage, often 
composed of process data captured from the different components of the PMTCT cascade 
(see Figure 2.1.), is a common proxy for program effectiveness (Rollins et al., 2007; E. 
Stringer, 2008; J. S. Stringer et al., 2013). However studies have found such measures 
overestimate participation in PMTCT (E. M. Stringer et al., 2010; J. S. Stringer et al., 
2003), as pregnant women who are dispensed nevirapine to take during labor may not 
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actually ingest it (E. M. Stringer et al., 2010), or clinic record keeping may be poor (Mate 
et al., 2009). There continues to be a need to understand the impact ofPMTCT programs 
on transmission, and identify consensus on methods and standards for doing so (Rollins 
et al. , 2007; E. Stringer, 2008). 
In 2012 the WHO released a guide of methods to measure the impact ofPMTCT 
programs. The methods are population-based household surveys, modeling, cohort 
studies, case reporting, analysis of Early Infant Diagnosis (EID) data, and facility-based 
data collection (WHO, 2012b). 
The PEARL study (PMTCT Effectiveness in Africa: Research and Linkages to 
Care and Treatment), supported by the US Centers for Disease Control and Prevention 
(CDC), the Bill and Melinda Gates Foundation, and the Elizabeth Glaser Pediatric AIDS 
Foundation (EGPAF), is an example of a population-based household survey with a 
facility-based component. The well-known PEARL study proposed using HIV-free child 
survival as the gold standard metric for evaluating the impact ofPMTCT (E. Stringer, 
2008), and recently released highly anticipated study findings (J. S. Stringer et al. , 2013). 
Starting in 2007, study data were collected from four African countries (Cameroon, Cote 
D'Ivoire, South Africa, and Zambia) at facility and community levels (J. S. Stringer et al., 
2013). 
Members of the PEARL study published findings from the first portion of data 
collection in 2010, which assessed the coverage of minimum service PMTCT. Through 
testing umbilical cord blood samples for HIV and nevirapine, and directly observing if an 
infant ingested nevirapine, study authors determined only 51% of institutionally 
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delivered, HIV-exposed infants received the minimum provision of ARV prophylaxis (E. 
M. Stringer et al., 2010). 
The community-level portion of the PEARL study involved a household survey 
based on the Demographic and Health Survey (DHS), and HIV testing of mothers and 
infants. HIV-free survival at 24 months ofHIV-exposed children was determined to be 
about 80%. Although rates of testing were high, overall coverage of PMTCT was found 
to be low with only 46% of infants receiving ARV prophylaxis during gestation or post-
partum. The study found lower risk of death among children using more potent ARV 
regimens, although this finding was not statistically significant due to power issues. 
Nonetheless, this finding bolsters the WHO's newest treatment guidelines for PMTCT 
supporting more complex combination drug therapy (J. S. Stringer et al., 2013). Although 
correlated, the PEARL study found that facility level data overestimates coverage of 
PMTCT compared to community-level data. The authors concluded facility attendees 
should be considered a subset of the total community population as an examination of 
facility-based data alone would overestimate coverage (J. S. Stringer et al., 2013). 
Important benefits of the PEARL method include its rigorous design and, as a 
household survey, its ability to capture data on women who do not access institutional 
care (E. Stringer, 2008; J. S. Stringer et al. , 2013). A benefit of the cord blood portion of 
the study is its provision of information on actual uptake of ARV prophylaxis, rather than 
relying on self-report. However, PEARL also has important limitations, primarily its 
complexity and the financial and personnel resources needed to undertake the study. For 
example, the sampling for the study required intricate protocols for mapping catchment 
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areas and visiting households. Ultimately almost 29,000 households were visited by at 
least two study members (including at least one registered nurse) to identify about 9,000 
eligible households (J. S. Stringer et al. , 2013). The survey used was lengthy including 
questions on household information; demographics; HIV knowledge, attitudes, and 
perceptions; and obstetrical history, PMTCT, delivery, and infant feeding. The length of 
the survey could represent significant participant burden. Given the commitment of 
resources needed to undertake this study, the authors suggest the use of the DHS as a 
platform for future data collection. DHS surveys, however, are only conducted every few 
years and therefore are less feasible for providing rapid assessments on the performance 
of PMTCT. An additional limitation of the PEARL study is that the data from the cord 
blood portion ofthe study comes from institutional births (E. M. Stringer et al., 2010). 
Institutional births in Malawi account for just over half of all births (UNICEF, 2009), and 
thus would not give a good estimate of population coverage rates. 
Other methods for measuring the effectiveness ofPMTCT in the field are models, 
prospective cohort studies, case approaches, analysis of EID data, and facility-based data 
collection. 
Mathematical modeling is a useful tool for developing estimates ofvalues that are 
difficult to measure directly (WHO, 2012b). Spectrum is a free and commonly used 
modeling software that is used in Malawi to estimate the MTCT rate (Government of 
Malawi, 2010a). Assessing the effectiveness ofPMTCT using modeling has the benefit 
of being relatively easy and inexpensive to implement. However the results generated by 
the model are only as good as the quality of the data and the assumptions entered into it. 
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In a 20 1 0 HIV monitoring and evaluation report, the Malawi Ministry of Health 
government presented a modeled estimate of vertical transmission, but explicitly 
questioned the accuracy of the estimate in the report text citing data quality issues 
(Government of Malawi, 2010a). 
The cohort approach for evaluating the effectiveness of PMTCT involves 
identifying the HIV status of mothers, following them over time, and eventually linking 
their data to the HIV outcomes of their infants (WHO, 2012b). The approach may also 
include following exposed infant cohorts after birth and periodically testing them for HIV 
(Colvin, 2007). Ideally, tracking and retaining mother-infant pairs at risk of vertical 
transmission should be a part of routine HIV prevention programming and clinical care, 
thereby avoiding the need of additional data collection (WHO, 20 12b ). However, in 
many developing world settings linking records and retaining participants is difficult. 
Cohort studies must actively attempt to locate participants who are lost to follow up, 
which can require substantial manpower, time, and resources. Considerable loss to follow 
up is an expected issue in cohort studies, particularly those that extend several years (E. 
Stringer, 2008; WHO, 2012b). In addition, the values ofthose lost to follow up and those 
who do not access facility-based care need to be estimated and included into calculated 
rates. Nonetheless, cohort studies are a viable option for evaluating PMTCT where HIV 
prevalence is not high enough to make facility or household studies cost effective (WHO, 
2012b). 
Assessing PMTCT impact using a case approach entails identifying PMTCT 
participants through facility registers, and locating them post-partum. Infants are tested 
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for HIV and mothers are interviewed to ascertain their level of participation in PMTCT. 
One case report study in South Africa determined a transmission rate but described two 
important limitations. First, the sampling frame excluded pregnant women who did not 
participate in PMTCT, thus created an estimate of transmission that may not be 
generalizable beyond PMTCT participants. Secondly, in the already limited sample, 
nearly 20% of infants selected to be tested could not be traced (Coetzee et al., 2005). 
Early Infant Diagnosis (EID) is a clinical care program intended to test exposed 
infants early to assess HIV status and start ARVs to improve survival (WHO, 2012b). 
Routinely collected and available EID data can be used to determine transmission rate 
without requiring additional data collection. In settings where there is high coverage of 
EID, analyses can be regularly and inexpensively conducted with reasonable confidence 
in the validity ofthe result (WHO, 2012b). However in settings where EID coverage is 
low transmission rate estimates must be interpreted with caution (WHO, 20 12b ). 
2.4.2. Rollins Approach to Evaluating PMTCT- Facility-Based Data Collection 
Dr. Nigel Rollins, a medical officer with the WHO, developed the novel facility-
based impact evaluation approach that was adapted for the evaluation. The metric used 
for measuring the effectiveness of PMTCT was transmission rate. Rollins tested the 
feasibility of collecting anonymous heel-stick dried blood spot (DBS) samples from 
infants attending their first immunization visit in South Africa (Rollins et al. , 2007). He 
also tested the same approach with the samples linked to a password to enable the 
confidential return of infant HIV test results (Rollins et al., 2009). The unlinked and 
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linked approaches to PMTCT surveillance were found to be affordable, technically 
feasible, and well tolerated in that setting, with acceptance rates approaching 90% 
(Rollins et al. , 2007, 2009). At the 2011 International AIDS Society conference 
representatives of Swaziland and Rwanda presented plans to implement evaluations of 
PMTCT transmission rate using the Rollins method (Lyambabaje & Mugwaneza, 2011; 
Mulima, 2011 ), however no results on the implementation in these settings have been 
released via peer-reviewed publications. 
Routine collection of data on transmission rates is critical to understand the 
success of PMTCT efforts and inform program improvement. In countries with 
generalized epidemics, surveillance efforts are often conducted at ANC clinics and are 
considered a reliable source of prevalence data (Seguy et al. , 2006). However, as ANC 
testing occurs during pregnancy, it cannot gauge the impact of PMTCT on vertical 
transmission or identify prevalence rates among infants. 
The Rollins approach offers two major benefits for evaluating the impact of 
PMTCT in Malawi over the alternatives. First, given high rates of immunization of 
infants in Malawi (National Statistical Office & ICF Macro, 2010; National Statistical 
Office Malawi & UNICEF, 2006)? sampling from immunization clinics will give a better 
approximation of transmission rates in the population than sampling only among women 
who attend ANC or participate in PMTCT. Secondly, the Rollins approach can be 
implemented relatively quickly and easily, unlike the PEARL method, which relies on the 
robust, but cumbersome household survey process. Additionally the Rollins approach 
was tested successfully in Sub-Saharan Africa in a setting with similarly high prevalence 
25 
rates. However, limitations to the methodology do exist, including the use of maternal 
antibodies to assess exposure. As infants shed maternal antibodies over time the method 
can only be used with young infants, thus the method can determine neither transmission 
across the entire breastfeeding period nor HIV free survival. In addition, the approach 
requires facility attendance, and will miss infants who are not brought to a health facility 
for immunizations as well as those who have died prior to their first immunization 
(WHO, 2012b). 
2.5. Evaluation Conceptual Framework 
The conceptual framework for this evaluation is a modified version of the RE-
AlM model. This framework is particularly appropriate as it was developed to move 
beyond evaluation assessments of efficacy alone to include considerations of public 
health impact. Five factors of quality comprise the framework: Reach, .Efficacy, 
Adoption, Implementation, and Maintenance (Glasgow, Vogt, & Boles, 1999). Previous 
research defined an intervention's impact as "reach" times "efficacy" (Abrams et al., 
1996). Glasgow and colleagues added the dimensions of adoption, implementation, and 
maintenance to more fully describe key components of impact and to contextualize 
evaluation data collected. 
The five factors ofRE-AIM were a useful way to conceptualize the evaluation as 
they integrate the primary outcome (transmission rate) into a broader context. RE-AlM 
provided the structure to incorporate multiple complex factors into the analysis to 
examine how they influence the reality of program implementation and success. 
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I describe the use ofRE-AIM as a "modified" version of the framework as it was 
not possible to assess the five factors to the level of depth described by Glasgow and 
colleagues given time and budgetary constraints. For example I did not include 
"behavioral, quality of life, and participant satisfaction outcomes" in the measure of 
efficacy (Glasgow et al. , 1999). In addition, instead of using RE-AlM to develop a 
summary score of each of the five components, I used the framework to ensure all five 
factors were considered when developing the evaluation and drawing conclusions. RE-
AlM definitions as described by King and colleagues (King, Glasgow, & Leeman-
Castilla, 201 0) and how they were measured are included in Table 2.1. 
RE-AlM authors describe the first factor, reach, as an individual-level measure of 
participation and representativeness. The reach of PMTCT programs across the country is 
assessed by the Malawi Ministry of Health (MOH) quarterly, including monitoring the 
number ofHIV tests provided at ANC and the provision of ARVs. Reach was assessed 
through survey questions examining the characteristics of participants to understand their 
representativeness. 
The efficacy of interventions is the second factor of RE-AlM. PMTCT is 
considered highly efficacious in reducing transmission, which has been well documented 
in numerous studies (WHO & UNICEF, 2007; World Health Organization, 2004). As the 
efficacy of PMTCT is well-established in high-resource and low-resource settings, 
efficacy was not measured as part of the evaluation. 
Adoption, the third factor of RE-AlM concerns the proportion and 
representativeness of the target settings adopting the intervention. PMTCT in Malawi is 
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available in 585 health facilities across the country and is considered fully integrated into 
maternal and child care (Government of Malawi, 2012a; Schouten et al., 2011). Adoption 
was considered in the selection of districts and health facilities to include in the sampling 
frame. This factor was used to consider the generalizability of the results given the 
representativeness of the selected districts and health facilities. 
Glasgow and colleagues describe the fourth factor, implementation, as an 
individual- and program-level measure of fidelity to developed protocols. Fidelity to 
program protocols is required to understand program success. If program components are 
not implemented as intended it is unclear what the evaluation results are actually 
measuring. Through the review of published literature on PMTCT evaluation, major 
implementation issues faced by PMTCT programs in Malawi and other settings were 
identified, including limited CD4 cell count infrastructure, poor linkages between HIV 
testing and treatment, difficulty accessing health facilities , and stigma (Ferguson et al. , 
2012; Levy, 2009; Mandala et al., 2009; MMWR, 2013; Rosen & Fox, 2011; Weigel et 
al., 2012; Wettstein et al., 2012; Zachariah et al., 2006). Although I was unable to provide 
a comprehensive investigation of all these factors influencing implementation, I was able 
to record adherence to PMTCT through an analysis of survey data. ANC attendance, HIV 
testing, and ARV use by HIV positive mothers and exposed infants were examined 
through the survey. 
The final factor, maintenance, assesses the stability of public health interventions 
and their inclusion into normal processes. I assessed this factor by examining the 
institutionalization of PMTCT interventions at a policy level. There is considerable 
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commitment to PMTCT in Malawi as evidenced by the adoption of Option B+. Option 
B+ is the novel PMTCT prevention strategy to put all HIV positive pregnant and 
breastfeeding women on ARVs for life regardless of clinical stage or CD4 count (see 
section 2.3.1.1 .). This strategy has great potential to reduce vertical infection through 
maximum coverage of infected mothers (MMWR, 2013; Schouten et al. , 2011), and 
requires careful and rigorous evaluation to ensure it is performing to its potential. The 
data resulting from the evaluation is uniquely positioned to serve as baseline for an 
evaluation of Option B+ as it is scaled up as the primary PMTCT strategy in Malawi. For 
this factor I also examined elements integrated into the evaluation design to support 
sustainability. 
The RE-AlM model was selected as the framework for the evaluation as its five 
factors take the complexity of implementing public health interventions in the real. world 
into account. This framework informed the analysis ofthe effectiveness ofPMTCT in 
Malawi by providing contextualizing information to the primary outcome variable, MTC 
HIV transmission rate. 
29 
Table 201 0 Applying RE-AlM to PMTCT Evaluation- Defmitions and Measurement 
RE-AlM Factor Definition* Measurement 
Reach # people & % of target population Characteristics of participants in 
affected & the extent to which the the evaluation- survey data 
individuals reached are 
representative 
Efficacy A measure of effects on health Existing literature 
behaviors 
Adoption # & % of settings participating & MOH district & health facility 
representativeness of settings data on provision of PMTCT 
Implementation Level of adherence to Implementation of PMTCT -
implementation guidelines survey data 
Maintenance Change is maintained on the Commitment to PMTCT on the 
setting-level policy level; components 
designed into the evaluation that 
support sustainability 0 0 
*from Kmg (Kmg et al., 2010), defimtwns abbreviated 
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CHAPTER 3: RESEARCH DESIGN AND METHODS 
3.1. Project Overview 
This project is an outcome evaluation ofPMTCT programs in four districts in 
Malawi, adapting a surveillance system based in under-5 clinics where immunizations are 
provided. The vertical transmission rate of HIV from mother to child was calculated 
through testing heel stick DBS samples collected from infants attending their first 
immunization visit. A cross-sectional design was employed using a multi-stage cluster 
sampling to select the four districts and 53 health facilities sampled. Within health 
facilities, caregiver infant pairs in the under-5 clinics were sampled consecutively. 
Figure 3 .1. depicts the flow of the evaluation for eligible participants. All 
caregivers of infants younger than 3 months of age attending the under-5 clinic at 
participating health facilities for the infant's first immunization were invited to 
participate in the evaluation. DBS samples were collected via heel stick from infants 
whose caregivers consented for their participation. In conjunction with the sample 
collection, caregivers were surveyed to characterize the sample and gather information on 
the mother's experiences with PMTCT. All invited caregivers and infants were offered a 
rapid HIV test (RHT) to allow them to immediately know their status and be linked to 
care if needed. The RHT was included as a service to allow us to be responsive to the 
needs of the participants as testing the DBS sample returning the result was anticipated to 
take up to eight weeks. Due to the presence of maternal antibodies, a positive RHT test 
for an infant does not necessarily indicate the infant is HIV positive, but a positive RHT 
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result is strongly indicative of HIV exposure. The standard confirmatory test to determine 
infant infection is a DNA-PCR test, which was used in this evaluation on HIV-exposed 
DBS samples. 
Figure 3 .1. Evaluation Flow Diagram 
All infants attending thei r first 
immunization visit 
(< 3 months old) 
Caregiver invited to participate in 
PMTCT surveillance project 
to participate 
Infant heel stick, caregiver survey 
questions 
available to caregivers 
RHT offered to all 
caregivers & 
infants 
The DBS samples were sent to the MOH National HIV Reference Laboratory in 
the capital, Lilongwe, and were first tested for the presence of HIV antibodies using an 
enzyme-linked immunosorbent assay (ELISA) test. If a pregnant woman is HIV -positive, 
her HIV antibodies transfer to her baby during pregnancy. The presence of maternal HIV 
antibodies does not indicate the infant is HIV positive, but rather that the infant is HIV 
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exposed (Horwood et al., 2010). If an infant's DBS sample tested positive for HIV 
antibodies, (indicating maternal HIV infection), the sample was transferred to the 
University of North Carolina (UNC) laboratory, also in Lilongwe, for a DNA PCR test to 
determine the infant's HIV status. All test results were sent back to their clinic of origin 
to be returned to infant caregivers at the infant's next immunization. 
Planned activities to assess the implementation ofthe surveillance methodology 
included conducting a data collector training satisfaction survey, documenting sample 
collection and site issues through using an evaluation-specific supervision form, 
providing space on the survey to collect information from eligible caregivers who refused 
to participate, and examining the survey and DBS data for quality. 
3.2. Study Infrastructure 
3.2.1. Collaborating Organizations 
Management Sciences for Health (MSH), a nonprofit international health 
organization, led the evaluation with funding from USAID. The Ministry of Health 
(MOH) of Malawi partnered in all aspects of the study with representatives from the 
Epidemiology Unit, the HIV/AIDS Department, and the National HIV Reference 
Laboratory. Other collaborating organizations were non-governmental organization 
(NGO) Dignitas International and the University ofNorth Carolina Laboratory in 
Lilongwe. 
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3.2.2. Evaluation Personnel 
Lead study staff included representatives from Boston University School of 
Public Health (BUSPH), MSH, and the Malawi MOH. Lead study staff conceived of the 
evaluation and led its planning and implementation. Study staff from BUSPH, MSH, 
MOH, and local District Health Offices (DHO) led data collector trainings and conducted 
supervision visits to participating health facilities during data collection. Study data were 
analyzed by BUSPH. Additional evaluation personnel included the data collectors, data 
entry assistants, and laboratory personnel. 
Data Collectors- Existing staff from the selected health facilities were trained as 
data collectors. Rather than hiring dedicated, professional data collectors, the MOH 
strongly recommended the use of health facility staff, reasoning that any aspect of the 
evaluation that can be feasibly incorporated into existing structures should be 
incorporated to support sustainability. The evaluation was launched as a pilot with the 
intention of both repeating and expanding the methodology to become a regular 
surveillance activity; hence sustainability was a paramount consideration. The use of non-
professional research staff was not anticipated to be problematic as data collection for 
similar efforts, namely MOH-run antenatal care (ANC) surveillance survey, is conducted 
by existing health facility staff. 
One concern of using health facility staff expressed prior to data collection was 
how they would balance normal clinical responsibilities with the added activities of the 
evaluation. Due to the short duration of data collection (eight weeks) the disruption was 
expected to be insignificant. Some higher-volume health facilities were expected to fulfill 
34 
their sample size quickly and thus return to normal routines earlier. Additionally, since 
immunizations are not offered every day except district-level hospitals, the disruption to 
the overall health facility routine would be minimal. 
Data collector responsibilities included recruiting participants, obtaining informed 
consent, collecting the DBS samples, surveying caregivers, returning results, and 
providing referrals. Data collectors attended district-level training. In addition training 
was provided in their health facility at the launch of the study about three weeks after the 
district training. 
Data Entry Assistants- Data entry assistants based at the MSH offices in 
Lilongwe conducted data entry of survey forms and lab results. The data were entered 
into a Microsoft Access database. All survey data and laboratory results were double 
entered and checked for consistency. 
Laboratory personnel- The National HIV Reference Laboratory was contracted 
for ELISA testing and the UNC laboratory for DNA PCR testing. The National HIV 
Reference Laboratory tests samples for national ANC surveillance and the DHS. 
Laboratory managers participated in the training of data collectors and joined supervision 
visits to ensure the proper collection of DBS samples. 
3.3. Sample Size 
The projected confidence intervals for a range of possible sample sizes are 
presented in Table 3.1. Confidence interval widths were calculated based on an estimated 
prevalence of 11% (Government of Malawi, 2010b), an estimated transmission rate of 
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13.8% (Government of Malawi, 2010a) and an alpha-level of 5%. 
I calculated 10 possible sample sizes to determine how precisely I could estimate 
MTCT given budgetary constraints. I concluded that collecting 5,455 samples to obtain 
about 600 HIV -exposed samples balanced the need for precision with limited resources 
(yellow highlighted row) (Lohr, 1999). The reasonably precise confidence interval width 
of 5.5% allows us to be 95% confident that the true transmission rate is within about 2.75 
percentage points above or below our point estimate, while collecting a realistic number 
of samples given resources. Based on the then current estimated transmission rate 
(13.8%), I expected approximately 83 ofthe 600 exposed infants to be HIV positive. 
Table 3.1. Single Group Table- Project Sample Size Calculation2 
Sample Size 
Sample Size Est. of Exposed Est. 
of All (N) Prevalence (N) Transmission Alpha-level CI Width 
909 11.0% 100 13.8% 5.0% 13.4% 
1,645 11.0% 181 13.8% 5.0% 10.0% 
1,818 11.0% 200 13 .8% 5.0% 9.5% 
2,727 11.0% 300 13.8% 5.0% 7.8% 
3,636 11.0% 400 13.8% 5.0% 6.7% 
4,545 11.0% 500 13.8% 5.0% 6.0% 
5,455 11.0% 600 13.8% 5.0% 5.5% 
6,364 11.0% 700 13.8% 5.0% 5.1% 
7,273 11.0% 800 13.8% 5.0% 4.8% 
8,182 11.0% 900 13 .8% 5.0% 4.5% 
The goal was to invite about 7,000 caregiver-infants pairs to participate, thereby 
allowing up to 22% of invited participants to refuse and still permit the target sample size 
2 The estimated prevalence is for women in Malawi between the ages of 15-49. 
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to be reached. The 22% refusal rate was considered conservative and more than double 
the 10% refusal rate experienced by the Rollins study (Rollins et al., 2009), the South 
African model for this evaluation. Refusal rates for other MSH Malawi activities in 
which biological samples have been collected have similarly been low at about 10% or 
less. 
3.3.1. Estimated Time to Achieve Sample Size 
Prior to data collection, study staff from MSH and MOH visited each of the 
districts to inform the District Health Officer about the study and gather information on 
immunization numbers from each district. The immunization program in Malawi is called 
the Expanded Programme on Immunization (EPI). EPI for infants is conducted in under-5 
clinics. District EPI data were used for developing the sampling frame (which is 
discussed in additional detail below in section 3.4.) and to determine that about eight 
weeks of data collection would be needed to achieve the sample size. 
3.4. Sampling 
Multi-stage cluster sampling was employed for selecting study districts and health 
facilities. Within health facilities, caregiver-infant pairs who met the inclusion criteria in 
the under-5 clinic were sampled consecutively. 
3.4.1. Selected Districts 
Four of28 districts in Malawi were selected purposively for data collection. The 
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districts were chosen primarily to reflect regional diversity. Accessibility was also 
considered in district selection as several districts are extremely remote. Likoma, for 
example, is a district composed of two islands in Lake Malawi in closer proximity to the 
Mozambique coast than to the Malawi coast. An additional factor in the selection of 
districts was access to HIV treatment for study participants identified as exposed or HIV 
positive. High-quality, accessible treatment services for infected infants and adults are 
available in the selected districts through the MOHand, in Zomba, through the NGO 
Dignitas International. An additional consideration in district selection was the likelihood 
to rapidly scale up Option B+ as districts vary in their capacity to provide health services 
to the district population. The results from this evaluation are expected to act as baseline 
when examining the effectiveness of Option B+. 
The four districts selected for data collection were: Nkhata Bay (Northern region), 
Salima (Central region), Mulanje, and Zomba (Southern Region) (see the district level 
map of Malawi Figure 3.2.). Districts were sampled proportionate to HIV prevalence, and 
as HIV prevalence is twice as high in the Southern region (17.6% compared to 8.2% and 
9.0% in the North and Central regions respectively), twice as many districts were chosen 
in that region (National Statistical Office & ICF Macro, 201 0). 
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Figure 3.2. District-Level Map3 
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3.4.2. Selected Health Facilities 
The under-5 clinics in 53 health facilities were sampled across the four selected 
districts (Table 3.2.). The number of facilities sampled per district was selected 
proportional to population size, however, health facilities in Nkhata Bay were 
oversampled (collected data from 10 facilities instead of six), due to the small number of 
immunizations per month at facilities in Nkhata Bay and the limited window for data 
collection. The intended number of caregiver-infant pairs to invite from each district is 
presented in Table 3.3 . The number per district was proportionate to population size of 
the districts to reach the goal of inviting 7,000 caregiver-infant pairs to achieve the 
sample size of 5,455. 
The sampling frame of health facilities was developed with consideration of 
geographic accessibility and EPI data. A complete list of health facilities in each selected 
district was obtained from the DHOs. Total number of health facilities in each district 
was as follows: Nkhata Bay 29, Salima 20, Mulanje 25, and Zomba 39. Health facilities 
were removed from the sampling frame for three reasons. First, health facilities were 
eliminated if determined to be too difficult to access . One site in Nkhata Bay was 
excluded because it is accessible only by boat. Next, using EPI data, health facilities were 
excluded if they gave fewer than 40 immunizations on average per month in 2010. Two 
health facilities in Mulanje and 10 health facilities in Zomba were excluded for this 
reason. This rule was not applied in Nkhata Bay as only seven of the 21 health facilities 
in the district gave over 40 immunizations on average per month in 2010. Finally, health 
facilities were excluded from the sampling frame if no EPI data were available. Three 
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health facilities in Salima, three in Mulanje, and three in Zomba were excluded because 
of a lack of EPI data. The resulting sampling frame contained 28 eligible health facilities 
in Nkhata Bay, 17 in Salima, 20 in Mulanje, and 26 in Zomba. 
Table 3.2. Number of Sites and Target Number of Samples to be Collected by District 
District Population Proportion of #samples to #sites per 
the total be gathered district 
population 
NkhataBay 213 ,800 12% 855 10 
Salima 340,300 19% 1,361 10 
Mulanje 525,400 30% 2,102 15 
Zomba 670,500 38% 2,682 18 
Total 1,750,000 100% 7,000 53 
Health facilities were stratified to sample proportionately by urban and rural 
location. However, as Nkhata Bay and Mulanje have one urban health facility each, and 
Salima has two, all urban sites from those three districts were automatically selected. All 
urban and rural health facilities in Nkhata Bay, Salima, and Mulanje were sampled 
proportionate to the average number of first immunizations (the pentavalent vaccine) the 
health facility gave per month in 2010. Zomba has 13 urban health facilities, all located 
in the city of Zomba. Ten of the urban health facilities were excluded from the sampling 
frame due to a low average number of immunizations per month in 2010 (seven health 
facilities) or due to EPI data missing entirely (three health facilities) . All of the remaining 
three urban health facilities were included as data collection sites. As the majority of 
Malawians live in rural areas (over 80%) (Food and Agriculture Organization ofthe 
United Nations, 2011), the urban health facilities in Zomba were sampled proportionate 
to the population of the city compared to the rest of the district (13%) to avoid 
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oversampling urban caregivers-infant pairs. 
Table 3.3. Target Number of Samples from Selected Health Facilities 
Health Facility Name #samples Health Facility Name #samples 
Nkhata Bay DH 211 SalimaDH 227 
Chinteche 118 Old hospital 109 
Liuzi 84 Chipoka HC 162 
Khan de 80 Khombedza HC 147 
Maula 79 GamangaHC 143 
Mpamba 79 Thavite HC 131 
Kachere 72 Senga BayHC 114 
Kavuzi 55 Chinguluwe HC 112 
Tukombo 50 Kaphatenga HC 109 
Chilambwe 50 MchokaHC 107 
· Total 877 Total 1,361 
Mulanje District 15 Sites Sampled Zomba District 18 Sites Sampled 
Health Facility Name #samples Health Facility Name #samples 
Mulanje DH 200 Zomba- 3 urban sites 
Mulanje Mission 285 Matawale 75 
MpalaHC 235 City Clinic 71 
Mulomba HC 193 ZA C.Hosp 232 
Muloza HC 184 Total 378 
MimosaHC 160 Zomba- 15 rural sites 
Namasalima HC 154 May aka 343 
ChambeHC 133 Pirimiti 248 
MbizaHC 106 Makwapala 229 
ChinyamaHC 102 Ngwelero 170 
Kambenje HC 86 Chamba 153 
Chisitu HC 77 Nasawa 145 
Bondo HC 69 Magomero 141 
Lujeri HC 63 Thondwe 134 
Namulenga HC 53 Namikango Mat 134 
Total 2,102 Lambulira 133 
Domasi 126 
Namasalima 112 
St,Luke's 103 
Chilipa 84 
Naizi 77 
Total 2,333 
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The random digit generation function in Microsoft Excel was used to select the 
rural health facilities to be sampled from the sampling frame in each district. The target 
number of samples to be collected from the health facilities by district is included in 
Table 3.3. The target number of samples was calculated proportionate to population size. 
The exception was in three health facilities (two in Nkhata Bay and one in the city of 
Zomba) where the calculated proportion would set the target number of samples below 
50. Fifty was set as the minimum target number of samples that could be collected from 
each health facility. 
Some health facilities have outreach sites visited by health workers who 
periodically provide care in more remote sections of the district. Some outreach sites 
have a physical presence, such as a building or a room in a building, while other outreach 
sites are locations with no physical building (e.g. services are provide under a tree). Due 
to the general lack of appropriate space and time for DBS samples to be dried dust-free 
prior to transport, the outreach sites of health facilities were excluded from data 
collection. 
3.5. Recruitment 
3.5.1. Recruitment Procedures 
At each selected health facility, caregivers whose infant received her or his fust 
immunization (scheduled to occur at six weeks of age) was invited to participate in the 
evaluation by health facility staff trained as data collectors. The Malawi infant 
immunization program is strong with participation rates at 90% for the pentavalent 
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vaccine (a single shot that includes diphtheria, tetanus, pertussis, Hib, and hepatitis B 
vaccines) that is scheduled for the six-week visit (National Statistical Office Malawi & 
UNICEF, 2006; WHO & UNICEF, 2009; WHO, 2012c). Therefore, sampling at 
immunization clinics would provide an approximation of the total population of mother-
infant pairs in Malawi. Although all caregivers (not only mothers) bringing an infant into 
the under-5 clinic for her or his first immunization visit were invited to participate in the 
evaluation, we expected the vast majority of caregivers would be the infant's mother, 
similar to Rollins ' findings in South Africa where almost 85% of immunization clinic 
attendees were the infant's mothers (Rollins et al., 2007). 
Participant recruitment involved health facility staff identifying caregivers whose 
infant presented to receive her or his first immunization. The Rollins studies, which 
occurred in similar settings (Southern Africa in areas of high HIV prevalence) found high 
participation rates using similar recruitment procedures (87% to 90% accepting in three 
separate studies) (Horwood et al., 2010; Rollins et al., 2007, 2009). 
Data collector training highlighted the importance of inviting all eligible infants 
and caregivers who enter the under-5 clinic to receive the infant' s first immunization to 
participate in the evaluation. The level of participation in the evaluation was to be 
assessed by retaining incomplete forms listing district, health facility name, and reason 
for refusal to participate. 
3.5.2. Subject Identification 
Subject identification procedures varied by health facility. Rather than prescribing 
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a specific process for identifying participants that would not account for the considerable 
variation in health facility procedures, during training representatives from each health 
facility were asked to describe how they planned to recruit and implement the study at 
their facility. These presentations provided an opportunity for the trainers and the other 
data collectors to identify problems, solutions, and alternative processes. Additionally, 
general best practices for recruiting were shared. For example, some health facilities 
provide education to caregivers in the under-5 clinic waiting areas. The health education 
talks were identified an opportunity to inform caregivers about the evaluation. The need 
to inform other health facility staff of the study was also highlighted to facilitate 
recruitment. Some facilities have dedicated staffto screen patients and send them to the 
appropriate clinic within the facility for cared. During the trainings, data collectors and 
study staff determined that these staff members, in particular, should be informed about 
the evaluation to ensure eligible infants were recruited into the evaluation. 
3.5.3. Inclusion Criteria 
The evaluation was limited to infants younger than three months who were 
brought to the under-5 clinic for their first immunization. The surveillance methodology 
used relies on identifying exposed infants through maternal antibodies. Maternal 
antibodies clear from infants at varying rates and are usually undetectable by nine 
months, but may be detectable up to 18 months of age (Gulia, Kumwenda, Li, & Taha, 
2007; Homsy et al., 2007). One study found the time that the ELISA test stops detecting 
maternal antibodies in exposed, but uninfected infants, ranges from 18 to 82 weeks 
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(Chantry et al., 1995). For infants between 1.5 and three months, rapid HIV testing 
(RHT) in Uganda was found to have 6.5% specificity due to the persistence of maternal 
HIV antibodies in infant blood (Homsy et al., 2007). The implication is that, even in 
infants three months of age or younger, approximately 5% of exposed but HIV -negative 
infants will not test positive for maternal antibodies. Consequently, using the presence of 
maternal HIV antibodies to identify HIV exposed infants becomes increasingly less 
precise. The older the infant, the more likely the maternal antibodies may have cleared 
from the infant' s system, thus we would miss identifying exposed infants. To ensure the 
identification of infants exposed to HIV is as accurate as possible; samples were only 
collected from infants at their first immunization visit up to three months of age. Infants 
were tested for HIV exposure rather than mothers to ensure infants not brought in by their 
mothers were not missed. The transmission rate would be underestimated if infants 
brought in by other caregivers were excluded because the mother died ofHIV. 
An additional inclusion criterion concerned the caregiver' s relationship to the 
infant. It must be one in which she or he can consent for biological data to be collected 
from the infant. Appropriate caregiver roles included mother, father, or legal guardian. 
3.5.4. Exclusion Criteria 
Any infant three months of age or older was excluded from participating, even if 
the infant was brought in for her or his first immunization. Additionally, an infant could 
only participate in this evaluation once; therefore any infant who had already participated 
was excluded. 
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3.6. Data Collection 
Once eligible caregiver-infant pairs were identified, the caregiver was read a very 
brief description of the study and was invited to participate. Informed consent was 
obtained from those who agreed to participate, and a single, optional question was asked 
of those who refused to participate to learn the reason for their refusal. The caregiver' s 
reason for refusal was intended to be recorded on the data collection form and to be 
analyzed to inform adjustments to future iterations of the evaluation. 
Participation in the study included answering survey questions on mothers' 
participation in PMTCT and a heel stick blood sample from the infant for HIV testing. 
Data collection involved a one-time interaction between data collectors and caregiver-
infant pairs. There was no follow-up data collection for this study, although caregivers 
interacted again with health facility staff in the context of the evaluation when infant HIV 
test results were returned. 
3.6.1. Data Collection Instruments 
The instruments used in this evaluation were: PMTCT Evaluation Screening and 
Questionnaire form (referred to as "the survey") and the DBS filter paper (biological 
sample). Identical numerical bar code labels were used as ID numbers to connect all data 
to each caregiver-infant pair. The ID number was also the mechanism to allow HIV test 
results to be returned to infant caregivers. Details on the ID number are included below 
(section 3.6.3.). 
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3.6.1.1. PMTCT Evaluation Screening and Questionnaire Form 
For logistical purposes and to ensure all evaluation activities were conducted in 
the appropriate order, the screening, informed consent, and questionnaire forms were 
combined into one document ("the survey") (see Appendix A). After completion, the 
survey was labeled with a unique ID number sticker to link it to companion records from 
the same caregiver-infant pair in the evaluation. 
The survey begins with the screening section to filter out ineligible participants. 
The first four questions in the screening section are for administrative purposes and do 
not require information from the participant. These questions (district name, clinic name, 
interviewer name, and date) were used to stratify the data by district and health facility. 
Additionally, supervisors were able to identify data collectors who needed additional 
training since the forms were collected and reviewed every two weeks during data 
collection. Questions five through eight in the screening section identified ineligible 
participants by asking for the date of birth of the infant, if the child younger than three 
months of age, if the child was at the under-5 clinic for her or his first pentavalent 
vaccine, and if the caregiver was the infant's biological mother or the legal guarding aged 
18 years or older. 
The date of birth of the infant was obtained by the data collector either by asking 
the caregiver for that information, or, preferably, by checking the infant's health passport. 
Health passports are a common and accepted transportable medical record in Malawi. 
Every individual is provided a health passport in which health facility staff record 
information from each clinic encounter. By recording the exact date of birth from the 
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health passport, ineligible infants were not included in the analysis due to a calculation 
error or misinterpretation of the less-than-three-months eligibility requirement. The 
survey prompted data collectors to screen out potential participants who responded "no" 
to questions six through eight (younger than 3 months of age, at clinic for pentavalent 
vaccine, caregiver is mother or legal guardian). 
If caregivers and infants were deemed eligible through the screening section, the 
form then prompted the data collector to read a one sentence description and invitation to 
join the evaluation. If the caregiver agreed, the survey then prompted the data collector to 
obtain informed consent. If the caregiver refused to participate, the data collector was 
prompted by the survey to ask for the reason for refusal and record the response in space 
provided. 
For those who agreed, the two-page informed consent document was included as 
the last two pages of the survey. The form was written in Chichewa, the official language 
of Malawi. The bottom of the informed consent form contained space for caregivers to 
sign or mark their agreement to participate. 
After obtaining informed consent, the questionnaire section of the survey began. 
This section comprised of 12 questions with the first seven questions about the health 
status of the infant's mother, including questions on ANC, labor and delivery, and prior 
HIV testing. The last five questions queried PMTCT management of the mother and 
infant, and breastfeeding. These data were intended to provide information on coverage 
of PMTCT interventions among pregnant women in the chosen districts. 
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3.6.1.2. Dried Blood Spot (DBS) Sample on Filter Paper 
The second data collection tool was the filter paper for collecting the DBS sample 
from the infant. DBS is a preferred method for collecting biological samples from infants 
as it requires simple supplies and little blood. DBS samples can be transported easily as 
they are light weight and safe (Biggar et al., 1997). Training for early infant diagnosis 
(EID) programs was launched as a clinical care program in 2011. EID was rolled out in 
health facilities across the country and included DBS collection training. Some of the 
data collectors in the evaluation had already been trained in DBS collection from the EID 
program. All data collectors were trained or re-trained on collecting DBS samples by lab 
technicians from the National HIV Reference Laboratory prior to data collection. 
The DBS samples were collected using a spring-loaded, single-use lancet to prick 
the inner side of the infant's heel. Blood from the puncture site was dripped directly onto 
circles on the filter paper. Data collectors were trained to fill at least three of four circles 
and were taught the difference between valid and invalid DBS. Data collectors labeled 
each DBS filter paper to match the ID number on the survey form for each caregiver-
infant pair. Samples were dried overnight and sealed in batches in envelopes with 
desiccant. Supervisors collected and transported DBS samples every two weeks during 
data collection from the health facilities to the laboratory to be tested. 
3.6.2. PMTCT ID Survey Register 
The PMTCT ID Survey Register was created as a health facility-based companion 
to the evaluation. One Register was placed in each participating health facilicy. The 
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Register had two purposes; first it allowed the health facilities to track the number of 
participants at their site and thereby know when they had reached their sample size and 
could end data collection. Second, the Register was the link between study ID number 
and infant name to allow the infant's HIV test results to be returned. Only health facility 
staff, who would already have access to confidential health information like HIV test 
results, could link names to study ID numbers. The Register also recorded if the test 
results were returned to the caregiver. 
3.6.3. ID Number 
Each caregiver-infant pair was assigned a unique 4-digit ID number to link all 
their evaluation data. The process for generating the ID numbers was modeled after the 
national ANC surveillance data collection that occurs every two years. ID numbers were 
pre-printed on barcode stickers with consecutive, non-repeating numbers and distributed 
to all the health facilities collecting data with other evaluation materials. 
When a caregiver agreed to participate in the evaluation, matching ID numbers 
stickers were placed on the survey, the DBS filter paper, the PMTCT Survey ID Register, 
and in the infant' s health passport. The matching stickers on the survey and filter paper 
allowed for the survey responses with the DBS test results to be linked for the analysis. In 
addition, the ID number sticker in the infant ' s health passport alerted health facility staff 
that the infant participated in the evaluation and the results should be returned. 
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3.6.4. Laboratory Testing 
DBS samples were sent to the MOH National HIV Reference Laboratory in 
Lilongwe every two weeks when picked up from health facilities during data collection. 
At the laboratory, each DBS sample was first tested for the presence ofHIV antibodies 
using an enzyme-linked immunosorbent assay (ELISA) test. If a sample tested positive 
for HIV antibodies, (indicating maternal HIV infection), a second blot from the filter 
paper was tested by DNA Polymerase Chain Reaction (PCR) test to determine if the child 
was infected as well. The DNA PCR test was conducted at the UNC laboratory at 
Kamuzu Hospital in Lilongwe. 
Considerations for selecting the partner laboratory included sustainability, 
timeliness, and budget constraints. The National HIV Reference Laboratory agreed to 
conduct the initial ELISA test on the collected samples. The samples with positive 
ELISA results were sent to the UNC laboratory for DNA PCR testing as National HIV 
Reference Laboratory did not offer PCR testing at that time. Prior to data collection, we 
anticipated about 600 samples would test positive for exposure and would be forwarded 
from the National HIV Reference Laboratory to the UNC laboratory. 
The DBS samples were collected during the bi-weekly supervision visits during 
data collection, and sent in batches to the National HIV Reference Laboratory for testing. 
It was anticipated that the test results would be returned to the health facilities within 
eight weeks of the sample being drawn. As the first immunization visit for infants is 
scheduled at six weeks of age, the timeframe fit with returning the results to caregivers 
when the infant returned for her or his 14-week immunization. 
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3. 7. Returning Results 
After processing, the laboratories returned all results to the health facilities where 
the sample originated, and MSH in Lilongwe for data entry. HIV test results came in four 
permutations: infant is HIV positive; infant is HIV negative, but is exposed; infant is not 
exposed to HIV; or the results are inconclusive. Specific protocols developed around 
returning each ofthese types of results to caregivers, and are further described below. 
Caregivers were told to return for the infant HIV test results eight weeks after the sample 
was drawn or at the infant's 14 week immunization visit. 
Returning a Positive Result: All DBS samples that test positive for antibodies 
with the ELISA test were then tested with DNA PCR to determine the infant's HIV 
status. Every effort was made to return all DNA PCR positive tests, indicating infant HIV 
infection. Given high mortality rates (50% of infected infants die before their second 
birthday if untreated (Newell et al. , 2004)), was crucial to link infected infants to care and 
treatment. All data collectors were trained to return test results confidentially. 
Returning a Negative Result with a Positive Antibody Test: Infants who had a 
positive ELISA but negative DNA PCR test were at continued risk for HIV infection if 
they were still being breastfed. Caregivers of these infants were counseled on 
breastfeeding best practices. Breastfeeding mothers could also start on ARV s if not 
already initiated. 
Returning a Negative Result: The results of DBS samples that tested antibody 
negative were returned to health facilities without being forwarded on for testing with 
DNA-PCR. The infants who were antibody negative with ELISA were most likely HIV 
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negative. 
Returning an Inconclusive Result: Standard practice for inconclusive test results 
was to recommend the mother take a rapid HIV test (RHT) to determine the mother's 
status. If positive, we recommended the infant should be enrolled in EID for DNA PCR 
testing. If the mother was not available for testing and no information on her HIV status 
was available, health facility personnel were recommended to perform a rapid HIV test 
(RHT) on the infant. Although an RHT test has low specificity for detecting the presence 
of infection in young infants, it can be used as a screening tool to identify exposed infants 
(Menzies et al., 2009). Infants who were positive for exposure to HIV can be enrolled 
into EID and tested with DNA PCR, the standard confirmatory test for infants. 
3. 7.1. Ethical Considerations of Returning Results 
High levels of stigma continue to exist around HIV in Malawi (Chinkonde, 
Sundby, & Martinson, 2009; Dlamini et al., 2007), thus the privacy of HIV positive 
mothers and their infants were protected during the evaluation in three distinct ways. 
First, all aspects of participating in the evaluation were voluntary. Caregivers could 
refuse to participate if they were concerned about the social consequences of a positive 
HIV test. Secondly, all health facility personnel returning results were trained to do so 
confidentially. Finally, the use of identification numbers helped protect the 
confidentiality of the participants. 
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3.8. Data Flow 
Figure 3.3. depicts the flow of data to and from the health facilities. DBS samples 
and the survey were picked up by supervision teams every two weeks from the health 
facilities . The supervision teams were composed of MSH, MOH, laboratory 
representatives, and DHO representatives. DBS samples were taken to National HIV 
Reference Laboratory for processing. DBS samples that tested positive for maternal HIV 
antibodies were forwarded in batches to the UNC laboratory for DNA PCR testing. 
Samples that were ELISA negative at the National HIV Reference Laboratory were sent 
to MSH and MOH for data entry and analysis, and back to the health facilities to be 
returned to caregivers. The results were transported back to the health facilities at the end 
of data collection. Similarly, all test results from the UNC laboratory were sent to MSH 
and MOH for data entry and analysis, and back to health facilities to be returned to 
caregivers. The survey forms were delivered to MSH and MOH for processing, data 
entry, and analysis. 
55 
Figure 3.3. Data Flow Diagram 
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To ensure the evaluation was responsive to the immediate needs of the 
community, voluntary rapid HIV tests (RHT) were offered to caregivers and infants 
during the data collection interaction with health facility staff. RHT test kits were 
supplied to all facilities implementing the evaluation and were offered in addition to, not 
as an alternative to, the infant DBS sample collection. The RHT results allowed 
caregivers to know immediately if the infant should be linked to EID as the DBS test 
results were expected to take a minimum of eight weeks to be returned to the health 
facilities . Due to the presence of maternal antibodies, a positive RHT test does not 
necessarily indicate the infant is HIV positive, but a positive RHT result is highly 
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indicative ofHIV exposure. DNA-PCR is the standard confirmatory test. Caregivers 
would additionally benefit from knowing their HIV status, so they were also offered rapid 
tests. The RHTs were administered by the health facility staff trained in counseling and 
testing, not necessarily by the staff acting as data collectors. Rapid testing of infants did 
not replace the DBS test results, which is the diagnostic standard for infants, but allowed 
caregivers to link themselves and their infants to appropriate care sooner. 
3.10. Data Collector Training 
All data collectors participated in 1.5 days of training. Five trainings were held in 
sum; one in Nkhata Bay, one in Salima, one in Mulanje, and two in Zomba due to the 
larger number of health facilities involved in data collection in that district. Study staff 
from BUSPH, MSH, MOH, and the laboratories led the five trainings. All study staff 
attended the first training in Zomba to ensure standard procedures were then implemented 
in the subsequent trainings. Study staff broke into smaller training teams, each containing 
a member from MSH or BUSPH, MOH, and the laboratory for the remaining four 
trainings. 
The training covered research ethics, recruitment, screening, obtaining consent, 
data collection, data management, returning results, and linking to care. 
The training provided demonstrations and practice in addition to didactic 
components. Data collectors practiced administering the survey several times with a 
partner. Trainers collected the completed surveys, reviewed them, and provided 
corrections to errors in completing the survey. Data collectors also practiced DBS 
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collection, pricking each other's fingers, filling the circles on the filter paper, drying the 
samples overnight, and packaging them the next day of the training. A satisfaction survey 
was conducted at the end of the training to learn the data collector's perspective of what 
went well and what needed adjusting for future trainings. Trainers were also asked for 
feedback on the trainings. 
A training manual was developed based on materials from the Rollins study 
(Rollins et al., 2007, 2009) and existing MOH training manuals, and was provided to all 
data collectors. The training manual was limited to practical details for implementing the 
evaluation, and was intended to be used as a reference guide during data collection. 
Additional training of data collectors occurred at the launch of data collection 
approximately three weeks after the original training. Supervision teams composed of 
MSH, MOH, laboratory representatives, and DHO representatives went to each health 
facility to drop off study supplies and officially launch data collection. At least half a day 
was spent at each site to ensure study procedures were in place and to observe the first 
day of data collection. Supervising the first day of data collection was critical to ensure 
correct processes were in place from the start. 
3.11. Quality Control Procedures 
A variety of quality control procedures were implemented throughout the 
evaluation, starting with the development ofthorough training materials to ensure 
standard training and implementation of the evaluation. Additional procedures included 
plans for data quality checks during data collection, laboratory testing, and data analysis; 
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arranged opportunities to improve data quality during the eight weeks of data collection; 
and established standard processes for data entry. 
3.11.1. Non-Laboratory Quality Control Procedures 
Study staff from MSH, MOH, the laboratory, and DHO conducted quality 
assurance activities during supervision visits. Supervision team visits occurred ever two 
weeks to retrieve collected data, provide additional training, and conduct quality 
assurance activities. At each visit, supervisors examined the data collection forms and 
procedures to ensure data were being gathered correctly and completely, and that 
procedures were being followed. 
Study staff conducting supervision visits were also responsible for the practical 
aspects of quality for the evaluation, ensuring that collected samples were kept organized 
and transported appropriately, and ensuring evaluation supplies did not run out at the 
health facilities. 
Quality control procedures were put in place for data entry. Data entry assistants 
were hired to enter survey and lab data into Microsoft Access at MSH. All survey and 
laboratory results data were double entered to identify data entry errors. 
Data analysis began with data cleaning. Data were first checked for ineligible 
participants (e.g. infant older than 3 months, caregiver under 18 years of age), who were 
removed from the final data set. The data were also checked for outliers and implausible 
values. 
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3.11.2. Laboratory Quality Control Procedures 
The two laboratories that participated in the evaluation have existing quality 
control protocols in place. The primary activities of the National HIV Reference 
Laboratory are research and referral. The National HIV Reference Laboratory processes 
samples for national ANC surveillance and for the DHS Malawi survey, and also offers 
quality assurance services to other HIV testing sites. For example, one HIV testing site 
sends a DBS of every 20th client they test to The National HIV Reference Laboratory to 
be re-tested. The results are then compared to ensure concordance. If discordant, the 
discrepancy is investigated and corrective action is taken. 
The National HIV Reference Laboratory has enrolled in the WHO and US 
Centers for Disease Control and Prevention' s (CDC) Strengthening Laboratory 
Management Toward Accreditation (SLMTA), which helps laboratories in developing 
counties move towards accreditation. 
Laboratory staff provided information to MSH and MOH study staff on samples 
that were invalid from improper collection or otherwise compromised. This information 
was important for identifying health facilities and data collectors who would benefit from 
additional training or supervision. 
The National HIV Reference Laboratory implemented their standard quality 
assurance protocols for running ELISA samples. For ELISA, validation includes both kit 
controls and three CDC controls for every plate of ELISA samples they run. The CDC 
controls are HIV negative, low HIV positive, and high HIV positive. The optical densities 
of the controls are plotted on the Levy Jennings plot (a quality control graph) to monitor 
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trends over time. Validation also depended on the controls being within plus or minus 
two standard deviations of the mean. Any outlier was investigated. 
3.12. Human Subjects Protection and Confidentiality 
Precautions were taken in the evaluation to protect human subjects and guard the 
confidentiality of the data provided. Institutional Review Board (IRB) approval was 
obtained from Boston University Medical Center and the National Health Sciences 
Research Committee (the IRB for the Malawi MOH). 
All data collectors received 1.5 days of training including information on research 
ethics, protecting human subject rights, and appropriately acquiring informed consent. 
The ethics training used an NIH-approved module designed for international settings. 
During the evaluation design phase, potential .risks and benefits for study 
participants were identified. The primary risks were infant discomfort from the heel stick, 
and HIV status disclosure ofthe infant and/or the infant ' s mother. The risk of physical 
discomfort of the infant during sample collection was minimized by using DBS rather 
than more invasive venipuncture. Data collectors were trained on how to use the single-
use lancets, including the correct placement on the heel to collect the sample (the fatty 
inner portion of the underside of the heel, which may render the stick less painful). Data 
collectors were also trained in techniques to distract and comfort the infant. Despite 
possible physical discomfort, the heel stick is a quick and relatively painless procedure. 
Caregivers could also feel emotional distress from the infant's discomfort from the heel 
stick. Data collectors were trained to fully inform caregivers of the procedure, including 
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that the infant may feel pain, but that it would likely only last a matter of seconds. If the 
caregiver continued to feel uncomfortable, she/he could choose to discontinue 
participation in the evaluation. 
Regarding the risk of disclosure of status, given that HIV infection is stigmatized 
in Malawi (Chinkonde et al., 2009; Dlamini et al., 2007), caregivers may have felt 
concerned that their, or the infant's, HIV status could become disclosed through 
participating in the evaluation. The status of HIV positive mothers and infants was 
protected by training data collectors to understand and respect confidentiality. However, 
confidentiality could not be fully guaranteed, therefore during the consent process 
caregivers were encouraged to weigh the benefit of determining the status of their infant 
against the repercussions of possible disclosure when making the decision to participate. 
An additional protection against disclosure was to label study data with ID numbers 
rather than names. Only appropriate health facility staff (who would already have access 
to confidential health information, such as HIV status) had access to the PMTCT ID 
Survey Register where ID number and name were linked. 
Participation in the evaluation had potential benefits for caregivers and infants. A 
benefit of participating in the evaluation was that caregivers had the opportunity to learn 
the HIV status of their infants. If an infant was HIV positive, data collectors were trained 
to link the infant to care, a critical activity given high mortality rates among untreated 
HIV infected infants (Newell et al., 2004). Caregivers also had the opportunity to learn 
their own HIV status through the offer ofRHT. Any person identified as HIV positive 
was linked to appropriate care. 
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Participation in the evaluation was completely voluntary. Caregivers could 
withdraw at any time or refuse to participate in any portion of the evaluation. There was 
no follow-up data collection, although caregivers may have interacted again with health 
facility staff in the context of the evaluation when results were returned. 
Written informed consent was obtained from all caregivers prior to data 
collection. 
To protect the privacy of participants, data collection was required to be 
conducted in a space configured such that interactions could not be overheard. 
Additionally, all caregivers attending the under-5 clinic had equal access to participate in 
the study, so there was no mechanism for individuals who were HIV positive to be 
identified by virtue of agreeing to participate in the evaluation. 
Confidentiality of the data was protected by using unique ID numbers on the data 
collection instruments rather than names. Names and ID numbers are linked in the 
PMTCT ID Survey Register and in the infant's health passport only. Study data were 
linked to names in order for infant HIV test results to be returned to caregivers. Only 
health facility staff, who routinely have access to confidential health information, were 
able to link study ID number and participant name. Study staff only had access to de-
identified data for analysis. 
3.13. Analytic Methods 
The analysis calculated population and district level vertical transmission rate 
estimates and determined participation rates in PMTCT for mothers with ELISA positive 
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infants . 
This evaluation collected a multi-stage cluster sample, with larger sampling units 
formed by districts (sampled purposively) and health centers within the selected districts 
(sampled randomly). Given the clustered nature of the data, the observations could not be 
assumed to be independent. The source ofthe clustering is possible differences between 
the populations in the catchment areas of the health facilities sampled such that 
individuals attending one clinic may differ systematically from individuals attending 
another. Transmission rate and risk ratio estimates in this evaluation were calculated 
using Generalized Estimating Equations to account for the clustered nature of the data 
(Hardin & Hilbe, 2003). 
Preliminary analyses entailed running frequencies on all variables to characterize 
both the whole sample and the subset of participants who tested ELISA positive 
indicating HIV exposure. 
All analyses were undertaken using SAS software version 9.3 (SAS Institute Inc., 
2011). 
3.13.1. Analysis for Aim 1 
Aim I : Determine vertical transmission rate of infants attending their first immunization 
visit. 
The evaluation was designed to determine the transmission rate of HIV from 
mothers to infants in a context where some women fully participate in PMTCT, some 
women partially participate in PMTCT, and some women do not participate in PMTCT. 
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Transmission rates were calculated by dividing the number of infants found to be 
HIV positive through DNA PCR by the number of infants exposed to HIV (infants who 
tested antibody positive) as identified by an ELISA positive result. Transmission rate was 
presented overall and by the four study districts. A binary regression model with a log 
link was used to evaluate the effect of district on the transmission rate. Generalized 
estimating equations correction to the variance was used to account for clustering by 
health clinic. This model was fit using the GENMOD procedure in SAS. 
For this aim I originally intended to develop models to identify covariates 
associated with HIV transmission. However, given the small number ofHIV 
transmissions identified, inferential statistics beyond bivariate analyses would not have 
been appropriate. Bivariate risk ratios (RR) were conducted to examine the risk of 
transmission (dependent variable) related to variables associated with, or protective 
against, transmission in the literature (independent variables). Risk ratios were calculated 
using a binary regression model with a log link and Generalized Estimating Equations 
were used in these analyses to account for clustered data. The independent variables were 
collected via the survey and included mother's age, ANC attendance, previous testing, 
and use of ARVs. 
3.13.2. Analysis for Aim 2 
Aim 2: Determine the rate of participation in PMTCT among mothers whose infants 
receive their first immunization. 
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Survey data were used to examine participation in PMTCT. All analyses were 
stratified by district. First frequencies were run to document participation in early 
PMTCT activities (ANC attendance, HIV testing) by the whole sample given that all 
pregnant women are invited to participate in PMTCT until their HIV status is established. 
Next the analysis focused on participation in PMTCT by HIV positive mothers only, as 
defined by a positive ELISA test in this evaluation. In addition, we examined the 
frequencies of delivery-related risk variables, such as place of delivery (e.g. medical 
setting or home), and baby' s birth position (e.g. breech). Finally frequencies of specific 
AR V regimens taken by HIV positive mothers during pregnancy and labor were 
examined as the use of more or less efficacious regimens could impact vertical 
transmission. All frequencies were run using the Proc Freq function in SAS. 
3.13.3. Analysis of Pilot Implementation Data 
In addition to the stated research aims of determining the vertical transmission 
rate and examining participation in PMTCT by district, the evaluation was designed as a 
pilot to assess the performance of a novel methodology to evaluate PMTCT in 
immunization clinics. We formally and informally collected data throughout 
implementation to understand the success of the methodology. Assessment included 
gathering satisfaction information from participants during data collector training, 
documenting sample collection and site issues through an evaluation-specific supervision 
form, providing space on the survey to collect information from eligible caregivers who 
refused to participate, and examining the survey and DBS data for quality. 
66 
CHAPTER 4: RESULTS 
4.1 Characteristics of the Overall Sample 
The linked survey and DBS sample data for 5,068 caregiver-infant pairs were 
used in the analysis. Fewer caregiver-infant pairs were enrolled than the designated 
sample size (5 ,500 caregiver-infant pairs), however more exposed infants were identified 
(764) than expected given reported HIV prevalence rates for women 15-49 in Malawi 
(600 exposed infants were expected from the sample size calculation). Due to the larger 
number of exposed infants, the precision of estimates for vertical transmission from these 
data will be as good, or better, than originally planned. 
Eligible caregivers were parents and legal guardians 18-years-old and older. 
Although non-maternal caregivers were eligible, the majority of caregivers across all four 
districts were the infant's mother (98 .20%) (Table 4.1). A larger proportion of legal 
guardians participated in the study in Nkhata Bay compared to the other districts, but the 
overall number was low (22 individuals), comprising less than 5% of caregivers from that 
district. The average caregiver age was 25 years old, and the average infant age was 57 
days (about 8 weeks). Almost all mothers were reported to be healthy (99.19%), attended 
ANC (98.36%), and previously tested for HIV (94.45%). These proportions were 
similarly high across all four districts. 
67 
Table 4.1. Sample Characteristics, All Caregiver-Infant Pairs (N=5,068) 
Variables All districts Nkhata Bay Salima Zomba Mulanje 
Relationship to 
infant N=5,068 N=505 N=1,018 N=1,766 N=1,779 
Mom 4,977 (98.2) 475 (94.1) 1,009 (99.1) 1,734 (98.2) 1,759 (98.9) 
Legal guardian 33 (0.7) 23 (4.6) 1(0.1) 7 (0.4) 2 (0.1) 
Missing 58 (1.1) 7(1.4) 8 (0.8) 25 (1.4) 18 (1.0) 
Mother's age 
18-20 yrs 1,216 (24.0) 144 (28.5) 219 (21.5) 386 (21.9) 467 (26.3) 
21-30 yrs 2,866 (56.6) 294 (58.2) 591 (58.1) 1,004 (56.9) 977 (54.9) 
31-40 yrs 880 (17.4) 53 (10.5) 197 (19.4) 339 (19.2) 291 (16.4) 
40+ yrs 30 (0.6) 4 (0.8) 3 (0.3) 13 (0.7) 10 (0.6) 
Missing 76 (1.5) 10 (2.0) 8 (0.8) 24 (1.4) 34 (1.9) 
Mother's health 
Healthy 5,027 (99.2) 497 (98.4) 1,012 (99.4) 1,750 (99.1) 1,768 (99.4) 
Sick 20 (0.4) 5 (1.0) 4 (0.4) 7 (0.4) 4 (0.2) 
Dead 3 (0.1) 0 (0) 0 (0) 2 (0.1) 1(0.1) 
Missing 18(0.4) 3 (0.6) 2 (0.2) 7 (0.4) 6 (0.3) 
ANC 
Yes 4,985 (98.4) 495 (98.0) 1,011 (99.3) 1,739 (98.5) 1,740 (97.8) 
No 29 (0.6) 1 (0.2) 1 (0.1) 6 (0.3) 21 (1.2) 
Missing 54 (1.1) 9 (1.8) 6 (0.6) 21 (1.2) 18 (1.0) 
Mom HIV test 
result 
Never tested 163 (3.2) 25 (5.0) 17 (1.7) 53 (3.0) 68 (3.8) 
Neg 4,197 (82.8) 442 (87.5) 912 (89.6) 1,433 (81.1) 14,10 (79.3) 
Pos 590 (11.6) 30 (5.9) 80 (7.9) 233 (13 .2) 247 (13 .9) 
DK 44 (0.9) 4 (0.8) 7 (0.7) 15 (0.9) 18 (1.0) 
Missing 74 (1.5) 4 (0.8) 2 (0.2) 32 (1.8) 36 (2.0) 
4.2. Characteristics of ELISA Positive Caregiver-Infant Pairs 
Background characteristics of ELISA positive caregiver-infant pairs were similar 
to those ofthe overall sample (Table 4.2.). Ofthe infants who tested ELISA positive, the 
caregiver with the infant was most often the infant's mother (98.3%). One difference 
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between all respondents and the ELISA positive subset was in the sample of all 
respondents, a larger number of infants in Nkhata Bay were brought to the health facility 
by a caregiver who was not their mother. However among the ELISA positive infants in 
Nkhata Bay, only one legal guardian participated in the evaluation. An additional 
difference was that a smaller proportion of mothers were in the youngest age category 
(18-20 years) in the subset of ELISA positive infants compared to all infants enrolled in 
the evaluation. The proportion of mothers in the 31-40 year-old category almost doubles 
in the ELISA positive subset compared to participants overall (30.6% from 17.4%). 
Similar to the results of the overall sample, most mothers of ELISA positive infants 
reported to be healthy (98.3%), however the proportion of mothers reported to be sick is 
larger among the ELISA positive subset. In Nkhata Bay, sick mothers comprise about 1% 
Table 4.2. Sample Characteristics, ELISA Positive Caregiver-Infant Pairs Only (N=764) 
Variables All districts Nkhata Bay Salima Zomba Mulanje 
Relationship to N=764 N=46 N=106 N=293 N=319 
infant 
Mom 751 (98.3) 44 (95.7) 106 (100.0) 286 (97.6) 315 (98.8) 
Legal guardian 3 (0.4) 1 (2.2) 0 (0) 1 (0.3) 1 (0.3) 
Missing 10 (1.3) 1 (2.2) 0 (0) 6 (2.1) 3 (0.9) 
Mother's age 
18-20 yrs 72 (9.4) 5 (10.9) 5 (4.7) 27 (9.2) 35 (11.0) 
21-30 yrs 442 (57.9) 24 (52.2) 64 (60.4) 158 (53.9) 196 (61.4) 
31-40 yrs 234 (30.6) 16 (34.8) 36 (34.0) 104 (35.5) 78 (24.5) 
40+ yrs 7 (0.9) 1 (2.2) 0 (0) 2 (0.7) 4 (1.3) 
Missing 9 (1.2) 0 (0) 1 (0.9) 2 (0.7) 6 (1.9) 
Mother's health 
Healthy 751 (98.3) 42 (91.3) 105 (99.1) 287 (98.0) 317 (99.4) 
Sick 11 (1.4) 3 (6.5) 1 (0.9) 5 (1.7) 2 (0.6) 
Missing 2 (0.3) 1 (2.2) 0 (0) 1 (0.3) 0 (0) 
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of the sample among all participants, but comprise over 6% among the ELISA positive 
subset. These proportions, however, are small and represent very small absolute numbers 
(five mothers in the full sample, and three mothers in the ELISA positive subset). 
4.3. Results for Aim 1 
The first aim was to determine vertical transmission rate of infants attending their 
fust immunization visit. Transmission rates were calculated by dividing the number of 
infants found to be HIV positive through DNA PCR by the number of infants exposed to 
HIV (infants who test antibody positive with the ELISA test). Of the 5,068 DBS samples 
in the analysis, 764 tested ELISA positive indicating 15.1% (14.1-16.1 %) of mothers 
were HIV positive and passed HIV antibodies to their infant. Sixty-five of the 764 
ELISA-positive samples tested positive with DNA-PCR, indicating a vertical 
transmission rate of 8.5% (6.6-10.7%) across the four districts (Table 4.3 .). There was 
some cross-district variation with similar transmission rates in Nkhata Bay (1 0.9%), 
Salima (9.4%), and Mulanje (10.3%), and a lower rate in Zomba (5.8%). 
Table 4.3. Transmission Rates Overall and by District 
Overall NB Salima Zomba Mulanje 
PCRpos 65 5 10 17 33 
ELISA pos 764 46 106 293 319 
Transmission rate 8.5% 10.9% 9.4% 5.8% 10.3% 
(95% Cl) (6.6-10.7%) (3.6-23.6%) (4.6-16.7%) (3.4-9.1 %) (7.2-14.2%) 
p-value -- 0.91 0.81 0.02 ref 
70 
An additional43 mothers self-reported positive HIV status on the survey, but 
their infant' s DBS sample tested ELISA negative. There are several possible explanations 
for the discrepancy between the survey response and the laboratory results, including a 
previous false HIV positive test, a false negative study ELISA test, participant reporting 
error, data collector recording error, or the exposed infant may have already shed their 
maternal HIV antibodies. As the true reason for the discrepancy is not known, and as 
those DBS samples did not receive subsequent DNA-PCR testing, these 43 mother-infant 
pairs were not treated in the analysis as HIV positive or HIV exposed. 
Relative risks were run to identify covariates associated with transmission. Table 
4.4. presents the number and proportion ofPCR positive infants over ELISA positive 
infants, and the relative risk (RR) of transmission for factors associated with vertical 
transmission. The largest proportion of vertical HIV transmission occurred in the 
youngest age group of mothers; 12.5% of mothers aged 18-20 transmitted HIV to their 
infants, compared to about 8% or less for the other age groups, however the RR was not 
statistically significant. Transmission rates were also proportionally higher among 
mothers who did not attend ANC, delivered at home and/or with a Traditional Birth 
Attendant (TBA), never tested for HIV, did not receive HIV treatment during pregnancy 
or labor, and whose children did not receive prophylactic ARVs. Only infants who did 
not receive prophylactic ARVs after birth had a borderline significant (p=0.07) increased 
risk of transmission. 
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Table 4.4. Relative Risk ofHIV Transmission by Risk Factor Among ELISA Positive 
Infants 
Variables # ofPCR-pos/ #ELISA pos Relative Risk P-value 
(% ofELISA-pos) (95% Cl) 
Age of Mother 
18-20 years 9/72 (12.5) 1.3 (0.8-2.9) 0.19 
21-30 years (ref) 36/442 (8.1) 
31-40 years 20/234 (8.6) 1.0 (0.7-1.7) 0.84 
Mother Attended ANC 
Yes (ref) 631750 (8.4) 
No 1/5 (20.0) 2.4 (0.4-15.4) 0.36 
Place of Delivery 
Hospital or Clinic (ref) 53/649 (8.2) 
Home and/or with 121102 (11.8) 1.4 (0.8-2.4) 0.18 Traditional Birth Attendant 
Mother's Most Recent HIV 
Test Result** 
Positive (ref) 411546 (7.5) 
Never tested 3116 (18.8) 2.5 (0.8-7.7) 0.11 
Negative 201179 (11.2) 1.5 (0.9-2.6) 0.15 
Mother Received HIV 
Treatment During Pregnancy 
and/or Labor 
Yes (ref) 37/495 (7.5) 
No 24/230 (1 0.4) 1.4 (0.9-2.2) 0.15 
Infant Received Prophylactic 
ARVs 
Yes (ref) 24/358 (6.7) 
No 37/355 (10.4) 1.6 (1.0-2.5) 0.07 
* PCR pos N=65, ELISA pos N=764- "don't know" and "missing" responses are not 
presented in the table 
**Caregiver report prior to ELISA testing 
4.4. Results for Aim 2 
The second aim was to determine the rate of participation in PMTCT among 
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mothers whose infants received their first immunization. The cascade of PMTCT 
interventions begins when a pregnant women attends antenatal care (ANC). Participation 
in ANC was high across the entire sample with caregivers reporting 98.4% of infant 
mothers attended ANC at least once during their pregnancy (Table 4.5.). Rates of ANC 
attendance were similarly high across the four districts. Almost 95% of caregivers in the 
overall sample reported that infant mothers previously tested for HIV. Of those, about 
88% reported previously testing negative and 12% reported testing positive. Only about 
3% of the entire sample had never tested for HIV. Rates of never testing were highest in 
Nkhata Bay (5.0%) and lowest in Salima (1.7%). Higher proportions of mothers reported 
testing positive in Zomba and Mulanje (13.2% and 13.9% respectively) than in Nkhata 
Bay and Salima (5.9% and 7.9% respectively). After receiving an HIV test, only women 
identified as HIV positive would continue though the cascade of PMTCT interventions. 
Table 4.5. Caregiver Reported Maternal Participation in PMTCT, All Respondents by 
District (N=5 ,068) 
ANC All districts Nkhata Bay Salima Zomba Mulanje 
Yes 4,985 (98.4) 495 (98.0) 1,011 (99.3) 1,739 (98.5) 1,740 (97.8) 
No 29 (0.6) 1 (0.2) 1 (0.1) 6 (0.3) 21 (1.2) 
Missing 54 (1.1) 9 (1.8) 6 (0.6) 21 (1.2) 18 (1.0) 
Mother's Most Recent HIV 
Test Result** 
Never tested 163 (3.2) 25 (5.0) 17 (1.7) 53 (3.0) 68 (3.8) 
Neg 4,197 (82.8) 442 (87.5) 912 (89.6) 1,433 (81.1) 1,410 (79.3) 
Pos 590 (11.6) 30 (5.9) 80 (7.9) 233 (13.2) 247 (13 .9) 
DK 44 (0.9) 4 (0.8) 7 (0.7) 15 (0.9) 18 (1.0) 
Missing 74 (1.5) 4 (0.8) 2 (0.2) 32 (1.8) 36 (2.0) 
**Caregiver report pnor to ELISA testmg 
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The majority ofHIV positive mothers (as defined by an ELISA positive result in 
this evaluation) received some components ofPMTCT (Table 4.6.). Most ELISA 
positive mothers self-reported attending ANC at least once during their pregnancy 
(98.2%). The proportion of reported ANC attendance was similarly high in all four 
districts. Most ELISA positive mothers also reported testing for HIV (94.9%) and over 
70% reported previously testing positive, indicating most, but not all HIV positive 
women knew, or were willing to share their serostatus. One hundred seventy nine 
(23.4%) ELISA positive mothers reported their most recent HIV test was negative, 
suggesting some women may have recently seroconverted, received a previous false 
negative result, received a false positive ELISA result from this evaluation, or chose not 
to share their seropositive status with the interviewers. In Nkhata Bay a larger proportion 
of ELISA positive mothers reported never testing (6.5%) compared to other districts. No 
HIV positive mothers in Salima and two HIV positive mothers in Zomba (0.7%) reported 
never testing. In Mulanje 11 HIV positive mothers reported never testing comprising only 
3.5% of women from that district. By extension, a smaller proportion knew their positive 
HIV status in Nkhata Bay (63.0%) compared to other districts (over 70% in each of the 
other three districts). 
Although delivery by Caesarean section is recommended for HIV positive 
mothers in Western countries, limited resources make this recommendation difficult to 
implement and is not recommended in low-resource settings such as Malawi. Only 33 
HIV positive mothers (4.3%) delivered by Caesarean section. Mulanje had a slightly 
lower rate of Caesarean section (2.5%) compared to the other districts (5.1 %-6.6%). Over 
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90% ofHIV positive mothers in the sample had a spontaneous vaginal delivery. 
Table 4.6. Self-Reported Participation in PMTCT Activities Among ELISA-Positive 
Mothers by District (N=764) 
Variables All districts NkhataBay Salima Zomba Mulanje 
ANC N=764 N=46 N=106 N=293 N=319 
Yes 750 (98.2) 44 (95.7) 106(100) 287 (98.0) 313(98.1) 
No 5 (0.7) 1 (2.2) 0 (0) 2 (0.7) 2 (0.6) 
Missing 9 (1.2) 1 (2.2) 0 (0) 4(1.4) 4 (1.3) 
Mother's Most Recent 
HIV Test Result** 
Never tested 16 (2.1) 3 (6.5) 0 (0) 2 (0.7) 11 (3.5) 
Negative 179 (23.4) 12 (26.1) 28 (26.4) 65 (22.2) 74 (23.2) 
Positive 546 (71.5) 29 (63.0) 75 (70.8) 215 (73.4) 227 (71.2) 
DK/Missing 23 (3.0) 2(4.3) 3 (2.8) 11 (3 .8) 7 (2.2) 
Mode Delivery 
Vaginal Delivery 700 (91.6) 42 (91.3) 97 (91.5) 262 (89.4) 299 (93 .7) 
Vacuum Extraction 17 (2.2) 0 (0) 0 (0) 7 (2.4) 10 (3.1) 
Caesarean Section 33 (4.3) 3 (6.5) 7 (6.6) 15 (5.1) 8 (2 .5) 
DK 4 (0.5) 0 (0) 0 (0) 2 (0.7) 2 (0.6) 
Missing 10 (1.3) 1 (2.8) 2 (1.9) 7 (2.9) 0 (0) 
Mother received HIV 
drugs during pregnancy 
No 295 (38 .6) 20(43.5) 47 (44.4) 115 (39.3) 113 (35.4) 
Yes 423 (55.4) 24 (52.2) 55 (51.9) 158 (53 .9) 186 (58.3) 
DK/Missing 46 (6.2) 2 (4.4) 4 (3.8) 20 (6.8) 20 (6.3) 
Mom received HIV drugs 
during labor 
No 256 (33.5) 19 (41.3) 40 (37.7) 86 (29.4) 111 (34.8) 
Yes 465 (60.9) 26 (56 .5) 65 (61.3) 183 (62.5) 191 (59.8) 
DK/Missing 43 (5.6) 1 (2.2) 1 (0.9) 24 (8.2) 17 (5.3) 
Mom received HIV drugs 
during pregnancy or 
labor* 
No 230(30.1) 18 (39.1) 38 (35 .9) 80 (27.3) 94 (29.5) 
75 
Yes 495 (64.8) 27 (58.7) 66 (62.3) 193 (65.9) 209 (65.5) 
DK/Missing 39 (5.1) 1 (2.2) 2 (1.9) 20 (6.8) 16 (5.0) 
Infant received ARV s 
No 355 (46.5) 21 (45.7) 48 (45.3) 115 (39.3) 171 (53.6) 
Yes 358 (46.9) 21 (45.7) 56 (52.8) 153 (52.2) 128 (40.1) 
DK/Missing 51 (6.7) 4 (8.7) 2 (1.9) 25 (8.5) 20 (6.3) 
Breastfeeding 
Not exclusive 47 (6.2) 5 (1 0.9) 7 (6.6) 23 (7.9) 12 (3.8) 
Exclusive 707 (92.5) 40 (87.0) 99 (93.4) 267 (91.1) 301 (94.4) 
Missing 10 (1.3) 1 (2.2) 0 (0) 3 (1.0) 6 (1.9) 
**Caregiver report pnor to ELISA testmg 
* Combines variables for HIV drugs taken during pregnancy and HIV drugs taken during 
labor 
The provision of antiretroviral drugs to HIV positive pregnant women and 
exposed infants is a critical component of PMTCT. A little over half of mothers reported 
taking HIV prophylactic drugs during pregnancy (55.4%) and almost 40% reported 
receiving no drugs. The rates of mothers taking HIV drugs during pregnancy were similar 
across the four districts (range of 51.9%-58.3%). A larger proportion of women reported 
taking HIV drugs during labor (60.9%) than during pregnancy. The rates of mothers 
taking HIV drugs during labor were also similar across the four districts (range of 56.5%-
62.5%). The variables examining HIV treatment during pregnancy and during labor were 
combined to identify the number of HIV positive mothers who had any HIV treatment 
during pregnancy or labor. In total, 64.8% of ELISA positive mothers reported receiving 
some form of antiretroviral (ARV) treatment during pregnancy and/or during labor. The 
smallest proportion of women receiving treatment during pregnancy or labor was in 
Nkhata Bay (58.7%). The proportions of the other three districts were similar and ranged 
from 62.3% in Salima to 65 .9% in Zomba. A smaller proportion of exposed infants 
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received treatment compared to mothers, with caregivers reporting less than half of 
exposed infants in the sample received ARV prophylaxis (46.9%). The smallest 
proportion of infants receiving treatment was in Mulanje where only 40.1% of exposed 
infants received ARV s. Less than half of all infants in Nkhata Bay received treatment 
(45.7%), while just over half received treatment in Salima and Zomba (52.8% and 52.2% 
respectively). 
Safer feeding practices are the last component ofPMTCT. At the time of data 
collection, 92.54% of exposed infants (all aged younger than 3 months) were exclusively 
breastfed. The lowest exclusive breastfeeding rate was in Nkhata Bay (86.96%) and 
highest was in Mulanje (94.36%). 
The caregiver survey collected additional data at the request of the Ministry of 
Health to look at specific variables related to transmission. Caregivers were asked about 
place of delivery, if the baby was born in breech position, if the mother experience long 
labor (defined as labor that lasted longer than four hours after the rupture of membranes), 
if the mother had an episiotomy (defined as a surgical cut of the perineum during labor), 
or if the mother had any breast sores while nursing the infant (Table 4.7.). 
Most mothers reportedly delivered their infant at a hospital or clinic (85.0%). Of 
infants not delivered at a hospital or clinic, almost all were delivered at home and/or by a 
TBA (13.4%). Salima and Zomba had higher rates of hospital or clinic delivery (91.5% 
and 90.4% respectively) compared to Nkhata Bay and Mulanje (80.4% and 78.4% 
respectively) . Inversely, Nkhata Bay and Mulanje had larger proportions of births at 
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home and/or with a TBA (17.4% and 19.4% respectively) than Salima and Zomba (6.6% 
and 8.5%). 
Overall, the proportions of breech births, long labor, and episiotomy were low, all 
under 10%. Relative to the other districts, Mulanje reported a higher proportion of breech 
births, and Zomba reported a higher proportion of long labor and episiotomy. 
Table 4.7. Self-Reported Delivery-Related Risk Variables Among ELISA-Positive 
Mothers by District (N=764) 
All Nkhata 
Variables districts Bay Salima Zomba Mulanje 
Place of Delivery 
Hospital or 
clinic 649 (85.0) 37 (80.4) 97 (91.5) 265 (90.4) 250 (78.4) 
Home/TBA* 102 (13.4) 8 (17.4) 7 (6.6) 25 (8.5) 62(19.4) 
Other 9 (1.2) 0 (0) 2 (1.9) 1 (0.3) 6 (1.9) 
Missing 4 (0.5) 1 (2.2) 0 (0) 2 (0.7) 1 (0.3) 
Breech 
No 713 (93.3) 44 (95.7) 103 (97.2) 281 (95.9) 285 (89.3) 
Yes 51 (6.7) 2 (4.4) 3 (2.8) 12(4.1) 34 (10.7) 
Long Labor 
No 702 (91.9) 37 (80.4) 104 (98.1) 249 (85 .0) 312 (97.8) 
Yes 62 (8.1) 9 (19.6) 2 (1.9) 44 (15.0) 7 (2.2) 
Episiotomy 
No 730 (95 .6) 46 (100) 105 (99.0) 265 (90.4) 314 (98.4) 
Yes 34 (4.5) 0 (0) 1 (0.9) 28 (9.6) 5 (1.6) 
Breast sores while 
nursmg 
No 721 (94.4) 43 (93.5) 101 (95.3) 272 (92.8) 305 (95.6) 
Yes 30 (3.9) 2 (4.4) 3 (2.8) 18 (6.1) 7 (2.2) 
Missing 13 (1. 7) 1 (2.2) 2 (1.9) 3 (1.0) 7 (2.2) 
* Traditional Birth Attendant 
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In Malawi, the current treatment regimen for pregnant women under Option B+ is 
Tenofovir, Lamuvidine, and Efavirenz in a fixed-dose, single tablet per day (Schouten et 
al., 2011), but at the time of data collection, several antiretroviral drug regimens were 
available in Malawi. The HIV positive mothers in our study received several different 
treatment regimens with additional variation across districts. During pregnancy, the 
largest proportion of women (38.6%) reported not receiving any treatment compared to 
specific treatment regimens (Table 4.8.). This finding was consistent across all of the 
districts except Mulanje where the largest proportion of women (42.9%) reported 
receiving AZT. Among women who reported receiving treatment during pregnancy, ART 
was the most prevalent regimen in Nkhata Bay, Salima, and Zomba. 
Table 4.8. HIV Treatment Regimen During Pregnancy 
%Total (#) % NkhataBay % Salima %Zomba % Mulanje 
Treatment Regimen N=764 N=46 N=106 N=293 N=319 
None 295 (38 .6) 20(43.5) 47 (44.3) 115 (39.3) 113 (35.4) 
AZT 224 (29.3) 10 (21.7) 18(17.0) 59 (20.1) 137 (42.9) 
ART 199 (26.1) 14 (30.4) 37 (34.9) 99 (33.8) 49 (15.4) 
Don't know/Missing 46 (6.1) 2 (4.4) 4 (3.8) 20 (6.8) 20 (6.3) 
ART defined as defined as any of the first or second lme multi-drug regimens used m 
Malawi at the time of data collection 
When asked about receiving HIV treatment during labor, the largest proportion of 
women (33.5%) reported receiving no treatment (Table 4.9.) compared to specific 
treatment regiments. By district, the percent of mothers who reported not receiving 
treatment ranged from 29.4% in Mulanje to 41.3% in Nkhata Bay. Among women 
receiving treatment, similar proportions took single dose ofNevirapine (18.2%), 
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Nevirapine/AZT/3TC (22.3%), and ART (20.4%) with some variations across districts. 
For example, proportionately smaller numbers of women took single dose Nevirapine in 
Nkhata Bay (6.5%) and took ART in Zomba (11.9%) compared to the other districts. 
Table 4.9. HIV Treatment Regimen During Labor 
Total Nkhata Salima Zomba Mulanje 
Bay 
Treatment N=764 N=46 N=106 N=293 N=319 
Regimen 
None 256 (33.5) 19 (41.3) 40 (37.7) 111 (34.8) 86 (29.4) 
sdNVP 139 (18.2) 3 (6.5) 24 (22.6) 63 (19.8) 49 (16.7) 
NVP AZT 3TC 170 (22.3) 10 (21.7) 18(17.0) 90 (28.2) 52 (17.8) 
ART 156 (20.4) 13 (28 .3) 23 (21.7) 38 (11.9) 82 (28.0) 
Don't 43 (5.6) 1 (2.2) 1 (0.9) 17 (5.3) 24 (8.2) 
Know/Missing 
. ART defined as defined as any ofthe first or second lme mult1-drug reg1mens used m 
Malawi at the time of data collection 
4.5. Results of Piloting an Innovative Evaluation Approach in Malawi 
In addition to the stated research aims, the evaluation tested a novel approach 
based in immunization clinics. To understand the success ofthe approach, data were 
collected formally and informally throughout implementation, including gathering 
satisfaction information from participants during data collector training, documenting 
sample collection and site issues through using an evaluation-specific supervision form, 
providing space on the survey to collect information from eligible caregivers who refused 
to participate, and examining the survey and DBS data for quality. 
Each health facility that participated in the evaluation sent two to three clinical 
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staff members to be trained to collect data. Nkhata Bay, Salima, and Mulanje each held 
one training in the district capital. Two trainings were conducted in Zomba as more 
health facilities were sampled in that district. A total of 13 7 data collectors received 
training. Each training lasted 1.5 days and covered study goals, human subjects 
protection, screening and recruitment, informed consent, survey implementation, dried 
blood spot sample collection, and returning results . At the end of the training each 
participant filled in an anonymous survey to identify what went well during the training 
and what could be improved. Many of the surveys expressed overall satisfaction with the 
training. Most participants identified practice collecting DBS samples (from other 
training participants) as the most useful part of the training. Few changes to the training 
were recommended, but some suggestions by participants included lengthening the 
training, increasing the travel reimbursement amount, and increasing the number of data 
collectors per health facility. 
Study staff from MSH and MOH with DHO staff conducted supervision visits to 
all participating health facilities every two weeks during the eight weeks of data 
collection to pick up collected data, conduct quality control activities, and provide 
additional training as needed. Detailed implementation information was collected during 
each supervision visit. A supervision form created for the evaluation was completed by 
study staff at every visit at each health facility. The supervision form collected the district 
name, health facility name, date, start and end time of the visit, name of the supervisors, 
name of data collectors supervised, number of samples and surveys collected during the 
visit, and issues addressed. A repeated issue noted on the supervision forms was the 
81 
identification of invalid DBS samples (e.g. not enough blood on the collection card, 
samples not dried properly, samples not packaged with desiccant) . The supervision form 
also listed the corrective action taken, such as the provision of additional training on DBS 
collection or correction of drying and storage problems. When staffing changes resulted 
in the loss of evaluation-trained staff members, the supervisors trained replacement data 
collectors during the supervision visit. Supervision forms also identified reasons why 
some sites were not reaching their data collection goals. On a couple of occasions, high-
priority health initiatives drew evaluation data collectors away from normal clinic 
operations into short-term campaigns, such as a Jhpiego circumcision campaign in 
Mulanje. Overall, a review of the supervision forms indicated no systemic 
implementation problems. 
Data on caregivers who refused to participate in the evaluation was to be 
collected, both to ensure the identified transmission rate was representative of the 
population, and to provide information on the acceptability of the activity in the 
community. If an eligible caregiver-infant pair refused to participate, space was provided 
for the data collector to record the reason for the refusal. The incomplete survey was to 
be retained with the completed surveys and collected during supervision visits. Only 17 
forms documenting refusals were returned to study staff. It is highly unlikely that only 17 
eligible caregivers refused to participate in the evaluation. Fifteen ofthe 17 refusal forms 
were from five health facilities in Salima. One refusal form each came from Nkhata Bay 
and Zomba, no refusal forms were returned from Mulanje. According to the forms, the 
most common reason (given by 10 caregivers) for the caregiver to refuse to participate 
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was that husbands' consent was needed. The second most common reason given (three 
caregivers) was that they were not ready to know the child's status. 
High numbers of ineligible participants were enrolled in the evaluation. Data were 
collected on 5,634 caregiver and infant pairs. Participants were excluded (not mutually 
exclusive) because they did not fit the inclusion criteria (age of infant (6 excluded), age 
of caregiver (325 excluded), presenting for first vaccination (113 excluded), and 
relationship to the infant (4 excluded)). An additional 88 caregiver-infant pairs were 
excluded due to invalid DBS sample, 80 were excluded due to missing DBS sample, and 
10 were excluded due to missing survey data. The data from a total of 5,068 caregiver-
infant pairs were used in the analysis. 
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CHAPTER 5: DISCUSSION 
5.1. Overview 
The three specific aims of the evaluation were successfully completed. The first 
aim was to determine the vertical transmission rate of infants attending their first 
immunization visit. The vertical transmission rate among infants in the four sampled 
districts was found to be 8.5%. The second aim was to determine the rate of participation 
in PMTCT activities among mothers whose infants received their first immunization. 
ANC attendance and HIV testing had almost universal participation, however smaller 
proportions of mothers and infants reported taking prophylactic ARV. The final aim was 
to develop a toolkit to provide guidance on implementing a routine surveillance system at 
immunization sites. The Toolkit has been developed and is available to facilitate the 
replication of the evaluation as a standard surveillance system. 
The evaluation emolled 5,068 eligible caregiver-infant pairs over eight weeks of 
data collection across four districts in Malawi. The primary population of interest was the 
subset of caregiver-infant pairs for whom the infant DBS sample tested positive for 
exposure to HIV. The transmission rate ofHIV in young infants and maternal 
participation in PMTCT activities was identified from this sub-population. Due to the 
small number of transmissions identified (65), the data analysis was mainly descriptive as 
the ability to conduct inferential statistics beyond bivariate risk ratios (RR) was limited. 
This chapter will interpret the evaluation results presented in the previous chapter, 
examine the performance of the approach in the Malawian context, describe the 
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limitations of the evaluation, appraise the performance of RE-AlM as the conceptual 
framework, and make recommendations for future implementation and research. 
5.2. Description of Data Collection Context 
Sampling was conducted at "under-5 clinics" in 53 health facilities in four 
districts in Malawi. In addition to other services, the under-5 clinics provide infant and 
childhood vaccines. One or more days a week are designated as vaccine days depending 
on the size of the health facility and the population in its catchment area. To ensure a 
population-based sample, all caregiver-infant pairs who met the inclusion criteria 
presenting at a participating under-5 clinic on a vaccine day were invited to participate in 
the evaluation. By not requiring known positive serostatus, participants who were not the 
primary population of interest (exposed infants) were enrolled. However it was critical to 
capture infants previously not known to have been exposed to attain an accurate 
population-based transmission rate. A total of 5,068 eligible caregiver-infant pairs with 
valid DBS samples and complete survey forms were included in the analysis. 
5.3. Description of the Overall Sample 
Although non-maternal caregivers were eligible to participate, almost all of the 
caregivers who enrolled in the evaluation with the infant were the infant's mother (over 
98%) (see Table 4.1.). This result was expected because in Malawi it is common for 
children's health care needs to be coordinated by mothers rather than fathers or other 
caregivers. Most infant mothers in this evaluation were young, with over 80% 30 years of 
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age or younger. Most infant mothers were described as healthy, attended ANC at least 
once, and had tested for HIV. All of these findings were consistent with expectations. 
Just over 11% of infant mothers were identified as HIV positive on the survey (prior to 
DBS testing). This finding was also consistent with expectations as the most recent DHS 
found the HIV prevalence rate in women 15-49 to be 12.9% (National Statistical Office 
& ICF Macro, 201 0). There was no notable variation in results by district in the 
characteristics of the sample with the exception of caregiver's relationship to the infant 
and reported HIV status of the infant's mother. In all districts except for Nkhata Bay, 98-
99% of caregivers presenting to the health facility were the infant's mother. The majority 
of caregivers in Nkhata Bay were also the mother, but a larger proportion compared to 
other districts, almost 5%, were legal guardians. The survey question did not ask if the 
legal guardian was the infant's father, or the circumstances of the guardianship. The 
proportion of mothers described as "sick" in Nkhata Bay was minimally higher than the 
other districts (1.0% compared to 0.2% to 0.4%) and thus may account for some ofthe 
increased proportion of non-maternal caregivers bringing the infant into the health 
facility if illness prevented mothers from escorting their infant for vaccination. Inviting 
infants with non-maternal caregivers to participate in the evaluation ensured the results 
did not yield an artificially low transmission rate due to the exclusion of infants whose 
mothers had died from HIV. The higher proportion of non-maternal caregivers enrolled 
in Nkhata Bay does not appear to be related to maternal HIV deaths as no mothers in 
Nkhata Bay were reported to have died (Table 4.1.). Without additional information 
conclusions cannot be drawn as to why proportionally more legal guardians enrolled in 
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the study in Nkhata Bay; however as the proportion was small and represents a small 
absolute number (25), it is likely this finding did not impact the evaluation results. 
The second variable with variation by district in the overall sample was HIV 
status of the infant's mother. About 6% reported positive HIV status in Nkhata Bay, 
about 8% in Salima, and about 13% in Zomba and Mulanje. Although these results are 
lower than the reported rates in the DHS, they mirror the relative difference in prevalence 
by region reported in the DHS. Nkhata Bay is located in the northern region where the 
prevalence rate reported in the DHS is 8%, the prevalence in the central region where 
Salima is located is 9%, and the prevalence rate in the southern region where Zomba and 
Mulanje are located is almost 18% (National Statistical Office & ICF Macro, 201 0). The 
differences in reported positivity rates by district confirm the sampling expectations. The 
country was sampled proportionate to HIV prevalence and thus twice as many districts in 
the southern regions were sampled as in the central and northern regions. 
5.4. Description of the ELISA Positive Subset 
The primary population of interest in the evaluation is the subset of infants who 
tested ELISA positive indicating HIV exposure. The background characteristics of this 
subset were similar to the characteristics of the overall sample (Table 4.2.) with a few 
exceptions. In the overall sample, 24% of mothers were 18 to 20 years of age, but only 
9% of mothers in the ELISA positive subset were in that age category. In the overall 
sample, 17% of infant mothers were 31-40 years of age, while over 30% of mothers in 
the ELISA positive subset were in that age range. The age differences between the 
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overall sample and the ELISA positive subset reflect patterns of child bearing and HIV 
prevalence in Malawi. Median age of first birth in Malawi is 18.9 years (National 
Statistical Office & ICF Macro, 201 0), therefore moderate representation in the overall 
sample in the youngest age category is expected. In Malawi, HIV prevalence among 
women increases with age until they reach their mid-40s (National Statistical Office & 
ICF Macro, 2010). Women accrue years of risk ofHIV exposure as they age, with the 
risk of exposure being particularly acute during child-bearing years. Again the findings 
reflect this trend with larger proportions of women in the ELISA positive subset falling 
into the older age category (31-40 years) than the younger age category (18-20 years). 
Another difference between the overall sample and the ELISA positive subset is 
the proportion of mothers reported to be sick. In the overall sample, only 0.4% of infant 
mothers were reported sick, compared to 1.4% in the ELISA positive subset. In Nkhata 
Bay specifically, the proportion of infant mothers reported to be sick increased from 1% 
to 6.5% from the overall sample to the ELISA positive subset. These data are difficult to 
interpret as the survey did not define the terms "sick" and "healthy." In the ELISA 
positive subset over 70% of women knew their positive HIV status but less than 2% were 
described as "sick." 
Finally, while Nkhata Bay emolled a larger proportion of legal guardians 
compared to the other districts in the overall sample (see section 5.3.), only one legal 
guardian emolled in Nkhata Bay was ELISA positive. Therefore it is unlikely the role of 
legal guardian would be an important factor influencing the primary outcome of interest, 
transmission rate. 
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5.5. Discussion of Aim 1 Results 
Aim 1: Determine vertical transmission rate of infants attending their first immunization 
visit. 
The proportion ofHIV positive mothers in the sample was higher than the HIV 
prevalence rate for women aged 15-49 (12.9%) reported by the 2010 Malawi DHS report 
(National Statistical Office & ICF Macro, 2010). Of the 5,068 infant DBS samples 
collected across the four districts, 764 tested ELISA positive, indicating 15.1% (95% CI: 
14.1-16.1%) of mothers were HIV positive and their infants were exposed to HIV. The 
differences in the rates are likely due to differences in sampling between the DHS and the 
evaluation. The DHS estimate is only one percentage point outside of the 95% confidence 
interval of our maternal prevalence point estimate. The small difference between 
estimates suggests the evaluation was successful in obtaining a sample representative of 
the larger population, increasing confidence in the validity of the results. 
The ELISA positive rate is also higher than the 11% of infant mothers identified 
as HIV positive on the survey. It is likely the evaluation identified mothers who 
previously did not know their positive serostatus. Of those who did not report their 
positive status on the survey, 16 reported never testing (1 0% of those who reported never 
testing) and 179 reported negative HIV status ( 4% of those who reported negative 
serostatus). Other explanations include some mothers may have chosen not to reveal their 
positive status on the survey, may have received a previous false negative result, or may 
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have received a false positive ELISA result. 
Of the 764 HIV exposed infants, 65 tested positive for HIV with a subsequent 
DNA PCR test. Therefore, the population based vertical transmission rate for young 
infants born between July and October 2011 was 8.5% (95% CI: 6.6-10.7%). This rate is 
considerably lower than the 24.7% transmission rate recently published by the 
government ofMalawi for 2010-2011 (Government ofMalawi, 2012a). Methodological 
differences may explain the large discrepancy between the rates in the evaluation and the 
government rate. The government rate includes transmission over the course of the entire 
breastfeeding period. The risk of HIV transmission from breastfeeding ranges from 5% to 
20% (WHO & UNICEF, 2007). In Malawi the median duration ofbreastfeeding is just 
under two years (National Statistical Office & ICF Macro, 201 0). The evaluation 
examined transmission in young infants only (infants less than 3 months of age) and 
therefore the transmission rate does not account for additional transmissions that may 
occur throughout the breastfeeding period. 
Other methodological differences are that the transmission rate produced by the 
evaluation was empirically derived while the government rate was generated by the 
Spectrum model using different assumptions and inputs. In 2010, the government 
published a 13% transmission rate from 2008-2009 data also generated by Spectrum 
model (Government of Malawi, 201 Oa), substantially lower than the recently published 
rate, but higher than the evaluation rate. Discussions with colleagues in the Ministry of 
Health (MOH) indicate no significant changes in policy or prevention and treatment 
practice that would result in a 1 0% increased rate of transmission between 20 1 0 and 
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2012, suggesting possible problems with the modeling assumptions as applied to Malawi. 
An alternative explanation is that the discrepancy in transmission rates is a result of the 
evaluation sample not accurately representing the population. However, several results 
from the evaluation are comparable to DHS results (maternal prevalence, ANC 
attendance), suggesting the sample is, in fact, representative ofthe population. 
There was some variation in the transmission rate ofHIV from mother-to-child by 
district. The lowest transmission rate was in Zomba (5 .8%), the highest in Nkhata Bay 
(10.9%), and the rates in Salima and Mulanje were similar to Nkhata Bay (9.4% and 
10.3% respectively). Although the differences were small, mothers in Nkhata Bay had 
generally lower rates of participation in PMTCT activities including proportionately 
higher rates of never testing for HIV and proportionately lower rates of receiving ARV 
during pregnancy and/or labor, accounting for the marginally higher transmission rate in 
NkhataBay. 
It is unclear why the transmission rate in Zomba is much lower than in the other 
districts. Mothers in Zomba participated in PMTCT activities at about the same rate as 
mothers in Salima and Mulanje. Although HIV prevalence is higher in the southern 
region where Zomba and Mulanje are located, the area is generally more developed, has a 
larger proportion of the population, and a more developed health care network with a 
larger non-governmental organization (NGO) presence than the northern region. The 
commercial capital of Malawi, Blantyre, is located in the southern region. Additionally, 
the infrastructure in the city of Zomba, in particular, is more established than other parts 
of the country as it was the capital until 1974 when the capital was moved to Lilongwe. 
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Chancellor College, the largest college of the University of Malawi, is located in Zomba. 
Public and private systems for HIV prevention and treatment are more developed and 
mature in Zomba with a greater number of health facilities providing PMTCT services 
and a strong NGO presence. For example, prior to data collection data from the district 
health offices showed that 49 health facilities in Zomba were providing PMTCT services, 
compared to 22 in Nkhata Bay, 21 in Salima, and 24 in Mulanje. It is possible that the 
higher level of development and stronger health care network in Zomba could account for 
the lower transmission rate. Alternatively the lower transmission rate in Zomba could be 
an artifact of the overall low number of transmissions in the evaluation; 5 in Nkhata Bay, 
10 in Salima, 17 in Zomba, and 33 in Mulanje. Variations in transmission rate by district 
would be a valuable avenue for future investigation. 
5.5.1. Risk Factors for HIV Transmission 
The ELISA test identified infants who were born to HIV positive mothers and 
were at risk for HIV transmission. This at-risk population of mothers and infants (the 764 
pairs where the infant tested ELISA positive) were intended to be examined and 
compared to the 65 mother-infant pairs in which the infant was found to be HIV positive. 
The small number of transmissions in the sample limited inferential statistics and the use 
of logistic regression to identify covariates associated with transmission. Bivariate 
relative risks (RR) of HIV transmission by risk factor among ELlA positive infants were 
calculated. 
The calculation of the relative risk of factors associated with transmission resulted 
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in effects in the expected direction, however given the small number of HIV positive 
infants in the evaluation, p-values were marginally significant or not statistically 
significant (Table 4.4.). The largest proportion of vertical HIV transmission occurred in 
the youngest age group of mothers ; 12.5% of mothers aged 18-20 transmitted HIV to 
their infants, compared to about 8% or less for the other age groups. Although younger 
mothers compose a smaller proportion ofHIV positive mothers in the sample (see Table 
4.2.), young mothers are more likely to transmit HIV to their infants (Torpey et al., 
2012). Proportionally fewer young mothers attended ANC, took ARVs during pregnancy 
or labor, and had infants who took ARVs; proportionally more young mothers never 
tested for HIV. Not attending ANC had a higher relative risk (2 .3) compared to most of 
the other variables in the evaluation, but was not statistically significant (p-value 0.36). 
Not attending ANC also had a proportionally high rate of transmission (20%) than 
attending ANC, however this proportion represents only one mother-infant pair who did 
not attend ANC and transmitted HIV, of the five ELISA positive mother-infant pairs who 
did not attend ANC. ANC is an important venue for identifying HIV positive pregnant 
women through standard screening. Pregnant women who do not attend ANC would not 
benefit from early identification of positive serostatus and intervention. 
A slightly larger proportion of women who delivered their infant at home and/or 
with a TBA transmitted HIV to their infants . The relative risk of transmission was 1.4 
and was not significant (p-value 0.18). Home delivery increases the risk of HIV 
transmission compared to delivery at a health facility (Koye & Zeleke, 20 13). 
Increased risk of transmission was found among both those who reported never 
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testing for HIV (RR=2.5), and to a lesser extent, those who reported being HIV negative 
on their most recent HIV test (RR=1.5) in the survey prior to ELISA testing. Both risk 
ratios are marginally significant (0.11 and 0.15 respectively), likely due to the small 
numbers of women in these categories. By never testing for HIV, pregnant HIV positive 
women are not in a position to receive treatment to reduce the risk of transmission from 
mother to child. Considerable emphasis has been placed on testing as an effective 
prevention strategy for HIV transmission, vertical and otherwise (WHO, 2012d). In 
Malawi, HIV testing rates have increased dramatically from 13%2004 to 72% in 2010 
among women aged 15 to 49 (National Statistical Office &ICF Macro, 2010). Our data 
show high rates of testing, with almost 95% ofthe overall sample and the ELISA positive 
subset reporting previously testing. 
Antiretroviral drugs are a critical component of PMTCT. Studies show the 
protective effects oftreatment of pregnant women to prevent transmission to their infants 
(Chasela et al., 2010; Shapiro et al., 2010; Taha, 2011). The compelling evidence of the 
protective nature of maternal ARV treatment led the government of Malawi to institute 
Option B+, which was launched in July 2011, immediately prior to data collection for the 
evaluation. Option B+ policy did not have a significant impact on the data collection as it 
was in the process of being launched rather than fully implemented. A marginally 
significant increased risk of transmission was identified for mothers who reported 
receiving no HIV treatment during pregnancy or labor (RR=1.4, p-value 0.15). 
Infants who did not receive prophylactic ARVs had proportionally higher 
transmission rates and a statistically significant increased risk oftransmission (RR=1.4, 
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p-value 0.07). The provision of ARTs to infants has been proven to protect infants against 
vertical transmission (Chasela et al., 2010; Kumwenda et al., 2008; Taha, 2011). 
5.6. Discussion of Aim 2 Results 
Aim 2: Determine the rate of participation in prevention of mother-to-child transmission 
(PMTCT) among mothers whose infants receive their first immunization. 
PMTCT is not a single activity, but rather a series of intervention activities often 
described as a cascade. The activities are sequential with each subsequent activity relying 
on the step before (see Figure 2.1.). All pregnant women participate in the first steps of 
the cascade, but after HIV testing, only HIV positive women continue through the rest of 
the interventions. The entire cascade must be completed for infants ofHIV positive 
mothers to receive maximum protection against vertical transmission. Data from this 
evaluation suggest many HIV positive pregnant women in Malawi are participating 
PMTCT activities, predominantly in the early stages of the cascade. However challenges 
to full implementation ofPMTCT remain, particularly around reported use of ARVs by 
both HIV positive pregnant women and exposed infants. 
Table 4.5. presents data on mothers' participation in PMTCT in the overall 
sample. The first activity in the cascade is ANC attendance. Over 98% of women in the 
overall sample reported attending ANC at least once during their pregnancy. Reported 
participation in ANC is similarly high in the ELISA positive subset of mothers with 98% 
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ofHIV positive mothers attending ANC at least once (Table 4.6.). High rates of ANC 
attendance indicate that it remains an important venue where HIV positive women can be 
identified. Many women who tested ELISA positive in the evaluation already knew their 
positive HIV status due to previous testing, likely at ANC. ANC also presents an 
important opportunity for HIV positive pregnant women to be linked to care and 
treatment. 
After attending ANC, the next steps of the PMTCT cascade relate to testing: 
women must be offered testing, agree to test, and receive the results. Prior to the advent 
of rapid testing and its widespread use, receiving HIV results was a major barrier to 
diagnosis as those who tested would have to return to the clinic at a later date after lab 
facilities processed the blood sample (V aldiserri et al., 1993; Wilkinson et al., 1997). 
Currently women who test at ANC in Malawi receive their results during the same visit. 
High rates of HIV testing were reported in both the overall sample in which only 3% of 
infant mothers reported never testing, and the HIV positive subset of mothers in which 
· only 2% reported never testing. Despite high rates of testing among the ELISA positive 
subset, only 71% of ELISA positive mothers reported receiving a positive test result in 
past testing. Almost a quarter of HIV positive mothers reported testing HIV negative. 
There are several explanations why such a large minority of HIV positive mothers 
reported testing HIV negative, including not wanting to share positive status with the data 
collectors, seroconversion occurring after ANC testing, ANC testing occurring during the 
window period4, a previous false negative result, or a false positive ELISA result in this 
4 The window period is the time period between when someone is infected with HIV and when 
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evaluation. An HIV positive pregnant woman who does not receive a HIV positive 
diagnosis at ANC represents a missed opportunity for diagnosis and linkage to treatment. 
The next steps on the PMTCT cascade relate to treatment of pregnant women 
identified as HIV positive through ANC testing. The steps are: antiretroviral drug 
treatment must be offered, eligible pregnant women must accept the drugs, and the 
women must take the drugs on the required schedule. ARV provision for PMTCT in 
Malawi has increased dramatically over time from about 2,000 women receiving ARVs 
through PMTCT in 2003 to about 15,000 women in 2007 (Government of Malawi, 
2010a). Despite these improvements, 30% ofHIV positive mothers reported not using 
ARVs during pregnancy or labor (Table 4.6). On the survey, 24% of mothers who were 
HIV positive reported being HIV negative; therefore at least 6% of women who knew 
they were HIV positive did not take any ARVs. Barriers to taking ARVs are persistent 
and well-documented in similar settings and include limited CD4 count testing to identify 
women eligible for treatment, poor linkages between HIV testing and treatment, 
difficulty accessing health facilities, and stigma (Ferguson et al., 2012; Levy, 2009; 
Mandala et al., 2009; MMWR, 2013; Rosen & Fox, 2011; Weigel et al., 2012; Wettstein 
et al., 2012; Zachariah et al., 2006). 
Sixty-four percent of mothers reported taking ARVs during pregnancy or labor, 
with many taking drugs during both pregnancy and labor, although more mothers 
reported taking drugs during labor (61 %) than during pregnancy (55%). Several drug 
regimens were available in Malawi at the time of data collection. Common treatment 
their bodies are producing sufficient level of antibodies to receive a positive HIV test 
(http://www.cdc.gov/hiv/topics/basic/). 
97 
regimens during pregnancy included short or long courses of AZT or ART5 (Table 4.8 .). 
The use of these two regimens during pregnancy was almost evenly distributed with 29% 
of women taking ART and 26% of women taking AZT. During labor, three common drug 
regimens were single dose nevirapine; single dose nevirapine, AZT, and 3TC; and ART 
(Table 4.9.). Again similar proportions of mothers reported taking each of these 
regimens, with 18% taking single dose nevirapine, 22% taking the three-drug cocktail, 
and 20% taking ART. At the time of data collection, single dose nevirapine was no 
longer a recommended treatment in Malawi, but the fact that almost a fifth of HIV 
positive pregnant women were provided single dose nevirapine demonstrates a lag 
between policy change and implementation. 
The next step on the PMTCT cascade is the provision of prophylactic HIV 
treatment to exposed infants. The data identified considerable room for improvement in 
the provision of prophylactic treatment to infants. HIV positive mothers reported less 
than half of their infants took ARVs (Table 4.6.). For infants, barriers to treatment 
include lack of knowledge and access to early infant diagnosis (EID), logistics of 
receiving results, lack of linkages between PMTCT and pediatric records, and the 
mother' s fear of disclosure of her own or her infant's HIV status (Ciaranello et al., 2011; 
Donahue, Dube, Dow, Umar, & Rie, 2012). 
The final step on the PMTCT cascade is safer feeding practices for infants. WHO 
guidelines recommend exclusive breastfeeding for the first six months. Complimentary 
foods should be introduced at six months with breastfeeding continuing through the first 
5 ART defined as defined as any of the first or second line multi-drug regimens used in Malawi at 
the time of data collection. 
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year. Breast feeding should end when an adequate and safe diet can be provided (Taha, 
2011 ). Ninety-three percent of infants in the evaluation were exclusively breastfed. As 
noted earlier, the evaluation approach used relies on the presence of maternal antibodies 
and therefore only young infants ( <3 months of age) were enrolled. Given breastfeeding 
in Malawi commonly extends to almost two years (National Statistical Office & ICF 
Macro, 201 0), the evaluation can provide no information on adherence to recommended 
feeding and weaning practices in this cohort of infants. 
A component of PMTCT in Western countries not included on the cascade 
diagram (Figure 2.1.) is Caesarean section delivery (Delicia et al., 2011). Although 
recommended in Western countries to reduce transmissions, Caesarean sections are not 
recommended or commonly performed in resource poor settings as a prevention 
intervention (Newell et al., 2004). Of the HIV positive mothers in the sample, only 4% 
had Caesarean sections (Table 4.6.). Data were not collected on the reason for the 
Caesarean section, therefore it is unknown if they were for HIV transmission prevention 
or were performed for other reasons. 
5.7. Summary of Conclusions from Both Aims 
Given the proportion of exposed infants in the study was larger than expected, the 
8.5% transmission rate is lower than anticipated, suggesting that Malawi's PMTCT 
program was performing well with many mothers and infants accessing services. 
However, challenges to full implementation ofPMTCT remain, particularly concerning 
the reported use of ARVs, which were found to be low (64.8% for pregnant women and 
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46.9% for exposed infants). 
Infant DBS testing at immunization clinics was identified as a critical opportunity 
for mothers to learn their own HIV status. Ofthe 5,068 women enrolled in the study 163 
(3.2%) reported never testing, of whom 16 women were ELISA positive (representing 
2% of all HIV positive women in the study). In addition, 179 mothers identified as HIV 
positive reported negative HIV status on the study survey, further suggesting that testing 
at immunization clinics has the potential to identify positive mothers as well as infants. 
5.8. Performance of the Evaluation Approach 
The novel approach used in the evaluation developed in South Africa by Nigel 
Rollins and colleagues was adapted and implemented for the first time in Malawi in this 
evaluation. Piloting the methodology to determine its feasibility and acceptability in the 
Malawian context was an important aspect of the evaluation. Implementation in the four 
selected districts was intended to provide evidence of the method's prospects for nation-
wide scale up. Overall, the implementation of the approach was successful. Existing 
health facility staff gathered data without significant disruption to their clinical duties, 
supervision visits ensured data collection was on track and improved the quality of the 
data collected, and sufficient numbers of eligible caregiver-infant pairs were enrolled in 
the study. 
Implementation identified components critical for successful execution as well as 
areas for improvement. 
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5.8.1. Features Contributing to Implementation Success 
During early planning stages, partners from the Ministry of Health suggested the 
evaluation use existing health system structures, to the extent possible, as a test of the 
method ' s sustainability and scalability. To this end the evaluation employed current 
health facility staff as data collectors, conducted all laboratory testing in-country, and 
engaged District Health Officers as partners for implementation. These elements facilitate 
sustainability, and were also found to be important contributors to successful 
implementation. 
Having existing health facility staff function as data collectors saved time and 
resources both prior to and during data collection. Professional dedicated data collectors 
did not have to be identified and hired, and their lodging, food, and travel expenses did 
not have to be paid as they moved from facility to facility. Furthermore, using existing 
health facility staff allowed for data to be collected from all sites simultaneously. Existing 
staff already familiar with facility procedures were likely better equipped than outside 
data collectors to identify and recruit eligible participants. In addition, some data 
collectors had previously participated in other surveillance activities and were familiar 
with heel stick for DBS collection from clinical care and widespread EID training. Health 
facility staff incorporated the evaluation activities into their clinical care duties with 
minimal disruption as the short data collection time period was eight weeks and 
immunizations were not provided every day in most health facilities . 
Using local laboratories to test the evaluation DBS samples allowed for timely 
testing and provision of results both to study staff and infant caregivers. In addition, using 
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local laboratories provided an opportunity to continue to build capacity. The MOH 
National HIV Reference Laboratory in Lilongwe was selected to conduct the ELISA 
testing to support sustainability by using existing government capacity and structures. 
The MOH laboratory has extensive experience testing DBS samples including for the 
DHS. Samples testing ELISA positive were transported to the UNC laboratory in 
Lilongwe for testing with DNA PCR. At the time of sample analysis, the MOH 
laboratory did not have the ability to conduct PCR tests. 
District health staff facilitated the success ofthe evaluation. During the early 
planning stages, meetings held with each of the DHOs of the selected districts gauged 
their interest and support for the evaluation. The DHOs provided current information on 
health facilities in the district, particularly the under-5 clinics. The District Health Officer 
and senior district health office staff (e.g. District Nursing Officer, District Medical 
Officer) attended the data collector trainings and partnered with MSH and MOH staff 
during the bi-weekly supervision visits. Having the support ofthe local DHO was critical 
for the participation of district facilities. 
Other aspects contributing to the success of the evaluation were MOH support and 
the supervision visits that occurred at all data collection sites every two weeks. The 
leadership, authority, and knowledge of the Malawi context ofMOH partners were 
critical to the success ofthe evaluation. Representatives ofthe PMTCT, Epidemiology, 
and Laboratory units in the MOH HIV I AIDS Department were heavily invested in the 
evaluation. MOH officials participated in planning meetings, reviewed instruments, led 
parts of the trainings, and participated in supervision visits. 
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The supervision visits were planned to retrieve collected data for laboratory 
testing during the data collection period, to conduct quality assurance activities, and to 
provide retraining as needed. The visits proved to be important for collecting high-quality 
data. In addition, the supervision visit forms used to document each visit were a valuable 
tool for monitoring and follow-up of sites with suboptimal operations, as well as for 
identifying site needs such as restocking DBS collection supplies. 
5.8.'2. Implementation Areas for Adjustment 
Although the implementation of the approach was successful overall, there were 
several areas for improvement. Specifically, changing aspects of the training and 
laboratory supply acquisition would both improve the quality of the data and the 
implementation timeline. 
Formal satisfaction survey data and informal feedback from trainers and trainees 
indicate the trainings were successful. However, anecdotal reports from the training in 
Nkhata Bay in the Northern region suggest some participants struggled in the training 
that was conducted primarily in English. The trainers in Nkhata Bay switched to speaking 
the local language to ensure all trainees understood the material. Although English and 
Chichewa are the official languages of Malawi and both widely spoken and understood, 
Chichewa is more commonly understood particularly in the more rural areas such as the 
North. In addition, several local languages are spoken in different geographic regions of 
the country. Ideally the trainings and training materials should be presented in the 
prevalent local language; however this may not be feasible given the diversity of 
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languages that may be present even within district boundaries. At a minimum, conducting 
the trainings in Chichewa rather than English would likely improve understanding, 
particularly for trainees from rural areas. 
Information on caregivers refusing to participate in the evaluation was planned to 
ensure the identified transmission rate was representative of the population, and to gauge 
acceptability of the activity in the community. The survey instrument included space for 
data collectors to record why an eligible participant refused to participate when invited 
into the evaluation. Only 17 forms indicated refusal to participate were returned from the 
participating health facilities. Adjusting the trainings to highlight the importance of 
retaining the survey forms of caregivers who refused would likely rectify the confusion. 
Supervision visits are another opportunity to reinforce the practice of retaining refuser 
forms . Even if reason for refusal is not provided, documenting the eligibility portion of 
the form would capture at a minimum the district and health facility of the refuser thereby 
providing data on the number of eligible participants. 
A large number of ineligible participants enrolled in the study were excluded from 
the analysis. The portion of the training on the inclusion and exclusion criteria should be 
revised to provide complete and understandable justifications for the criteria. Caregivers' 
age was the criteria with a substantially greater number of ineligible \participants 
enrolled (325), all of whom were excluded because they were younger than 18 years of 
age. Caregivers under the age of 18 were excluded as 18 years is the age of consent. The 
confusion was likely the result of data collectors believing mothers can consent for their 
infants' participation in the evaluation despite being under the age of 18 by virtue of 
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being the infant's mother. In fact, the decision to exclude 17-year-old mothers should be 
reexamined due to large numbers of young mothers, particularly ifthe evaluation is 
conducted as part of routine programmatic surveillance rather than as a research project. 
In addition to training revisions, laboratory supply procurement was identified as 
a place for improvement. Many of the supplies needed for DBS collection (e.g. lancets, 
filter paper, drying racks) and laboratory analysis (e.g. reagents) were able to be procured 
locally. Supplies that were acquired internationally were significantly delayed due to 
procurement procedures, customs requirements, and a natural disaster (the earthquake 
and tsunami in Japan in 2011 affected the delivery of some supplies). In the future, 
whenever possible, all supplies should be procured from within Malawi. For supplies that 
are not available within Malawi, every attempt should be made to acquire supplies from 
Southern Africa. In addition, all supplies, regardless of source, should be ordered for 
delivery well in advance of data collection to provide a time buffer against foreseen 
delays. 
5.8.3. Conclusions on the Performance of the Evaluation Approach 
The novel PMTCT evaluation approach was successfully piloted in four districts 
in Malawi. Existing clinic staff accommodated study data collection into their clinical 
responsibilities with minimal disruption. The supervision visits by study staff were an 
important component of ensuring high quality data were collected. However, training 
materials should be improved to ensure ineligible participants are excluded from the 
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study and information on refusals is recorded. It is likely that this method can be 
successfully replicated and scaled up in Malawi to assess vertical transmission. 
5.9. Limitations 
There are several important limitations in the evaluation. First, despite planning to 
collect information on refusal rates, the data were not collected. Without this information 
it is unclear how well the study results reflect the population of caregiver-infant pairs 
who attend immunization clinics. Response rate could not be calculated using standard 
approaches (e.g. American Association for Public Opinion Research calculator) given the 
missing refusal rates. In addition, the lack of refusal rates makes it difficult to draw 
definitive conclusions about the acceptability of this approach with the target population. 
However, regular supervision visits by study staff to all Clinic sites did not identify high 
refusal rates as an issue. 
The evaluation examines MTCT for young infants only ( <3 months of age) as this 
methodology relies on identifying exposed infants through maternal antibodies. Maternal 
antibodies clear from infants at varying rates and are usually undetectable by 18 months 
of age (Ciaranello et al., 2011; Homsy et al., 2007). The implication is that using the 
presence of maternal HIV antibodies to identify HIV exposed infants becomes 
increasingly less precise over time. The older the infant, the more likely the maternal 
antibodies may have cleared from the infant's system, thus we would miss identifying 
exposed infants. Despite the young age limitation, infant immunization clinics provide a 
unique opportunity for evaluating PMTCT outcomes given high immunization rates and 
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the early persistence of maternal antibodies. Testing for transmission beyond the 
breastfeeding period is complicated by the lack of opportunities for the target population 
to come to a centralized venue where testing would be accepted and appropriate, and a 
cadre of clinically trained data collectors are available. Rates of immunization decreases 
as children age (WHO, 2012c) thereby making later immunization visits less likely to be 
representative ofthe population. Furthermore, as 50% ofHIV positive infants die before 
their second birthday without treatment (Newell et al., 2004), testing infants beyond the 
breastfeeding period would likely result in missing HIV positive infants who already 
died, thereby underestimating the transmission rate. 
The vertical transmission rate was lower than expected, particularly given that the 
maternal prevalence rate was higher than expected. Although this suggests PMTCT 
programs are working well, it is important to remember the evaluation does not include 
the entire breastfeeding period during which additional transmissions would occur. The 
provision of ARVs during the breastfeeding period has been shown to reduce 
transmission (Thior et al., 2006; Torpey et al., 2012). The new Option B+ policy to 
provide ART for life to all pregnant and breastfeeding women should be carefully 
monitored to assess of and when decreases in transmission occur (e.g. perinatal period, 
breastfeeding period). If low transmission is found during breastfeeding under Option 
B+, despite including young infants only, this evaluation approach could be a reasonable 
proxy of all vertical transmission given its advantages of relatively simple and rapid 
implementation. 
The survey data may be subject to response bias with caregivers providing what 
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they believe to be the "correct" answer rather than the true answer. Particularly high 
levels of maternal ANC attendance (98%) and previous HlV testing (94%) were reported 
in the survey. However the DHS also found high rates of receiving ANC from a skilled 
attendant (95%) and HIV test coverage with some variation by women's age category 
(89%-92%) (National Statistical Office & ICF Macro, 2010) confirming the evaluation 
survey data. 
Finally, due to power issues, the analysis is primarily descriptive and factors 
associated with transmission were not examined in a logistic regression model as 
originally intended. Given the small number of identified HIV positive infants, p-values 
should be interpreted with caution. The study was not powered to investigate additional 
differences between subgroups. 
5.10. Performance of the Conceptual Framework 
The conceptual framework selected for the evaluation was the RE-AlM 
framework developed by Glasgow and colleagues (Glasgow et al., 1999). This 
framework was chosen due to its unique ability to provide a formalized mechanism for 
incorporating context into the evaluation design and conclusion drawing process. The 
five components of the RE-AlM framework are reach, efficacy, adoption, 
implementation, and maintenance. This section describes the performance of the RE-AlM 
framework, and how each dimension of RE-AlM was examined (Table 5.1.). 
Using the characteristics of participants to assess the first RE-AlM factor of 
"reach" allowed for a better understanding of the representativeness of participants in the 
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evaluation. DHS data show high participation in ANC and high levels of HIV testing by 
pregnant women (National Statistical Office & ICF Macro, 2010), both important early 
components ofPMTCT. The evaluation sample also showed high levels of participation 
in ANC and HIV testing (see Table 4.5), confirming DHS findings and suggesting that 
the evaluation sample may be a good reflection of the general population. However, as 
discussed in the study limitations section (section 5.9.), data were not collected on those 
who refused to participate in the evaluation, somewhat constraining the ability to 
definitively draw conclusions as to the representativeness of the sample. Nonetheless, the 
evaluation and DHS data suggest broad reach of early PMTCT. 
Efficacy, the second RE-AlM factor, was not assessed in the evaluation as the 
efficacy of PMTCT to reduce vertical transmission is widely accepted (WHO & 
UNICEF, 2007; World Health Organization, 2004). Establishing efficacy of an 
adaptation of an intervention is a critical component of evaluation. To this end, future 
research should evaluate the efficacy of the newly adopted Option B+ strategy to prevent 
vertical transmission. 
The third RE-AlM factor of adoption was central during evaluation planning and 
was used when designing the sampling strategy to maximize the generalizability of the 
findings given time and resource constraints. As PMTCT is fully integrated into maternal 
and child care in Malawi (Govef!lillent of Malawi, 2012a), no districts had to be excluded 
from the sampling frame. The final decision for district inclusion was chosen to reflect 
regional diversity, national HIV prevalence patterns, and accessibility issues. 
Generalizability, a function ofthe "adoption" dimension ofRE-AIM, was also factored 
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into the second and third levels of sampling through the decision to randomly sample 
health facilities, and consecutively sample within health facilities. 
Implementation is the fourth factor in the RE-AlM framework. This factor was 
also crucial to consider during study design. The inclusion of a survey to inform 
biological data was influenced by this dimension of the RE-AlM framework. The Malawi 
government monitors the number of participants in each component ofPMTCT (ANC 
attendance, HIV testing, and provision of ARV s ), however data are not captured on HIV 
positive mothers who do not avail themselves of ANC services (the linkage into PMTCT) 
or who are provided ARV s but do take them. The survey was designed to fill in these 
gaps by asking questions about PMTCT participation of all caregivers who attended the 
immunization clinic, not only those who are known HIV positive or known participants 
of PMTCT. By capturing a broader audience in the evaluation, the sample is believed to 
represent the population of caregiver-infant pairs in Malawi. As noted in the results 
chapter, high levels of participation in the early components of the PMTCT cascade 
(ANC attendance and HIV testing) were found, but lower reported levels of using ARVs 
among HIV infected mothers and exposed infants, demonstrating that PMTCT is not 
being implemented with full fidelity compromising its effectiveness. 
The final RE-AlM dimension of maintenance was used to incorporate elements of 
sustainability in the evaluation design, and to assess policy-level commitment to PMTCT. 
As discussed in section 5. 8 .1., sustainability was considered in all implementation 
decisions. Features such as using existing health facility staff as data collectors and using 
local laboratories was critical to the success ofthe evaluation. 
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Although primarily used for the evaluation of individual or structural level 
interventions, RE-AlM has been successful tested to evaluate policies as well (Jilcott, 
Ammerman, Sommers, & Glasgow, 2007). The Malawi MOH launched PMTCT 
activities in 2003 and has continued to expand and adapt the PMTCT program to reflect 
current accepted science and best practices. In 2011 with the launch of Option B+ policy, 
the Malawi government demonstrated willingness to lead with innovative approaches to 
prevent vertical transmission. Using commitment to PMTCT on the policy level, Malawi 
MOH shows strong dedication to the maintenance ofPMTCT. As policies evolve over 
time, it is important for maintenance to be assessed at regular intervals (Jilcott et al., 
2007), both to ensure continued commitment and to evaluate the overall value ofthe 
policy. 
The five dimensions of RE-AlM may have been considered in the 
conceptualization and design of the evaluation even if the framework had not been 
adopted. However the framework provided a structure to systematically and explicitly 
consider and incorporate each dimension in a strategic way. In particular, the dimensions 
of adoption, implementation, and maintenance guided evaluation design, while reach, 
efficacy, and maintenance contextualized the evaluation results. 
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Table 5 .1. Applying RE-AlM to PMTCT Evaluation- Measurement and Performance 
RE-AlM Factor Measurement Performance 
Reach Characteristics of Sample characteristics reflected expected 
participants in the proportions, lack of refusal data constrains 
evaluation - survey data ability to have complete confidence in 
conclusions. 
Efficacy Existing literature PMTCT considered highly efficacious 
intervention for reducing vertical 
transmission; treated as a foundational 
assumption for the PMTCT program and 
the evaluation, therefore was not tested. 
Adoption MOH district & health Guided our sampling strategy, 
facility data on provision strengthened generalizability claims. 
ofPMTCT 
Implementation Implementation of Identified weaknesses in the 
PMTCT - survey data implementation ofPMTCT, namely use of 
ARVs by mothers and infants. 
Maintenance Commitment to PMTCT Prominent policy change signifies strong 
on the policy level; policy commitment to PMTCT; 
components designed into sustainability considerations incorporated 
the evaluation that support into all implementation decisions. 
sustainability 
5.11. Overall Conclusions and Recommendations 
This evaluation was designed to assist the government of Malawi's understanding 
of the effectiveness ofPMTCT in the selected districts. Additionally, if repeated, the 
evaluation will provide valuable trend data to assess the overall performance of PMTCT 
in reducing vertical transmission. The information was useful to districts, in particular, 
for understanding their local epidemic. Using the generated information, district and 
MOH officials are able to make data-informed decisions about allocating resources to 
HIV -infected infant care and treatment. 
The approach used for evaluating PMTCT programs at immunization clinics visits 
was successfully implemented in the four selected districts providing an empirical 
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population-based vertical transmission rate. PMTCT participation data appear valid given 
general consistency with measures from the country-wide population-based DHS. Few 
significant implementation issues were identified. 
There are several alternative methods developed to determine transmission rates 
through the breastfeeding period and HIV free survival, such as cohort studies, clinic 
service data, and the PEARL method which involves a household survey and the 
collection of an infant DBS sample (section 2.4.1.) (Mandala et al., 2012; E. Stringer, 
2008). The important benefits of the approach used in this evaluation compared to other 
methods are the ease of implementation and relatively low cost, both of which increase 
the feasibility of repeating this activity to evaluate trends in PMTCT performance over 
time. Survey and DBS collection require few supplies and many health facility staff are 
already familiar with collecting DBS samples for clinical care and EID. In addition, the 
implementation Toolkit (chapter 7) includes all training and study materials to facilitate 
the replication ofthe study with fidelity in Malawi and beyond. 
An important effort to reduce barriers to maternal treatment and decrease the 
complexity of ARV provision is Malawi's adoption and current scale up of Option B+. 
Approximately one year into implementation, the MOH in Malawi reported 58% 
coverage ofHIV positive pregnant women by Option B+ (Ministry of Health, 2012). The 
impact of Option B+ will need to be carefully documented and studied as it continues to 
be scaled up across Malawi. The approach used in the evaluation is well-suited for that 
task, and the data collected can act as a baseline for evaluating Option B+. 
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The evaluation was conducted to provide useful, actionable data to policy makers 
and health practitioners in Malawi. Rates of participation in PMTCT at the district-level 
can be used to inform decisions about allocation and service provision. In addition, the 
empirically-based vertical transmission rate can be used to improve assumptions in 
existing vertical transmission models. The value of the data produced by this evaluation 
can be augmented by repeating the evaluation over time and examining changes in 
transmission rate as influenced by changes in PMTCT policy and implementation. To 
that end, the following four recommendations provide specific suggestions for repeating 
the evaluation: 
• Recommendation 1: Scale up immunization clinic-based surveillance 
nationally and establish sentinel surveillance sites. 
Given the successful pilot in four districts, this approach should be scaled up to 
evaluate PMTCT nationally. Sentinel surveillance sites should be established for repeated 
implementation at regularly scheduled intervals. By using the same surveillance sites, 
heath facility personnel will be familiar with the activity and more skilled at its 
implementation. In addition, by conducting surveillance at regular intervals, supply 
procurement, training, and staffing needs can be prepared for in advance. 
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• Recommendation 2: Make improvements to the training, including 
translating all materials into the local language and providing clearer 
instructions regarding exclusion criteria and refuser data. 
The validity and quality of the evaluation data could be improved through 
relatively minor adjustments to the training. First, translating the training materials and 
conducting the training to the extent possible in local language can help ensure 
implementation details are not misunderstood due to language barriers. Clarified 
instructions on exclusion criteria will ensure data are not collected from ineligible 
participants. Finally, additional attention and practice for retaining refuser survey forms 
will ensure better understanding of the generalizability of the evaluation results. 
• Recommendation 3: Determine the transmission rate of HIV during the 
breastfeeding period in Malawi; if low under Option B+, use immunization 
clinic-based surveillance vertical transmission rate as a proxy of vertical 
transmission from utero through weaning. 
The surveillance methodology used in this evaluation has the important benefit of 
being relatively easy and inexpensive to implement. Data can be collected, tested, and 
analyzed rapidly to produce the vertical transmission rate. However, reliance on maternal 
antibodies that progressively clear to identify exposed infants prevents this method from 
being able to assess vertical transmission through weaning. If, as expected, Option B+ 
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provides substantial protection against transmission through the breastfeeding period, the 
vertical transmission rate produced by this methodology has the potential to be a 
sufficient approximation of vertical transmission through the breastfeeding period. This 
possibility, however, must be tested. 
• Recommendation 4: Replace ANC-based surveillance with immunization 
clinic-based surveillance. 
National scale up of the approach will provide data on the feasibility of using this 
immunization clinic-based method to replace ANC surveillance (not ANC testing) to 
estimate national HIV prevalence. The benefit of immunization clinic-based surveillance 
over ANC-based surveillance is that it can provide both maternal prevalence rate and 
vertical transmission rate from one interaction and a single sample collection. 
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ABSTRACT 
Background: Prevention of mother-to-child transmission of HIV (PMTCT) is an 
important component of HIV programs in generalized epidemics. Malawi has 
successfully expanded access to PMTCT services, yet effects on transmission are 
unknown. Understanding intervention impact is particularly important given the recent 
adoption of the ' Option B+' strategy, offering HIV -positive pregnant women life-long 
antiretroviral therapy. This study introduced a surveillance approach to assess mother-to-
child transmission rates in Malawi. 
Methods and Findings : A population-based sample of caregivers and infants <3 months 
from 53 immunization clinics were enrolled. Infant dried blood spot samples were tested 
for HIV exposure with an antibody test to determine maternal seropositivity. Positive 
samples were tested for HIV antigen using DNA PCR to determine infant seropositivity 
and the vertical transmission rate. Caregivers were surveyed about maternal receipt of 
PMTCT services. 
Of the 5,068 DBS samples, 764 were ELISA positive indicating 15.1% (14.1-
16.1%) of mothers were HIV -infected and passed antibodies to their infant. Sixty-five of 
the ELISA-positive samples tested positive with DNA PCR, indicating a vertical 
transmission rate of8.5% (6.6-10.7%). Survey data indicates 64.8% ofHIV positive 
mothers and 46.9% of HIV exposed infants received some form of antiretroviral 
prophylaxis. 
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The primary limitation of the study is that it assesses vertical transmission up to 3 
months of age only as the approach relies on identifying exposed infants through 
maternal antibodies that clear from infants over time. Transmissions through the 
breastfeeding period are not captured in this evaluation. 
Conclusions: The observed vertical transmission rate was substantially lower than 
predicted by earlier modeled analyses, suggesting that Malawi's PMTCT program has 
generated substantial benefits through averting perinatal HIV infection. Challenges to full 
implementation of PMTCT remain, particularly around low reported coverage of 
antiretroviral prophylaxis. These results provide a baseline for assessing changes in 
PMTCT effectiveness as Option B+ is introduced. 
Abstract word count: 298 
Keywords: Prevention of mother to child transmission I vertical transmission, Malawi, 
Infant, Immunization, HIV diagnostic tests 
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INTRODUCTION 
In 2011, 330,000 children were infected with HIV, with more than 90% ofthese 
children living in sub-Saharan Africa (UNAIDS, 2012). Transmission ofHIV from 
mother to child remains the primary mode of infection in children (Fasawe et al., 2013; 
Kaye & Zeleke, 2013), and prevention of mother-to-child transmission ofHIV (PMTCT) 
programs are the primary strategy to decrease vertical transmission ofHIV. Approaches 
to evaluating the success of PMTCT programs have mainly measured the implementation 
of individual PMTCT components (i.e. attendance at antenatal care clinics, HIV -testing 
for pregnant women, provision of prophylaxis for mother and infant, and safer feeding 
practices) with little information available on the impact on HIV transmission. It is 
possible that such evaluations have produced overly optimistic assessments of PMTCT 
effectiveness, because studies have found coverage measures overestimate PMTCT 
participation rates (E. M. Stringer et al., 201 0; J. S. Stringer et al., 2003), HIV -infected 
pregnant women dispensed prophylactic antiretrovirals during pregnancy and labor may 
not actually ingest them, clinic record keeping may be poor, or loss-to-follow-up of 
mothers and infants may bias results (Chetty et al., 2012; Mate et al., 2009; E. M. 
Stringer et al. , 201 0). Alternatively, examination of routine surveillance data by 
definition excludes those women who never accessed antenatal care and never realize the 
benefits of PMTCT. Consequently, the actual vertical transmission rate (VTR) remains 
unknown in most countries. To understand the true reach and impact of current PMTCT 
programming, it is critical to utilize methods that capture standardized outcome data on 
all children prenatally exposed to HIV, not just those impacted by PMTCT programs. 
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Malawi has made significant progress in implementing PMTCT since 
programming was launched in 2003, with the number of sites offering PMTCT services 
increasing from 357 in 2007 to 585 in 2012 (Government of Malawi, 2012b). PMTCT is 
fully integrated into maternal and child care, though there has been limited evaluation of 
the program's effectiveness. In 2011 the Malawian government adopted the 'Option B+' 
strategy, offering all HIV -positive pregnant and breastfeeding women antiretroviral 
therapy (ART) for life, regardless of clinical stage or CD4 count (Schouten et al., 2011). 
After the adoption of Option B+ but prior to wide-spread scale-up, we undertook an 
evaluation of Malawi's PMTCT program to derive population-based estimates of the 
VTR by testing a sample of infants presenting for their first immunization clinic visit in 
four districts. By comparing this estimate of VTR to the results of subsequent evaluations 
of the national program now that Option B+ is the established PMTCT strategy in 
Malawi, we will be able to assess trends in the effectiveness ofthe national PMTCT 
program, and by extension, the effectiveness of Option B+ as implemented in this setting. 
METHODS 
Between September and November 2011 we evaluated the national PMTCT 
program in four Malawi districts, adapting a surveillance approach based in under-5 
clinics developed by Nigel Rollins and colleagues in South Africa (Rollins et al., 2007, 
2009). We tested dried blood spot (DBS) samples from young infants ( <3 months of age) 
presenting for their first immunization visit for maternal HIV antibodies and 
· subsequently for HIV with DNA polymerase chain reaction (PCR) to calculate a 
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population-based HIV VTR. As almost all HIV exposed infants will test positive for 
maternal HIV antibodies below 3 months of age even if uninfected, the VTR can be 
estimated as the fraction of antibody positive infants with a reactive DNA PCR 
(indicating HIV infection). Since a substantial majority of infants present for their first 
immunization visit in Malawi, this is a convenient location around which to organize 
surveillance activities. 
Mother-infant pairs were sampled through a three-stage cluster design. The first 
stage purposively sampled four of the 28 Malawi districts to reflect regional diversity. 
Districts were sampled proportionate to HIV prevalence, and as HIV prevalence is twice 
as high in the Southern region (17.6% compared to 8.2% and 9.0% in the North and 
Central regions respectively), twice as many districts were chosen in that region 
(National Statistical Office & ICF Macro, 201 0). Sampled districts were Nkhata Bay in 
the Northern region, Salima in the Central region, and Mulanje and Zomba in the 
Southern region (Figure 1 ). The second stage randomly sampled 53 health facilities 
within the four districts. The health facilities were sampled proportionate to district 
population size and stratified by urban and rural location. In the third stage, all infant-
caregiver pairs meeting the inclusion criteria at the selected facilities between September 
and November 2011 were invited to participate. 
Infants were required to be less than 3 months of age to ensure detection of 
maternal antibodies, if present, as a marker of maternal HIV -infected status and neonatal 
HIV -exposure. In addition, the infant must have presented to the clinic for her or his first 
immunization (a pentavalent diphtheria, tetanus, pertussis, Hib, and hepatitis B vaccine) 
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scheduled for 6 weeks of age. The Malawi infant immunization program reports first 
immunization rates surpassing 97%, ensuring a reasonable approximation of the total 
population of mother-infant pairs in Malawi (National Statistical Office & ICF Macro, 
201 0). In addition, we reqUired the caregiver be in a position to provide consent for 
biological data to be collected from the infant. Appropriate caregiver roles include parent 
or legal guardian. Infants were excluded if the caregiver was younger than 18 years of 
age. 
Based on an estimated 2010 HIV prevalence rate of 11% for women aged 15-49 
(Government ofMalawi, 2010b), our sample size target was approximately 5,500 
caregiver-infant pairs to obtain a sample of 600 HIV -exposed infants. 
Existing clinic staff were trained to collect study data. After obtaining informed 
consent, DBS samples were collected via heel stick from infants, and caregivers were 
surveyed about receipt of maternal HIV testing and PMTCT services. Additional data 
were collected to determine the feasibility of this surveillance approach, including 
detailed implementation information from data collectors during supervision visits. Study 
staff conducted supervision visits to all participating health facilities every two weeks to 
pick up collected data, conduct quality control activities, and provide additional training 
as needed. 
DBS samples were sent to the Ministry of Health National HIV Reference 
Laboratory in Lilongwe and tested for maternal HIV antibodies using an enzyme-linked 
immunosorbent assay (ELISA) test (Vironostika brand6), imd if positive (indicating 
6 Vironostika HIV Uni-Form II Ag/Ab BioMerieux, The Netherlands 
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maternal HIV infection), the sample was transferred to the University of North Carolina 
(UNC) laboratory in Lilongwe to be tested for HIV-1 DNA using a PCR test (Roche 
brand7) to determine the infant' s HIV status. Individual test results were returned to 
clinics to be provided to infant caregivers at the subsequent infant immunization visit. 
We calculated population and district level VTR estimates and conducted 
analyses describing characteristics of PMTCT participation for mothers with ELISA 
positive infants. Estimates were calculated using Generalized Estimating Equations to 
account for the clustered nature of the data. All analyses were undertaken using SAS 
software version 9.3 (SAS Institute Inc., 2011). The study was reviewed and approved by 
the Malawi National Health Sciences Research Committee and the Boston University 
Medical Center Institutional Review Board. 
RESULTS 
Data were collected on 5,634 caregiver-infant pairs. Eighty-eight were excluded 
due to invalid DBS sample, 80 were excluded due to missing DBS sample, and 10 were 
excluded due to missing survey data. An additional476 caregiver-infant pairs were 
excluded from the analysis because they did not meet the inclusion criteria. Forty-four 
mothers self-reported positive HIV status on the survey, but their infant's DBS sample 
tested ELISA negative. We did not perform DNA PCR testing on these samples and, as 
we could not ascertain the reason for the discrepancy, these 44 caregiver-infant pairs 
were not included in the analysis as HIV positive or HIV exposed. The linked survey and 
7 Amplicor HIV-1 DNA PCR V1.5 Roche 
124 
sample data for 5,068 caregiver-infant pairs were used in the analysis. We enrolled fewer 
eligible caregiver-infant pairs than targeted, but our sample included a larger number of 
exposed infants than required by our sample size calculation. 
Eligible caregivers included parents and legal guardians 18 years and older, 
however the majority of caregivers (98.2%) were the infant's mother. The average 
caregiver age was 25 years old, and the average infant age was 8 weeks. The majority of 
participating caregivers reported maternal antenatal care (ANC) attendance (98.4%) and 
previous maternal HIV testing (95.3%). 
[FIGURE 6.1.] 
Of the 5,068 DBS samples included in the analysis 764 were ELISA positive, 
indicating 15.1% (14.1-16.1 %) of mothers were HIV-infected and had passed HIV 
antibodies to their infant. Sixty-five of the 764 ELISA-positive samples tested positive 
with DNA PCR, indicating a vertical transmission rate of 8.5% (6.6-10.7%) across the 
four districts. There was some variation between districts, with Zomba recording the 
lowest transmission rate at 5.8% and Nkhata Bay recording the highest at 10.9%; rates in 
Salima and Mulanje were similar to the rate in Nkhata Bay (9.4% and 10.3% 
respectively) (Figure 1). 
[TABLE 6.1 .] 
The majority ofHIV-infected mothers (as defined by their infant's positive 
ELISA result) self-reported receiving some PMTCT services (Table 1). Most HIV-
infected mothers (98.2%) reported attending ANC at least once during their pregnancy, 
with similarly high proportions in all four districts. Most HIV -infected mothers also 
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reported testing for HIV (94.9%) and over 70% reported previously testing positive, 
indicating most, but not all HIV positive women knew, or were willing to share their 
serostatus. One hundred seventy nine (23.4%) infected mothers reported their most recent 
HIV test was negative, suggesting some women recently seroconverted, received a 
previous false negative result or a false positive ELISA result, or chose not to share their 
seropositive status with the interviewers. In Nkhata Bay a larger proportion of ELISA 
positive mothers reported never testing (6.5%) compared to other districts (0.0-3.5%), 
and a smaller proportion knew their HIV status (63.0%) compared to other districts (over 
70% in each of the other three districts) . At the time of data collection, 92.5% of exposed 
infants (all younger than 3 months) were exclusively breastfed. 
[TABLE 6.2.] 
The provision ofantiretroviral (ARV) drugs to HIV-infected pregnant women and 
exposed infants is a critical component of PMTCT. In Malawi, the current treatment 
regimen for pregnant women under Option B+ is Tenofovir, Lamuvidine, and Efavirenz 
in a daily fixed-dose single tablet (Schouten et al., 2011). The HIV positive mothers in 
our study reported receiving several different ARV regimens with additional variation 
across districts. During pregnancy, the largest proportion of women (38.6%) did not 
receive any ARV prophylaxis (Table 2). This finding was consistent across all of the 
districts except Mulanje where the largest proportion of women (42.9%) received AZT. 
[TABLE 6.3.] 
When asked whether they received ARVs during labor, one-third reported 
receiving none (Table 3). By district, the percent of mothers who reported not receiving 
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ARVs ranged from 41.3% in Nkhata Bay to 29.4% in Mulanje. Among women receiving 
ARVs, similar proportions took single dose Nevirapine (18.2%), Nevirapine/AZT/3TC 
(22.3%), and ART, defined as any of the first or second line regimens used in Malawi at 
the time (20.4%), with some variations across districts. 
In total, 64.8% ofHIV-infected mothers reported receiving some form of ARV 
prophylaxis during pregnancy and/or labor. A smaller proportion of exposed infants 
received treatment with caregivers reporting less than half of exposed infants received 
ARV prophylaxis (46.9%) (Table 1). Recommended infant ARV regimens in Malawi at 
the time of data collection were single dose Nevirapine, single dose Nevirapine followed 
by 1-4 weeks of AZT syrup, or 1-4 weeks of AZT syrup only. 
[TABLE 6.4.] 
Table 4 presents the number and proportion ofPCR positive infants over ELISA 
positive infants, and the relative risk (RR) of transmission for factors associated with 
vertical transmission. The largest proportion of vertical HIV transmission occurred in the 
youngest age group; 12.5% ofmothers aged 18-20 transmitted HIV to their infants, 
compared to about 8% or less for older mothers; however this difference was not 
statistically significant. Transmission rates were also proportionally higher among 
mothers who did not attend ANC, delivered at home and/or with a Traditional Birth 
Attendant (TBA), never tested for HIV, did not receive HIV treatment during pregnancy 
or labor, and whose children did not receive prophylactic ARVs. Infants who did not 
receive prophylactic ARVs after birth had a marginally significant increased risk of 
transmission. 
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DISCUSSION 
This study found that the population based vertical transmission rate for infants 
born between July and October 2011 was 8.5%, considerably lower than recently 
reported modeled vertical transmission rates for Malawi (24.7%) (Government of 
Malawi, 2012a). We would expect the modeled rate to be higher as it includes the entire 
breastfeeding period during which the risk of transmission ranges from 5-20% (WHO & 
UNICEF, 2007), while our study examines transmission in young infants only (<3 
months of age). The proportion of infants exposed to HIV in our sample (15 .1%) is 
higher than the HIV prevalence rate for women aged 15-49 (12.9%) found by the 2010 
Malawi Demographic and Health Survey (DHS) (National Statistical Office & ICF 
Macro, 2010). Despite this difference, regional variation in DHS prevalence rates 
(Northern region: 8.2%, Central region: 9.0%, and Southern region: 17.6%) (National 
Statistical Office & ICF Macro, 2010) were similar to regional differences found in our 
results of maternal prevalence (Nkhata Bay in the Northern region: 9.1 %, Salima in the 
Central region: 10.4%, and Zomba and Mulanje in the Southern region: 17.9% and 16.6% 
respectively). 
The 8.5% transmission rate is lower than anticipated, suggesting that Malawi's 
PMTCT program prior to Option B+ implementation was exceeding expectations with 
many mothers and infants accessing services. However, low reported coverage of ARVs 
(64.8% for pregnant women and 46.9% for exposed infants) indicate challenges to full 
implementation ofPMTCT. Challenges with access to ARVs in Malawi and similar 
settings are persistent and well documented, and include limited CD4 cell count 
128 
infrastructure, poor linkages between HIV testing and treatment, difficulty accessing 
health facilities, and stigma (Ferguson et al., 2012; Levy, 2009; Mandala et al., 2009; 
MMWR, 2013; Rosen & Fox, 2011; Weigel et al., 2012; Wettstein et al., 2012; Zachariah 
et al., 2006). An important effort to reduce barriers to maternal treatment and decrease 
the complexity of ARV provision is Malawi ' s adoption of Option B+. By putting all HIV 
positive pregnant and breastfeeding women on ARVs for life, regardless of clinical stage 
or CD4 count, Option B+ has the potential to simplify access to treatment among HIV 
positive pregnant women and greatly reduce transmission of HIV to infants (MMWR, 
2013; Schouten et al., 2011). Approximately one year into implementation, the Ministry 
of Health in Malawi reported 58% coverage ofHIV positive pregnant women by Option 
B+ (Ministry of Health, 2012). The impact of Option B+ will need to be carefully 
documented and evaluated as it continues to be scaled up across Malawi, both to ensure 
delivery occurs as anticipated and to determine its effectiveness. 
Transmission rates varied by district, with similar rates found in Nkhata Bay, 
Salima, and Mulanje (1 0.9%, 9.4%, and 10.3% respectively), and a significantly lower 
rate found in Zomba (5.8%). Nkhata Bay's marginally higher VTR can be accounted for 
by lower rates of participation in PMTCT activities compared to the other districts. 
Although the differences were small, mothers in the more rural Nkhata Bay were more 
likely to report never testing for HIV and were less likely to report receiving ARVs. 
It is not clear why the transmission rate in Zomba was much lower than in the 
other districts. Mothers in Zomba participated in PMTCT activities at a similar rate as 
mothers in Salima and Mulanje and did not receive a higher proportion of more 
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efficacious ARV regimens. Public and private systems for HIV prevention and treatment 
are more developed and mature in Zomba with a greater number of health facilities 
providing PMTCT services. At the time of data collection, 49 health facilities in Zomba 
were providing PMTCT services, compared to 22 in Nkhata Bay, 21 in Salima, and 24 in 
Mulanje. The lower transmission rate in Zomba is likely an artifact of the overall low 
number of transmissions in the evaluation; however it may be valuable for future research 
to investigate differences in transmission rates by district. 
High rates of ANC attendance at least once during pregnancy among our study 
population (98.2%) indicate that ANC remains an important venue for HIV positive 
women to be identified and linked to care. Although many HIV -infected women already 
knew their status due to previous testing, we found infant HIV testing at immunization 
clinics was another critical opportunity for mothers to learn their HIV status as well as 
that of their children. Of the 5,068 women enrolled in the study 163 (3.2%) reported 
never testing, of which 16 women were ELISA positive (representing 2% of all HIV 
positive women in the study). In addition, 179 mothers identified as HIV positive 
reported their HIV status to be negative on the study survey, further suggesting that 
provision of testing at immunization clinics has the benefit of identifying previously 
unknown HIV -infected women. 
Several important limitations exist in this study. First, despite planning to collect 
information on refusal rates, these data were not collected. Without this information we 
do not know how well our study results reflect the population of caregiver-infant pairs 
who attend immunization clinics. In addition, the lack of refusal rates makes it difficult 
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for us to draw definitive conclusions about the acceptability of this methodology with our 
target population. However, regular supervision visits by study staff to all clinic sites did 
not identify high refusal rates as an issue. Our calculation of relative risk (RR) of factors 
associated with transmission resulted in effects in the expected direction; however given 
the small number of HIV positive infants, p-values were marginal or not statistically 
significant. Finally, the study was not powered to investigate additional differences 
between subgroups. 
This study examines mother-to-child transmission for young infants only ( <3 
months of age) as the methodology relies on identifying exposed infants through maternal 
antibodies which diminish as the child ages (Ciaranello et al., 2011; Homsy et al. , 2007). 
The implication is that using the presence of maternal HIV antibodies to identify HIV 
exposed infants becomes increasingly less precise over time. Despite this limitation, 
infant immunization clinics provide a unique opportunity for evaluating PMTCT 
outcomes given high immunization rates and the early persistence of maternal antibodies. 
It may be worthwhile to repeat this exercise during subsequent immunization visits to 
better understand HIV transmission through weaning, however the accuracy of VTR 
estimates will be affected by the fading of maternal antibodies compounded by decreases 
in immunization clinic attendance as children age (WHO, 2012c). Testing for 
transmission beyond the breastfeeding period is likely best accomplished through 
provider initiated testing in nutrition clinics, sick child visits, and hospital admissions, 
although such efforts alone will underestimate the VTR as they likely reflect a smaller 
proportion ofthe total population, and, without treatment, 50% ofHIV positive infants 
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die before their second birthday (Newell et al., 2004). 
Alternative methods have been developed to determine transmission rates through 
the breastfeeding period and HIV free survival, such as cohort studies, clinic service data, 
and the PMTCT Effectiveness in Africa: Research and Linkages to Care (PEARL) 
method which involves a household survey and the collection of infant DBS samples 
(Mandala et al., 2012; E. Stringer, 2008) . The important benefits of the methodology used 
in this study are the ease of implementation, the relatively low cost, and the relatively 
short time frame (approximately 6 months from sampling to conclusion of data analysis), 
all of which increase the feasibility of repeating this activity to evaluate trends in PMTCT 
performance over time. Survey and DBS collection require few supplies and many health 
facility staff are already familiar with collecting DBS samples for clinical care and Early 
Infant Diagnosis (EID). In addition, we are developing an implementation toolkit, 
including all training and study materials, to facilitate the replication of the study with 
fidelity in Malawi . 
This novel approach used to evaluate PMTCT and develop a population based 
VTR was successfully piloted in four Malawi districts. Existing clinic staff were able to 
accommodate study data collection into their clinical responsibilities with minimal 
disruption. The supervision visits by study staff were an important component of 
ensuring high quality data were collected. However, training materials should be 
improved to ensure ineligible participants are excluded from the study and information on 
refusals is recorded. It is likely that this method can be successfully replicated and scaled 
up in Malawi and elsewhere to assess the impact of Option B+ on vertical transmission. 
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Figure 6.1. Transmission Rates Overall and by District 
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Table 6.1. Self-Reported Participation in PMTCT Activities among HIV -infected 
Mothers 
Total Nkhata Bay Salima Zomba Mulanje 
N=764 N=46 N=106 N=293 N=319 
Mother attended ANC 
at least once 
Yes 98.2% (750) 95.7% (44) 100.0% 98.0% (287) 98 .1%(313) (106) 
No 0.7% (5) 2.2% (1) 0.0% (0) 0.7% (2) 0.6% (2) 
Missing 1.2% (9) 2.2% (1) 0.0% (0) 1.4% (2) 1.3% (4) 
Mother's Most Recent 
HIV Test Result8 
Never tested 2.1% (16) 6.5% (3) 0.0% (0) 0.7% (2) 3.5%(11) 
Negative 23.4% (179) 26.1% (12) 26.4% (28) 22.2% (65) 23.2% (74) 
Positive 71.5% (546) 63.0% (29) 70.8% (75) 73.4% (215) 71.2% (227) 
Don't know/Missing 3.0% (23) 2.3% (2) 2.8% (3) 3.8% (11) 2.2% (7) 
Mother Received ART 
During Pregnancy 
and/or Labor 
Yes 64.8% (495) 58.7% (27) 62.3% (66) 65.9% (193) 65.5% (209) 
No 30.1% (230) 39.1%(18) 35 .9% (38) 27.3% (80) 29.5% (94) 
Missing 5.1% (39) 2.2% (1) 1.9% (2) 6.8% (20) 5.0% (16) 
Infant Received ART 
Prophylaxis 
Yes 46.9% (358) 45.7% (21) 52.8% (56) 52.2% (153) 40.1% (128) 
No 46.5% (355) 45.7% (21) 45.3% (48) 39.3% (115) 53.6% (171) 
Missing 6.7% (51) 8.7% (4) 1.9% (2) 8.5% (25) 6.3% (20) 
Exclusive Breastfeeding 
Yes 92.5% (707) 87.0% (40) 93.4% (99) 91.1% (267) 94.4% (301) 
No 6.2% (47) 10.9% (5) 6.6% (7) 7.9% (23) 3.8% (12) 
Missing 1.3% (10) 2.2% (1) 0.0% (0) 1.0% (3) 1.9% (6) 
8 Caregiver report prior to ELISA testing 
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Table 6.2. HIV Treatment Regimen during Pregnancy 
%Total (#) % NkhataBay % Salima %Zomba % Mulanje 
Treatment Regimen N=764 N=46 N=106 N=293 N=319 
None 38.6 (295) 43.5 (20) 44.3 (47) 39.3 (115) 35.4 (113) 
AZT 29.3 (224) 21.7 (10) 17 (18) 20.1 (59) 42 .9 (137) 
ART'} 26.1 (199) 30.4 (14) 34.9 (37) 33 .8 (99) 15.4 (49) 
Don't 6.1 (46) 4.4 (2) 3.8 (4) 6.8 (20) 6.3 (20) know/Missing 
Table 6.3. HIV Treatment Regimen During Labor 
Total NkhataBay Salima Zomba Mulanje 
Treatment Regimen N=764 N=46 N=106 N=293 N=319 
None 33 .5 (256) 41.3 (19) 37.7 (40) 34.8 (111) 29.4 (86) 
Single-dose 18.2 (139) 6.5 (3) 22.6 (24) 19.8 (63) 16.7 (49) 
N evirapine (NVP) 
NVP AZT3TC 22.3 (170) 21.7 (10) 17 (18) 28.2 (90) 17.8 (52) 
ART 10 20.4 (156) 28 .3 (13) 21.7 (23) 11.9(38) 28 (82) 
Don't Know/Missing 5.6(43) 2.2 (1) 0.9 (1) 5.3 (17) 8.2 (24) 
9 Any of the first or second line regimens used in Malawi at the time, including: D4T+3TC+NVP, 
d4T+3TC/EFV, AZT+3TC/EFV, AZT+3TC/TDFILPV/r 
10 Any of the first or second line regimens used in Malawi at the time, including: 
D4T+3TC+NVP, d4T+3TC/EFV, AZT+3TC/EFV, AZT+3TC/TDF/LPV/r 
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Table 6.4. Relative Risk ofHIV Transmission by Risk Factor Among ELISA Positive 
Infants 
Variables # ofPCR-pos 11 Relative Risk P-value 
(%of ELISA- (95% CI) 
pos) 
Age of Mother 
18-20 years 9 (12.5) 1.5 (0.8-2.9) 0.19 
21-30 years (reference) 36 (8.1) 
31-40 years 20 (8.6) 1.0 (0.7-1.7) 0.84 
Mother Attended ANC 
Yes (reference) 63 (8.4) 
No 1 (20.0) 2.4 (0.4-15.4) 0.36 
Place of Delivery 
Hospital or Clinic (reference) 53 (8.2) 
Home and/or with Traditional 
12(11.8) 1.4 (0.8-2.4) 0.18 
Birth Attendant 
Mother's Most Recent HIV Test 
Result 12 
Positive (reference) 41 (7.5) 
Never tested 3 (18.8) 2.5 (0.8-7.7) 0.11 
Negative 20 (11.2) 1.5 (0.9-2.6) 0.15 
Mother Received HIV Treatment 
During Pregnancy and/or Labor 
Yes (reference) 37 (7.5) 
No 24 (10.4) 1.4 (0.9-2.2) 0.15 
Infant Received Prophylactic ARVs 
Yes (reference) 24 (6.7) 
No 37 (10.4) 1.6 (1.0-2.5) 0.07 
11 N=65- "don't know" and "missing" responses are not presented in the table 
12 Caregiver report prior to ELISA testing 
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Acronyms 
AIDS - acquired immunodeficiency syndrome 
ANC- antenatal clinic 
ART - antiretroviral therapy 
AR V - antiretroviral 
DBS -dried blood spots 
DNA PCR- DNA polymerase chain reaction 
EID- Early infant diagnosis 
ELISA- Enzyme-linked immunosorbent assay 
HIV - human immunodeficiency virus 
HSA - Health Surveillance Assistants 
MSH - Management Sciences for Health 
MTC -mother-to-child transmission (of HIV) 
PMTCT- prevention of mother-to-child transmission (of HIV) 
RHT - Rapid HIV test 
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Introduction and Overview 
Introduction 
This Toolkit will provide you with samples, templates, and manuals to help you establish 
and implement a surveillance system in health facilities to measure the effectiveness of 
prevention of mother-to-child transmission (PMTCT) efforts in reducing HIV 
transmission to young infants. 
The approach described in this Toolkit was developed in South Africa by researcher 
Nigel Rollins 13 , and is based on its adaptation and pilot in four districts in Malawi in 
2011 . The pilot project on which the toolkit is based was led by the non-governmental 
organization Management Sciences for Health (MSH) in collaboration with the Ministry 
of Health in Malawi. 
Evaluating the impact of PMTCT programs is critical to understanding the extent that 
your PMTCT programs are reducing transmission and for making improvements to 
PMTCT services. 
13 Rollins N, Mzolo S, Moodley T, Esterhuizen T, van Rooyen H (2009) Universal HIV testing of 
infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in 
high HIV prevalence settings. AIDS (London, England) 23: 1851-1857. 
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Overview 
The Toolkit will guide you through the process of collecting the data for the evaluation 
from infants and their caregivers who go to selected health facilities for their first 
immunization visit, which is usually scheduled for 6 weeks of age. This approach for the 
evaluation works best in settings where immunization rates are high (>90%) so the 
sampled caregivers and infants are more likely to be similar to the population as a whole. 
The sequence of evaluation activities is presented below (Figure 1 ). 
Caregivers who agree to participate in the evaluation are given a short survey on the 
infant mother' s experience with HIV testing and PMTCT interventions. These questions 
provide information on coverage of PMTCT interventions among pregnant women in the 
participating areas. After the survey, dried blood spot (DBS) samples are collected from 
infants by heel stick. The DBS samples are analyzed in a laboratory to measure HIV 
antibody using an ELISA test (to determine mother's HIV status). Infants who are ELISA 
positive have been exposed to HIV from their mothers. Samples that are positive with the 
ELISA test are then tested with DNA-PCR to identify HIV positive infants. The 
transmission rate of HIV from mother to child is calculated by dividing the number of 
HIV positive infants by the number of HIV exposed (ELISA positive) infants. 
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Figure 1: Evaluation Flow Diagram 
I 
I 
All infants receiving their first 
immunization <4 months 
I 
Caregiver invited to participate in 
PMTCT surveillance project 
I 
I I 
Caregiver consents to testing Caregiver does n ot consent to 
nfant infant testing i 
I 
Infant heel stick, 
Caregiver survey 
I 
I I 
ELISAPos I I ELISA Neg I 
I 
DNAPCR I 
I 
Results returned to caregivers 
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It is important to note that this evaluation approach works on young infants only and 
therefore does not measure transmission from mother-to-child through the breastfeeding 
period in settings where breastfeeding typically extends beyond the fust four months. 
The results of the evaluation are of immediate use for policy makers providing evidence 
of the field-effectiveness of current PMTCT efforts, and also providing a baseline against 
which new approaches can be measured. In Malawi, the results of the evaluation will be 
used to measure the effectiveness of the new national PMTCT strategy called Option B+ 
to put all HIV positive pregnant and breastfeeding women on antiretroviral therapy 
(ART) for life. 
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How to Use This Toolkit 
This Toolkit provides instructions and all the implementation pieces and templates you 
will need to launch an immunization clinic-based evaluation of PMTCT. 
The Toolkit sections are: 
• Section 1: Evaluation Set Up 
• Section 2: Training 
• Section 3: Evaluation Procedures & Implementation 
• Section 4: Data Analysis 
The Toolkit contains information to help you set up the evaluation, train data collectors, 
implement the evaluation, and analyze the data. Copies of the actual implementation 
materials (e.g. training slides) can be found in the appendix at the end of the Toolkit. 
Editable copies of forms, slides, and templates are available on a flash drive/ CD to allow 
for customization. 
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Section 1: Evaluation Set Up 
1.1. Calculating Sample Size 
1.2. Getting the Supplies 
1.3. Selecting the Sites for the Evaluation 
1.4. Identifying Data Collectors 
1.1. Calculating the Sample Size 
One of the first decisions you will have to make in planning your evaluation is to 
determine the number of samples to collect. This is called the sample size, which is the 
number of caregiver-infant pairs you need to enroll in the evaluation to calculate a 
vertical transmission rate that represents the larger population. The larger population you 
want to draw conclusions on can be district-, region-, or country-level. 
The sample size is also important for program planning. Knowing the number of samples 
you will collect is important for decisions related to budgeting, supply procurement, and 
personnel hiring. 
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Sample size decisions are often based on finding a balance between precision (larger 
samples result in more accurate estimates) and budgetary constraints. 
The flash drive/CD contains a customizable sample size Excel table that will give you a 
range of sample size options. The sample sizes presented in the table are based on local 
data you will need to input: 
1. Local HIV prevalence (column 2), preferable the prevalence of woman aged 15-
49 
2. Current local estimated vertical transmission rate (column 4) 
Table 1 shows the sample size calculation table used in Malawi. You will notice that the 
larger the sample size (column 1) the narrower the confidence interval width (column 6). 
As the sample size increases and the confidence interval narrows your estimate of the 
vertical transmission rate becomes more precise. 
To estimate the amount of time you need to achieve the sample size, you should look at 
records of the number of first immunization conducted per month at health facilities. 
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Table 1. Sample Size Calculation 
Coil Col2 Col3 Col4 Col5 Col6 
Sample Size Est. Sample Size of Est. 
of All (N) Prevalence Exposed (N) Transmission Alpha-level CI Width 
909 11.0% 100 13.8% 5.0% 13.4% 
1,645 11.0% 181 13.8% 5.0% 10.0% 
1,818 11.0% 200 13.8% 5.0% 9.5% 
2,727 11.0% 300 13 .8% 5.0% 7.8% 
3,636 11.0% 400 13.8% 5.0% 6.7% 
4,545 11.0% 500 13.8% 5.0% 6.0% 
5,455 11.0% 600 13.8% 5.0% 5.5% 
6,364 11.0% 700 13.8% 5.0% 5.1% 
7,273 11.0% 800 13.8% 5.0% 4.8% 
8,182 11.0% 900 13.8% 5.0% 4.5% 
1.2. Getting the Supplies for the Evaluation 
You will need supplies for survey administration, record keeping, and DBS sample 
collection. The number of supplies you need will depend on the sample size. 
The complete list of supplies needed for survey administration, record keeping, and DBS 
sample collection is included in Appendix 1 and on the flash drive/CD. You can enter the 
number of each supply you need and the cost of supplies into the form. Also included in 
Appendix 1 and the flash drive/CD is a sample of a supply Delivery Note. The Delivery 
note is a mechanism to ensure all required supplies have been delivered and received to 
participating health facilities. A Delivery Note should be completed every time supplies 
are delivered to each facility. 
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You may also need to purchase laboratory supplies, such as testing kits. As the individual 
or organization managing the evaluation, you will need to identify the laboratory(ies) that 
will test the DBS samples. Expectations of what supplies will need to be procured and by 
whom will vary by laboratory. You will need to have this discussion with the laboratory 
that will test your samples. 
1.3. Selecting the Sites for the Evaluation 
Random sampling is considered the "gold standard" for site selection as it is more likely 
to result in a sample that represents the larger population. However there are good 
reasons to purposively sample (choosing specific areas to sample). In Malawi, we 
purposively sampled four districts, choosing the districts to reflect regional diversity. We 
also considered accessibility when choosing districts as sampling from the more remote 
districts would greatly increase transport costs. 
To decide how many health facilities to sample you will need to consider the number of 
samples needed to feasibly reach your sample size in the time allotted for data collection. 
In Malawi we reviewed the number of immunizations in each selected district from the 
previous year and decided that we needed to sample 53 health facilities to reach our 
sample size given the 8 weeks allotted for data collection. 
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Once you have determined how many facilities you need, you will select them using a 
random sampling technique. Obtain a complete list of health facilities within the selected 
regions or districts for your random sampling. In Malawi we obtained a complete list of 
health facilities per district. We eliminated any health facility that did not conduct infant 
immunizations and those that were difficult to access. From the remaining health 
facilities were randomly selected 53. We selected more health facilities in districts with 
larger populations. 
1.4. Identifying Data Collectors 
Existing health facility staff usually make the best data collectors. First, they are already 
familiar with the clinic and clinic procedures. Second, data can be captured across all 
sites concurrently. Finally, existing staff may already be familiar with DBS collection 
from clinical care responsibilities. The person best suited to be trained to collect data is 
the health facility worker who gives infant vaccinations. 
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Section 2: Training 
2.1. Training Overview 
2.2. Training Manual 
2.3. Training Slides 
2.1. Training Overview 
The training lasts one and a half days and provides data collectors the information they 
need to implement the evaluation at the.ir health facility. Hands-on practice for 
administering the survey and collecting the DBS sample make up a large part of the 
training. 
Depending on the number of data collection sites and the distance between sites, you may 
want to hold multiple trainings so the number of trainees is not too large or the distance 
they have to travel is not too far. In Malawi we held four trainings total; one in each of 
three participating districts, plus two in the fourth district with the largest number of data 
collection sites. 
The training team should include the project leads who have a strong understanding of 
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the evaluation methods and can answer a variety of questions that may be posed during 
the training. Laboratory representatives who are familiar with DBS collection and testing 
should lead the sessions related to DBS collection. 
Training Agenda Day 1 
Time Activity 
8.30hrs Welcome, Opening Remarks, & Overview of 
8.45hrs Overview of the Research Project 
9.00hrs Recruitment, Screening, & Obtaining Consent 
JO.OOhrs Break 
10: 15hrs Questionnaire Theory & Practice 
12.15noon Lunch 
13 .15hrs Dried Blood Spot Collection Theory 
14.15hrs Dried Blood Spot Collection Practice 
15.00hrs Break 
15: 15hrs Dried Blood Spot Collection Practice (continued) 
16.50hrs Summary of day 1 
17.00hrs End of day 1 
Training Agenda Day 2 (half day) 
Time Activity 
8.30hrs Review of day 1 
8.45hrs Dried Blood Spot Collection Practice 
9.30hrs Data Management 
JO.OOhrs Break 
10:15hrs Rapid HIV Test, Returning Results, & Linking to Care 
11 :OOhrs Practice: Rehearsal Data Collection Start to Finish 
12:10hrs Wrap-up & Logistics 
12.25hrs Closing remarks 
12:30hrs End training 
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2.2 Training Manual 
The training manual provides an overview of the training and can serve as an excellent 
reference during data collection in the health facilities. Each data collector should receive 
a copy of the training manual at the start of the training. 
Inside the manual you will find implementation information as covered in more detail 
during the training. The manual also includes an evaluation form to collect participant 
feedback on the training. The evaluation form will help you make improvements to the 
training. In Malawi we also provided a table in the manual that listed every data 
collection site and the sample size target for that site. 
The Training Manual used in Malawi is included in Appendix 2 with an edible Microsoft 
Word version on the flash drive/CD that you can adapt for your particular situation. 
2.2. Training Slides 
The Power Point slides developed for each session of the training will help you 
communicate information on the evaluation goals, procedures, and implementation 
details to the data collectors. Opportunities for trainee participation and hands-on practice 
are indicated in the slide presentations. 
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The session content covered in the slides is as follows: 
• Session 1 : Welcome, Opening Remarks, & Overview of Training 
o Review training agenda 
o Training logistics -length, allowances 
o What is PMTCT 
o Expectations 
• Session 2: Overview of the Evaluation 
o Evaluation goals and overview 
o Evaluation districts, methods, & process 
• Session 3: Recruitment, Screening, Informed Consent 
o Recruitment - who & how to invite 
o Screening - determining who can & cannot take part 
o Informed consent- description & implementation 
• Session 4: Questionnaire Theory & Practice 
o Walk through of all questions in the questionnaire 
o Practice in pairs 
• Session 5: DBS Collection Theory (lecture) 
o Collection process 
o Identifying valid & invalid samples 
• Session 6: DBS Collection Practice 
o Demonstration by trainers 
o Practice in pairs using finger pricks 
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• Session 7: Data Management 
o PMTCT Evaluation Register 
o Study ID numbers 
• Session 8: Optional Rapid HIV Test, Returning Results, & Linking to Care 
o Providing optional rapid HIV test for immediate results 
o Returning HIV test results to infant caregivers 
o Matrix of care based on DBS test result 
• Session 9: Practice Complete Evaluation Process 
o Practice evaluation implementation from recruitment to providing results 
• Session 10: Study Implementation 
o Number of samples 
o Data collection period 
o Evaluation supplies 
o Supervision visits 
o Payment of data collectors 
• Session 11: Closing Remarks 
You can find copies of all slides in Appendix 3 with editable versions on the flash 
dri ve/CD. You can adapt these slides to meet the specific needs of your training program. 
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Section 3: Evaluation Procedures & Implementation 
3 .1. Implementation Overview 
3 .2. Recruitment of Participants 
3.3. Screening Participants 
3.4. Obtaining Informed Consent 
3.5. Assigning Study ID Numbers 
3.6. Administering the Questionnaire 
3.3. Collecting Dried Blood Spots 
3.4. Keeping the PMTCT Evaluation Register Up-To-Date 
3.5. Completing the Supervision Visit Form 
3.6. Assuring Maintenance of Evaluation Data 
3.1. Implementation Overview 
When you are ready to implement your program you will need to successfully 
accomplish several specific activities. In your facility you will have to recruit caregiver-
infant pairs for the program, screen them for eligibility, obtain informed consent, assign 
each caregiver-infant pair a study ID number, administer a short questionnaire, collect a 
dried blood spot from the infant, fill out the PMTCT evaluation register, organize and 
lead the program supervisory visits, and ensure the maintenance of study data. In this 
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section you will learn about each of these steps and review the process for collecting data 
at your facility (see Box 1). 
3.2. Recruitment of Participants 
You should invite all the caregivers who come to your health facility for their infant's 
first immunization to participate in the evaluation. The process for identifying the 
caregivers and infant pairs will likely vary from health facility to health facility. Larger 
health facilities may have a staff person who registers the infant and directs caregivers 
where to receive care. In smaller clinics one person may greet, register, and provide 
immunizations. 
You will have to train the staff person who registers infants for care about the study so 
that all eligible participants can be invited into the study. The evaluation approach relies 
on the participation of all eligible participants who agree to take part in the study. 
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Box 1: A summary of the data collection steps for every caregiver-infant pair are: 
1. Recruit participants - invite caregivers and infants pairs into the evaluation 
2. Screen participants- exclude caregivers and infants who are not eligible to 
participate 
3. Obtain informed consent- inform caregivers about everything that happens 
in the study so they can freely decide if they want to participate 
4. Assign a study identification number- give a unique number to all forms 
attached to each caregiver-infant pair, numbers are pre-printed on stickers 
5. Complete the survey form- read the survey to caregivers and record their 
answers 
6. Collect dried blood spot (DBS)- prick the infant's heel and drip 4 blood 
drops in the circles on the form provided 
7. Complete Evaluation PMTCT Register- record date, infant name, and 
study ID in the clinic-based log 
3.3. Screening Participants 
The eligibility requirements for participants are listed in Box 2. 
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The evaluation is designed to include infants 16 weeks of age ( 4 months) or younger 
only. Only young infants are included in the evaluation because the HIV test that is used 
to determine the number of exposed infants (infants whose mothers are HIV positive) 
becomes less accurate as infants age. 
Box 2: Screening Criteria for Study Eligibility 
The study has requirements of who can participate. 
These requirements are: 
• Infant MUST be 16 weeks of age or younger 
• Infant MUST receive their first immunization during the visit to the health facility 
• Caregiver MUST be a parent or legal guardian 
Although the first immunization is scheduled at 6 weeks, infants may come in earlier or 
later. For this evaluation you should only include infants who are 16 weeks of age or 
younger, even if they come in for their first immunization visit. Older infants cannot be 
included because the HIV test you will use may not work correctly with older infants. 
Only caregivers who are parents or legal guardians of the infants can give permission for 
a DBS sample to be collected. Therefore if a caregiver is not a parent or legal guardian, 
neither they, nor the infant can participate. 
The screening, questionnaire, and informed consent document are combined in a single 
form (see Appendix 4). One you have invited all caregivers and infants to participate in 
the evaluation, the data collectors at your facility will use the Screening Form and 
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PMTCT Evaluation Survey to identify caregivers and infants who are not eligible to 
participate. One form should be used for each caregiver-infant pair. 
Data collectors read the prepared text at the top of the Screening and PMTCT Evaluation 
Survey form and ask the caregivers the two screening questions: 
Is this child here today for her/his first vaccination? y N 
Is the child younger than 16 weeks of age? y N 
If the caregiver answers "No" to either of these questions, they and their infant cannot 
participate in the study. If they are not eligible to participate, data collector should let 
them know and thank them for their time. 
3.4. Obtaining Informed Consent 
After the screening questions, the survey form will prompt the data collector to obtain 
informed consent from caregivers who are eligible. Caregivers will be consenting for 
both their participation and the participation of their infant. 
"Informed consent" means that the research participants understand the study goals, 
procedures, benefits, and risk well enough to be truly informed when making their 
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decision whether or not to participate in the research. For consent to be genuine there 
must be no coercion of any kind. It is very important that no pressure is put on caregivers 
to encourage them to participate. 
If a caregiver agrees to participate in the study they must sign the Informed Consent 
letter. 
Participation in the study must include BOTH the caregiver and the infant. If the 
caregiver will answer the survey questions, but will not consent for a blood sample from 
the infant, then the caregiver cannot be enrolled in the study. If the caregiver agrees to the 
infant blood sample, but will not answer the survey questions, again, neither can 
participate in the study. Caregivers can refuse to answer some questions in the survey, but 
cannot refuse the survey entirely. 
If a caregiver refuses to give consent to participate instruct the data collectors to record 
the reason why the caregiver will not consent in the space provided on the form. Data 
collectors should retain all partially completed forms . Incomplete forms will give you 
information on the number of eligible participants not included in the sample and 
therefore the representativeness of the sample. 
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3.5. Assigning Study ID Numbers 
After providing informed consent, the caregiver-infant pair is considered "emolled" in 
the study and must be assigned a study identification ("ID") number. Instructions for 
labeling study components with ID numbers is included in Box 3. 
All data collected from a caregiver-infant pair must be labeled with the same ID number 
to link DBS and questionnaire results, and to return HIV test results to caregivers. 
Box 3: Instructions for Labeling DBS and Questionnaires with Preprinted ID Number Stickers 
Pre-printed ID number stickers should be provided to participating health facilities for data 
collection. A minimum of five stickers must have the same ID number to link the evaluation 
components to be placed on: 1.) the screening and questionnaire form (two stickers), 2.) the 
DBS filter paper, 3.) the Evaluation PMTCT Register, and 4.) each participating infant's 
health passport. The correct placement of the ID number sticker on each of the above 
components is indicated, with the exception of the infant's health passport. 
Readable bar codes on the ID number stickers are valuable if sample testing occurs in a 
laboratory that uses barcode scanners to enter samples into their computer system. 
An image of an ID sticker sheet from the Malawi study is below. Details for assigning 
study ID numbers are included in the training slides. 
161 
•• • ~ , _ ' J ·'·' M.·, .~ . . . -. ,·,·,·-v, • , _ ,,,• ,,, . ., ... ., -. .•J -...· . ~ ·~ ~ . -... -· .. ···"•"• .' ....... " ·•·• ~ .~..-. J .. ~· .... ·.-.· • .-~ , ,.;, , J- ·•· •"" ,,.,, ,.__.._ .,_,., ..... ~ .·) • ._. .•. _ .,., ,. ,.,.• .. • , ,., .. ,-, <.-.•; /,.y , , ., - ;,.,, •. ,,, A . .-. .' . . ... ,~ ·•,. 'J • • , ,.· .. , · ... . .. , , , _ 
A 111111111m11111111111  B 111111111 :1 1 1~1111111111 C ~1111111111~1111 1111: 111 O ~ lllllllll llll~llllllll E 1111111111 11111111111 
135 741 . 7 135 741 . 7 135 741 - 7 135 741 · 7 
A lllllllllm~llllllll ~l B IIIIIIIIWIIIIIIIIIIU c mlllllllll llllllllllll D mlllllllll l ml ~ lllll E llllllllllltmllllllll 
135 742 - 5 135 742 - 5 135 742 · 5 135 742 - 5 135 742 - 5 
• • • . • • • • . • . ·>·:· •• •• •.. • •.· ... ' .·• : " ' "·' .• :~ - • • «·. -:. ·•<' .......... . :.- .• .• •. '· • :· ~- < • .;. ~· • .••• • • . , .• •:-' •:· •:•< ,- .~~~ .. . ;. • ·)( . ..... •···• · o: ·:· ._.,. ,. ,. :• ·· ~ • Jl. •• • •:· .. ,, .... :• .. . , .• " • •• • :- · ..... -:· ..... ,_ • • , • • ••• ' 
• •• • • • .... ·: • • • .•••• ' ... ' ' •. •• .. . .. .• ' . ... .. ~ • ..... ·~ .• • ,. ' .... . ..... • ..... <:•·:• •. • • . .. •.· • ./·' . .. ..... _. ,',. • > .... ···.• • • . .. ·> • ••••• ••• ~ • •• •.· •. • .. .. ••• " • ' .. .. • • • .. 
A IIIIIIIIIIUIIIIIIII~I B UIIIIII I IIIIIIIIIIU c ~1111111111 1111~ 1111111 D ~llllllllllllll~lllllll E 11111111111111111111111 
135 743 . 3 135 743 . 3 135 743 - 3 135 743 - 3 135 743 . 3 
... J , ......... ~ , J , 'o ' ,o .. , 0 • ¥ •'O "''"" '· _,.,, ... _... 'h,'o 'W •J,'O V ·'"' 0 w, J', ..._ ,._ ,.,. ,,, ',V.', 'N' y ... .,.,,, "'·""-""'-"' " J o'o W o'Jo'o' ' J.'o' .. , ......... .... ... , . ,.. ' '<'•'O '"'·" " ' V o' ~'""""'"'' "'"'''N"· 'O '"'·'J ""Y , . .,, ,..,., . .,,.._..,, ........... .,.. Y """ '"".-.·A ........ ..,_ .;;, ........ ,.,. V '"' V • .,. ... , .,, ... ..__, 
i A 1111111111 11~11111111 ~~ B IIIIIIIIII IUIIIIIIIIII c lllllllllllllllllllmll o ~ 1111111111 111 1 111111111 E 11111111111~11 111111111 
135 744- 1 135 744 . 1 135 744 -1 
A lllllllliillllllllllllll a llllllllmllllllllml c ~ 11 11111111111~1 ~ 11'111 D n111111111 111  E IIIIIIIIUIIIIIIIIII 
135 745 - 8 135 745 . 8 135 745 - 8 135 745 - 8 135 745- 8 
, "' '""''H"'''' ·'/~··• ·•··"'r'•'w'•"' 'r ••.. , .,. •- •••y.•;•V ',' ',•'Y'(''"' ""' " "'" '" " '·"' ' '',._ . .. ,..,, .,. " "'!·" '.' ·· ~ ·"''''"'f''"t''t.'''"· , .. _.,n .. ~~ '¥"··""''·''"'!;'fY'"W "· 'f " "'( '''Y"''_. . ... ,,. , . .. ,. . .,. •• ,., .,._.,. . • ., • .,..,, ,, ,~ , .. , ·• '·"·'• • ... ,_ ... .... 
A 111111111~ 1 111111111m a llllllllmllllllllll ;~l c llllllllllllllllilllllll D mllllllllllllllllllll E 11111111111111111111111 
135 746 - 6 135 746 - 6 135 746 - 6 135 746 - 6 135 746 - 6 
, " " , ,. , . "".' _ , . ~ ,. •: ., _. •; ',",' !.""·'· ., ·.~"· ,. .1,. •: ''·'>" :.•: .•. ·;r:. • ·.w 't '.'," .' '•;.YY-''' _.,._. , .... , ·.".' ',".'.''' ,, y ·c. '."!.' •.' " .' ,, ._ .. _. . ,,.._. • .~"f'.<,",'.',•: .v ... , •: y.· :.- ·o: •.•s• : .• ., . '( ,,· -, ·-;,• 'f'' " Y.' ." W'·• ·:," · .\"rW"'';. .. . , " ' .' _ ,., , .. ., .. '' ' • '.• " ' •: .'· " ' " ' ' 
.... .. ~ ... -.. ~ .. -.. -~.-........ -..... .... _., .... _ .. ,..~.- .... -.. ...... ...................... , ... ..... .,., ...... ...... .... , ... .,, ..... ,. ......................... .................. ~ ......... "'•" '""···--··.,~·· · "•'"' '"''·'""·"' '-'· " ..... ... , ..... ............... .......... -... . ,.. ..... .. ~-.. -.... -... , ...... -. 
l A Ulllllll~llllllllll~l s llllllllllll'''lll!ll:ll c llllllllllllllllllllllll o mlllllllllllllmlllll E 1111111111111111111111 
1 135 747-4 135 747 -4 135 747- 4 135 747 - 4 135 747 - 4 
, , " ._. ' ' ,,.,..,,...,, _.-, ,o '• "''' ' • ..... o.·~ y ,,, ., <A .. ._;. " 0o, _., ,,, •o .... '-"'- ' ._, ,,...,. ... "'""'' .._ ,.,. ... ··~·- ...... , .... , Y<A ... .,._ ~ .,._ ~ o'• ,._ ,,, '• "v •o <o• v"'"' ....... " .,;. ,.._ h"' ,T, , , ...., V '•'" , _.... "'""""' ,,,._.. ""' .._,., '<'"V-'• ·~·'V- ' • 'V ""' ...... A , ,_;. oV '• .... •• 'A' V '""' - o -• ... w - •V " .... •, '• y '• 
, , ~· ·, •" , . ., , , • : ,•, '• · • '• ·· , > ~ .. '··~· •'·C-'"'•·• , ... , v ~" • ,. , .. ,, , . .,,,.,, .• ,,. v v ·~· "•· • , . , .,_ ._ • • • .,._ ... ~ ~ ' ' ' <"• f• ... ·• ·• ·'• ' ·' • :.~:·• V L 'o' '' ,.,,.,.., , .., .• ,••• •' • V' o· • ·•· •'•' " • •" • • > ., •"• •,•,• 
A lllllllllm~llllllml a IIIIIIIIIJII~IIIIIIml c ~IIIIIIIIIUIIII IIUIII D mllllllllllllll llllllll E llllllllllllllllllllll 
135 748- 2 135 748- 2 135 748 . 2 135 748 - 2 135 748- 2 
• • • ,. .. .... .. . ... ;;. •.• .... _. .. ... .. ... • .. . ;.;: : : -~· .. •• •; •. , ... ,, ; ·::.. ,-. -'·'· :.· ••• .,., ..... ,- ~-. .. ..... ,, ,·; :. •;, '\ ..... ·' .... ... ; ,, ........ ........ ....... : • .... ; . "J. ;,· ......... ·.-.. ~· .•: • ......... , .... ............. ... .... -~· :•. :: ..... ,._. .•: • .... ·'-' .. , .·: • • _., ,,;. •::.. . ......... ·>. ·••• >: •: . ... ..... ........ : . .... - .~. :, .•.••. ~-.. •::: ......... · • . : • . . •, ;... .' • 
; A llllllllllll~llllllll~l B nlllllllllllllllllm c ll llllllllll~~~l i iiUII o mllllllllllllllllllllll E ~llllllllllllllllllllll 
135 749 - 0 135 749-0 135 749 - 0 135 749 - 0 135 749-0 
;._ .,._,., ,_, ..,,.._ .• . , • "·-· •''"' ""' ''''"" ''• '" "" "'"'W'"' ,., , ., • o ' '' "''" '"'"''"'''" wo•o'""""""""''' ' ' • ... ··· · ·-·'"""'"'"''- ' '"" ·''•'•''""""w"-. ·· · - •••"·" "'"' ""'"'"' o ' '' ' """'"""" 
A 1111111111 11~11111111~1 B 1111111111 !1~11111111~1 c mlllllllllllmllllllll o Ulllllllllllllllllllll E 1111111111111111111111 
135 750 - 8 135 750- 8 135 750- 8 135 750 - 8 135 750- 8 
A 111111111111111111111111  B 11111111111111111111111 c fr llllllllll llllllllllll 0 ~JIIIIIIIII IIIII IIIIIII E 1111111111111111111111  
135 751- 6 135 751- 6 135 751- 6 135 751- 6 135 751 - 6 
·•· .. . • .. •• •• • •• •· ................ '· ... ·: ... ·: . ............ , J: -, .. ,·:.· ·' -~· ........ , ~-:-·.-.-. :: , • • ; ·: .... ; .. . ,,· .. ·; • ·: .. ~- .... ; •·. ·:.·.-. •.;·: • • ·' .. , ...... • ,., .-;: .... : ~-- . ... · ........... -.•• • • .... : • ... · • .. - ·• .', ,., ..... ·. • :. -• •• ·'. ;. •••••.•• .' .· .. · 
A.lllllllll lll~lllllllm B 111111111111~1111111m c 111111111 Ullllll lllll o ~IIIIIIIIIIIIIII IHIIII E 1!1111!111111!11! 11111 
135 752 - 4 135 752 - 4 135 752 . 4 135 752- 4 . 135 752-4 
! ·· ~-· illlli,,i.lil~lillilll.~i ··· ~ ·· ·· · ~ ... ,,,,,,lllirl~lllilllllr · ..... ~ -~ ··jlli!llll'~,~~~ irilll~'il .. ··· ·· ·-·· ·· -~--ill~l1i ilil illll~ li1i. ··· · ·-· -~· ·· illlllil-lnliltllill.ill··· 
i 135 753- 2 135 753 - 2 - 135 753 - 2 135 753 - 2 135 753 - 2 
" " '" " 'o· ,.,, , _, v,•,•.vo.• -.•o•; •,, -.,·,v " 'A' ¥ 1 .',_, _._.,.., ,,_.,._ .................. .. , . _. .. "" "'.'''""-"'Y 'A'"''"'·' •"'-"A',¥ ....... ... _..,~J',' '"""A',V'o'' ·"''A'"""' .. "•"·W"-'-Y·"~ '•""'' "., • ..., .. ,..., • ..,_,,.,_,,,0.•.-." ·'' "":"-'"'"Y'A' ,Y .... ,> .. .-.,' ' .'W'"''"'' '-'"''" A' v,• ... •,y,.,,'A' V,"'""'"W'A'"'" '"' .. _., 
PMTCf Surl'ey August 2011 Prtn!ed; andj.ah 2.6/08/201112:0.2.;:21 
162 
3.6. Administering the Questionnaire 
After obtaining informed consent, the data collectors ask the caregiver 14 questions on 
the health status of the infant' s mother, antenatal care, HIV testing, and PMTCT. The 
data collectors will read each question to the caregiver and record their response on the 
survey form. A copy of the Questionnaire as part ofthe Screening Form and PMTCT 
Evaluation Survey is included in Appendix 4 and as an editable Word document on the 
flash drive/CD. 
3.7. Collecting Dried Blood Spots 
The dried blood spot (DBS) sample is collected on filter paper specially designed to 
collect and store blood. A sample image of the filter paper is below. Data collectors 
should aim to fill at least four of the circles with a blood. The filter paper must be labeled 
with an ID number to link it to the questionnaire data and to ensure results can be 
returned to the infant caregiver. Details for DBS collection are included in the training 
slides. 
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3.8. Keeping the PMTCT Evaluation Register Up to Date 
You will use the PMTCT Study ID Register to record the names of all infants who 
participate in the evaluation in your facility. This Register is the only place in the 
evaluation where the infant ' s name is linked to their study ID number. This link exists to 
allow the return of the infant's HIV test results. In addition, the Register will help your 
staff keep track of the number of participants they have enrolled at their facility. 
A partial image of the Register used in Malawi is below and a copy of the Register as a 
Word document is included in Appendix 5 and on the flash drive/CD. 
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3.9. Completing the Supervision Visit Form 
Your facility will receive regular supervision visits to help you ensure data are being 
collected correctly. These visits should help you learn about how your staff is performing 
their tasks and help you address any performance problems. During the first supervision 
visit you will receive data collection supplies and the study supervisor will observe data 
collection from the first participants. They will use the Initial Visit Supervisory form to 
record information about your facility, the time of their visit, the number of samples 
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collected during their visit, and any issues that they uncovered with you that need to be 
addressed. In subsequent follow up visits, they will use the Follow-up Supervisory form 
that will collect information on your health facility, the total number of samples 
collected, and information on specific quality control questions, such as, "Are 
questionnaires filled out correctly?" 
Both Supervision Visit Forms are included in Appendix 6 as well as on the flash 
drive/ CD. 
3.10. Assuring Maintenance of Study Data 
One of your most important responsibilities is to keep all forms and samples organized 
and secure in your facility . 
You should keep all Blank Screening Form and PMTCT Evaluation Surveys, unused ID 
number stickers, and unused filter paper for DBS collection together in a secure space. 
Put the completed Screening Form and PMTCT Evaluation Survey forms in a large 
envelope of folder. Store the filter paper that contains DBS samples, once dried, in sealed 
plastic bags in batches of 15 as described in the training slides. Make sure your data 
collectors take care to ensure the same ID number is used to label all pieces of data 
collected from an infant-caregiver pair. 
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Section 4: Data Analysis 
4.1. Access Database 
4.2. SAS Code 
4.1. Access Database 
You can store survey data and laboratory results from the evaluation in a Microsoft 
Access database. The database shell is included on the flash drive/CD. 
Data entry assistants enter the data from the questionnaire and laboratory results into the 
Access database. Your organization may already have trained data entry assistants to 
complete this task or you may have to hire short-term personnel. Every survey and 
laboratory result should be entered into the database twice to ensure there are no errors. 
After all data are entered into the database Access can check to make sure the two entries 
of every participant are identical. If discrepancies are found the data entry assistants 
should refer back to the original questionnaire or laboratory result and correct the error. 
You can download the data from Access for analysis in SAS, Excel, or other statistical 
software package. 
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4.2. SAS Code 
In the Malawi evaluation we analyzed the data using SAS version 9.3 . SAS is a powerful 
computer software program you can use to run statistics. SAS however, is relatively 
expensive and requires writing code. If you are not already familiar with the program or 
with writing code, or if you do not have a statistician or epidemiologist on staff, SAS may 
not be the best choice for analysis. Simple statistics can be run in Excel. 
The data dictionary is a complete list of variable names and definitions included in the 
dataset. Variable names are often short to make it easier to work with in the database and 
in a statistical software program. The data dictionary provides additional information on 
the variable that is important for interpretation. For example, the question on mother's 
age at the time of data collection may be shortened to the variable name "momage." It 
would be important to know that "momage" is the age of the infant's mother at the time 
of data collection, not at the time of the infant' s birth or another time. In addition, in the 
dataset possible responses for a variable may be listed as "0" or " 1." The data dictionary 
lets you know that 0 is "no" and 1 is "yes." 
During the analysis you may want to create new variables, such as grouping together 
mothers ages into categories (e.g. 20-29 years). When you create new variables in your 
statistical software program you should ensure you add them to the data dictionary. 
The data dictionary and SAS coding are included in Appendix 7 and the flash drive/CD. 
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APPENDIX A: PMTCT Evaluation Screening and Questionnaire Form 
.---------- -- ---- ---
: PLACE 10 STICKER : 
: HERE : 
I 
: BARCODE LABEL 
.... ------ -- ----- ---- _, 
PMTCT Evaluation Screening and Questionnaire 
Impact Evaluation of Prevention of Mother-to-Child Transmission Programs 
SCREENING 
2 
3 
4 
5 
6 
7 
8 
District name (circle) 
... ·-·---------------- ------- ------ ·--- -··- .. ·-·-----.. --.. 
Clinic name 
Interviewer name 
Date (dd/mm/yy) 
Date of birth of the infant (dd/mm/yy) 
Is the child younger than 3 months of age? 
Is this child here today for the first pentavalent vaccination? 
Are you the biological mother or legal guardian aged 18 years 
or more? 
Nkhata Bay Zomba 
Salima Mulanje 
------- ----- ----
I I 
I I 
y N 
y N 
Y biological M N 
Y L Guardian>=18 
Clients are not eligible for the study if they answer "No" to Questions 6 OR 7 OR 8. Thank them 
for their time and end the survey. 
READ if cl ient answers "Yes" to Questions 6 and 7 and 8: 
Unduna wa za Umoyo ukuunika momwe nchito yothandiza mayi kupewa kupatsira mwana wake HIV (PMTCT) 
ikuyendera M' Malawi muno. Tikufuna tikufunseni mafunso angapo kuti tiwone ngati mwana wanu ndi woyenera 
kulowa m' kafukufukuyu . Tikufotokozerani za kafukufukuyu ndi kukupemphani chilolezo chanu cholowa 
m'kafukufukuyu. 
(The Ministry of Health is conducting an evaluation to determine how well the PMTCT programme is working in Malawi. 
We would like to ask you a few questions to see if your child is eligible to be entered in the study, explain what the study 
is about, and ask for your consent to participate in the study.) 
CONDUCT Informed Consent for all eligible participants (*SCRIPT ON LAST PAGE*) 
9 If no consent is given, what is the reason? 
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QUESTIONNAIRE 
10 Health status of the biological mother 
H s D DK 
11 Age of biological mother in years 
-*-" 
Did the mother attend antenatal care (ANC) during the y N OK pregnancy of this child? 
12 
Place of delivery for this child. Specify in this box if other: Hosp/ Home/ Oth DK 
clinic TBA 
13 
14 Mode of delivery SVD VacExt cs DK 
15 Did the following occur during labour and delivery? (circle ALL 
that happened) Breech WB+4 Episio-
to my 
HIV test results mother Never Neg Neg 
tested Before Since Pos DK Preg Preg 
16 
PMTCT management mother 
17 During pregnancy 
None AZT AZT ART ART DK 0-3w 4+w 0-3w 4+w 
-·------
During labour and post-partum NVP 
None Sd AZT ART OK NVP 3TC 
18 
Feeding and PMTCT management of infant 
-·--· 
19 Has this child received anything apart from breast milk since 
birth? (such as water, tea, goat or cow milk, porridge) y N 
20 Did the mother have any sores on her breasts since feeding this 
child? y N DK 
Infant ARVs given NVP 
None Sd + AZT DK NVP AZT only 
21 
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Read out to client: 
,-------------- - - - - ~ 
: PLACE ID STICKER : 
I HERE I 
I 
I 
: BARCODELABEL • 
._--- -- - -- - - --- -- --_I 
Mwanayu timutenga magazi pachidendene kuti tiyeze pompano kuti tidziwe ngati ali pa chiophyezo cha HIV. Zotsatira 
za magazi mulandira pasanathe mphind makumi atatu. Magazi otsalawo iakapangira kafukufuku. Tikamuyeza magazi 
pompano, ukhala mwayi wanu wodziwa ngati mwana wanu ali pa chiophyezo cha HIV kapena ayi. lzi zithandiza kupeza 
njira zomutetezera. Zotsatira za magazi omwe titenge pakafukufukuyu tidzakudziwitsani. 
Amayi a mwanayu kapena omusamalira athanso kuyezesa magazi mwaulere. 
(I would like to take some blood from the heel of the infant for the study and, if you would like, we I could use the same 
blood to do a rapid HIV test which will give a result within 30 minutes. The advantage of an immediate HIV test is that 
you will be informed about the status of your child immediately and protective measures can be taken. In any case you 
will be informed about the results of the blood taken for the study. Apart from the infant you (caregiver) can get a rapid 
HIV test as well.) 
TAKE heel-stick blood sample from infant. 
Results of OPTIONAL rapid HIV test 
22 Rapid HIV test on infant done today 
I 
y N 
Test 1 Test 2 Test 3 Final results given to client 
23 Outcome I Exp Not Exp Inc 
"Thank you for taking part in this study." 
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CODING KEY 
General y Yes 
N No 
OK Don't know I don't want to answer 
Oth Other 
08 Biological mother I age legal Y biological M The client is the infant's biological mother guardian 
Y L guardian The legal guardian is 18 years or older 
>=18 
010 Health status of mother H Healthy 
s Sick 
0 Died 
013 Place of delivery Hasp/clinic In hospital or health centre 
Home/TBA At own home, someone else home, or with Traditional Birth Attendant 
014 Mode of delivery SVD Spontaneous Vaginal Delivery 
VacExt Vacuum Extraction 
cs Caesarean Section 
-----
015 Occurred during labour & WB+4 Water broke more than 4 hours before delivery delivery 
Episiotomy Surgical cut of perineum during labour 
--------·--·-....... -.... - ...... , .. _, ____ 
016 HIV test resu lts mother Never Never tested 
Neg Before Negative test before this pregnancy Preg 
Neg Since Negative test since this pregnancy Preg 
Pes Positive 
017 During pregnancy AZT 0-3w AZT for less than 4 weeks 
AZT 4+W AZT for 4 weeks or longer 
ART 0-3w ART for less than 4 weeks 
ART 4+W ART for 4 weeks or longer 
018 During labour and post-partum Sd NVP Single dose nevirapine 
NVP AZT Single dose nevirapine, followed by 1 week AZT/3TC 3TC 
ART Antiretroviral therapy 
021 Infant ARVs given Sd NVP Single dose nevirapine 
NVP + AZT Single dose nevirapine followed by 1-4 weeks AZT syrup 
AZT only 1-4 weeks AZT syrup only 
023 Outcome Exp Exposed 
Not Exp Not exposed 
Inc Inconclusive 
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INFORMED CONSENT {CHEW A) 
KUPEREKA CHILOLEZO 
IMPACT EVALUATION OF PREVENTION OF MOTHER-TO-CHILD TRANSMISSION PROGRAMS 
Kafukufuku owunika momwe ndondomeko yolimbikitsa kuti kachilombo ka HIV kasafale kuchoka kwa 
mayl yemwe all nako kuplta kwa mwana wake {PMTCT) yayendera ku Malawi: Kafukufuku wa ana 
olandira katemera ku sikelo. 
Chiyambi ndi zolinga 
Unduna wa za Umoyo Mogwirizana ndi Bungwe Ia Management Sciences for Health (MSH) akonza 
kafukufuku owunika momwe nchito yothandiza amayi kupewa kupatsira mwana HIV (PMTCT) yayendera 
mmaboma anayi Mmalawi muno. 
Tili kukupemphemphani kuti mulowe nawo mu kafukufukuyu ngati momwe tikupemphera makolo onse 
amene abwera kusikelo ndi ana awo kudzalandila katemera woyamba. Ndikufotokozerani bwino lomwe 
kuti mumvetse za kafukufukuyu kuti choncho muthe kupanga chisankho ngati mungafune kulowa nawo 
mu kafukufukuyu kapena ayi. 
Cholinga cha kafukufukuyu ndi kutuna kuona momwe ndondomeko yoteteza ana kuti asatenge HIV 
kuchokera kwa amai omwe ali ndi HIV ikuyendera m'boma lino . Makamaka tifufuza kuti ndi ana angati 
akutenga HIV kuchokera kwa amayi awo . 
Zokambirana zathu zitenga mphindi makumi atatu . 
Ndondomeko za kafukufuku 
Ngati muvomera kulowa m'kafukufukuyu tikufunsani mafunso angapo okhudza mwanayu ndi amayi ake. 
Tikufunsani zamomwe sikelo yanu imayendera pa nthawi yomwe munali ndi pakati pa mwanayi,ngati 
munayezesa magazi oti awone ngati muli ndi kachirombo ka HIV,zomwe mukudziwapo momwe mayi 
angapewere kupatsira mwana wake HIV. Tikupemphaninso kuti tiwone timabuku ta zaumoyo kanu ndi 
kamwana. Komanso tikupemphani kuti titenge magazi pang'ono pa chidendene cha mwana wanu kuti 
tikayeze ngati mwanayo ali ndi kachirombo ka HIV kapena ayi. Zotsatira za magazi zikhoza kutenga miyezi 
iwiri kuti achipatala a pano adzakuuzeni. Ngati mwana wanu ali pachiopsyezo cha HIV ndiye kuti inunso, 
muli ndi HIV ngati muli amayi ake omubereka. 
Mwayi woyezetsa magazi kwa inu ndi mwana wanu kuti mudziwe ngati muli ndi kacirombo ka HIV 
pachipatala pompano ulipo. Zotsatira za magazi amene tatenga kwa mwana tidzazipereka pachipatala 
pano pakatha sabata zisanu ndi zitatu. Kuti zotsatira za magazi a mwanawanu muzazilandire, tidzampatsa 
mwana wanu nambala ndipo nambalayi igwirizana ndi magazi omwe tamutenga . lzi tidzalemba m'kabuku 
kake ka za umoyo. 
Zotsatira za magazi a mwanawanu zidzasungidwa mwa chinsinsi. Adokotala amene azipereka chithandizo 
kwa mwanayu ndi amene angadziwe zotsatirazi. 
Zowawa komanso Chiopsyezo 
Mwanayu abayida pang'ono pa chidendene kut i timtenge magazi ndipo mutha kukhala ndi nkhawa yoti 
amva kuwawa, koma izi zichitika mwachangu kuti asamve kuwawako. 
Ngati muli omangika kuyankha mafunso ena monga okhudza moyo wanu komanso nkhani zoyezetsa 
magazi muli ndi ufulu osayankha mafunsowo. 
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Phindu lomwe mungapeze 
Kafukufukuyu athandiza kutukula ntchito yopewa kufala kwa kachirombo ka HIV kuchoka kwa mayi 
kupita kwa mwana wa ke. Komanso inu kapena mwana wanu akapezeka ndi HIV tikuthand izani kuti 
mulandire chisamaliro ndi makhwa la. 
Ngat i mwasankha osa lowanawo mu kafukufukuyu, mutha kuyezetsa magazi inu ndi mwanawanu 
pachipatala pompano kuti mudziwe ngati muli ndi HIV kapena ayi. 
Malipiro kwa anthu olowa mu kafukufuku 
Kafukufukuyu ndi wa ulere. Simulandila kapena kulipira ndalama ch ifukwa cholowa mukafukufuku kapena 
kuyezesa magazi woti ayezedwe HIV. 
Chinsinsi 
Zonse zomwe tikambirane lero zikhala za chinsinsi. Zonse tikambirane zokhudza fukufukuyu komanso 
magazi omwe timutenge mwana wanu zipapsidwa nambala m'malo mwa dzina. Nambala ya mwanayu ndi 
imene ilembedwe mu buku lake Ia za umoyo komanso m'buku Ia pach ipatala pano. lzi zidzathandiza kuti 
mudzathe kuland ila zotsatira zake. lfe tinaphunzira kusunga chinsinsi pazonse zokhudza kafukufuku . 
Ndi ufu lu wa munthu kulowa m'kafukufukuyu. Muli ndi ufulu osalowa ndipo palibe ch ilango chi lichonse 
kwa munthu yemwe sana lowe. Mutha kutuluka m' kafukufukuyu nthawi il iyonse ngati mwasintha 
maganizo. Ngati mwabvomera kulowa mu kafukufukuyu lembani dzina m' munsimu. 
lne ... ... .... ... ... ... ... .... .... ... ... ... ... ... (lembani dzina Ia mayi/ kholo) ndamvetsa bwino 
zolinga ndi ndondomeko za kafu kufukuyu ndipo ndabvomera mwakufuna 
kwanga kut i ine ndi mwana wanga ... .... ... ... ... ... . . . ........ (dzina Ia mwana)kulowa mukafukufukuyu 
kuphatikizanso kuyeza magazi a mwana wanga omwe amutenge pa ch idendene chake. 
Siginichaya mayi/kholo Dzina Tsiku 
Siginicha ya ofunsa Dzina Tsiku 
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